ID   CXAR_HUMAN              Reviewed;         365 AA.
AC   P78310; B2R8V8; B7WPI3; D3YHP0; O00694; Q8WWT6; Q8WWT7; Q8WWT8;
AC   Q9UKV4;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   17-FEB-2016, entry version 167.
DE   RecName: Full=Coxsackievirus and adenovirus receptor;
DE            Short=CAR;
DE            Short=hCAR;
DE   AltName: Full=CVB3-binding protein;
DE   AltName: Full=Coxsackievirus B-adenovirus receptor;
DE   AltName: Full=HCVADR;
DE   Flags: Precursor;
GN   Name=CXADR; Synonyms=CAR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS A VIRUS RECEPTOR,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=9096397; DOI=10.1073/pnas.94.7.3352;
RA   Tomko R.P., Xu R., Philipson L.;
RT   "HCAR and MCAR: the human and mouse cellular receptors for subgroup C
RT   adenoviruses and group B coxsackieviruses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3352-3356(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9036860; DOI=10.1126/science.275.5304.1320;
RA   Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.,
RA   Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Finberg R.W.;
RT   "Isolation of a common receptor for Coxsackie B viruses and
RT   adenoviruses 2 and 5.";
RL   Science 275:1320-1323(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10543405; DOI=10.1007/s004399900136;
RA   Bowles K.R., Gibson J., Wu J., Shaffer L.G., Towbin J.A., Bowles N.E.;
RT   "Genomic organization and chromosomal localization of the human
RT   Coxsackievirus B-adenovirus receptor gene.";
RL   Hum. Genet. 105:354-359(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11573093; DOI=10.1038/nsb1001-874;
RA   He Y., Chipman P.R., Howitt J., Bator C.M., Whitt M.A., Baker T.S.,
RA   Kuhn R.J., Anderson C.W., Freimuth P., Rossmann M.G.;
RT   "Interaction of coxsackievirus B3 with the full length coxsackievirus-
RT   adenovirus receptor.";
RL   Nat. Struct. Biol. 8:874-878(2001).
RN   [5]
RP   FUNCTION (MICROBIAL INFECTION), NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS
RP   3; 4 AND 5), INTERACTION WITH COXSACKIEVIRUS TYPE B3, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=14978041; DOI=10.1074/jbc.M311754200;
RA   Doerner A., Xiong D., Couch K., Yajima T., Knowlton K.U.;
RT   "Alternatively spliced soluble coxsackie-adenovirus receptors inhibit
RT   coxsackievirus infection.";
RL   J. Biol. Chem. 279:18497-18503(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Andersson B., Tomko R.P., Andersson K., Darban H., Oncu D., Mizra M.,
RA   Sollerbrant K., Sonnhammer E., Philipson L.;
RT   "Putative regulatory domains in the human and mouse CAR genes.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RA   Dietel M.;
RT   "Identification and characterisation of CAR 4/6 as a new splice
RT   variant of the Coxsackie adenovirus receptor (CAR).";
RL   Submitted (JAN-2010) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cervix;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=10490761; DOI=10.1038/sj.gt.3301030;
RA   Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M.,
RA   Schoemaker R.G., van Veghel R., Houtsmuller A.B., Schultheiss H.-P.,
RA   Lamers J.M.J., Poller W.;
RT   "Expression of Coxsackie-adenovirus-receptor and alpha v-integrin does
RT   not correlate with adenovector targeting in vivo indicating anatomical
RT   vector barriers.";
RL   Gene Ther. 6:1520-1535(1999).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HUMAN ADENOVIRUS
RP   SUBGROUPS A/C/D/E/F FIBER PROTEINS.
RX   PubMed=9733828;
RA   Roelvink P.W., Lizonova A., Lee J.G.M., Li Y., Bergelson J.M.,
RA   Finberg R.W., Brough D.E., Kovesdi I., Wickham T.J.;
RT   "The coxsackievirus-adenovirus receptor protein can function as a
RT   cellular attachment protein for adenovirus serotypes from subgroups A,
RT   C, D, E, and F.";
RL   J. Virol. 72:7909-7915(1998).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HUMAN ADENOVIRUS
RP   FIBER PROTEIN, AND MUTAGENESIS OF 70-VAL--ILE-72.
RX   PubMed=10666333; DOI=10.1006/excr.1999.4761;
RA   Tomko R.P., Johansson C.B., Totrov M., Abagyan R., Frisen J.,
RA   Philipson L.;
RT   "Expression of the adenovirus receptor and its interaction with the
RT   fiber knob.";
RL   Exp. Cell Res. 255:47-55(2000).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH COXSACKIEVIRUS
RP   GROUP B CAPSID PROTEINS.
RX   PubMed=10814575; DOI=10.1006/viro.2000.0324;
RA   Martino T.A., Petric M., Weingartl H., Bergelson J.M., Opavsky M.A.,
RA   Richardson C.D., Modlin J.F., Finberg R.W., Kain K.C., Willis N.,
RA   Gauntt C.J., Liu P.P.;
RT   "The coxsackie-adenovirus receptor (CAR) is used by reference strains
RT   and clinical isolates representing all six serotypes of coxsackievirus
RT   group B and by swine vesicular disease virus.";
RL   Virology 271:99-108(2000).
RN   [18]
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=11549277; DOI=10.1006/bbrc.2001.5535;
RA   Thoelen I., Magnusson C., Tagerud S., Polacek C., Lindberg M.,
RA   Van Ranst M.;
RT   "Identification of alternative splice products encoded by the human
RT   coxsackie-adenovirus receptor gene.";
RL   Biochem. Biophys. Res. Commun. 287:216-222(2001).
RN   [19]
RP   TISSUE SPECIFICITY.
RX   PubMed=11457744; DOI=10.1161/01.CIR.104.3.275;
RA   Noutsias M., Fechner H., de Jonge H., Wang X., Dekkers D.,
RA   Houtsmuller A.B., Pauschinger M., Bergelson J.M., Warraich R.,
RA   Yacoub M., Hetzer R., Lamers J.M.J., Schultheiss H.-P., Poller W.;
RT   "Human coxsackie-adenovirus receptor is colocalized with integrins
RT   alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma
RT   and upregulated in dilated cardiomyopathy: implications for
RT   cardiotropic viral infections.";
RL   Circulation 104:275-280(2001).
RN   [20]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-318 AND 345-LEU--MET-348.
RX   PubMed=11316797; DOI=10.1074/jbc.M009531200;
RA   Cohen C.J., Gaetz J., Ohman T., Bergelson J.M.;
RT   "Multiple regions within the coxsackievirus and adenovirus receptor
RT   cytoplasmic domain are required for basolateral sorting.";
RL   J. Biol. Chem. 276:25392-25398(2001).
RN   [21]
RP   SUBCELLULAR LOCATION, INTERACTION WITH TJP1, AND FUNCTION.
RX   PubMed=11734628; DOI=10.1073/pnas.261452898;
RA   Cohen C.J., Shieh J.T.C., Pickles R.J., Okegawa T., Hsieh J.-T.,
RA   Bergelson J.M.;
RT   "The coxsackievirus and adenovirus receptor is a transmembrane
RT   component of the tight junction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:15191-15196(2001).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), SUBCELLULAR LOCATION, INTERACTION WITH
RP   CTNNB1, AND INTERACTION WITH HUMAN ADENOVIRUS FIBER PROTEIN.
RX   PubMed=12297051; DOI=10.1016/S0092-8674(02)00912-1;
RA   Walters R.W., Freimuth P., Moninger T.O., Ganske I., Zabner J.,
RA   Welsh M.J.;
RT   "Adenovirus fiber disrupts CAR-mediated intercellular adhesion
RT   allowing virus escape.";
RL   Cell 110:789-799(2002).
RN   [23]
RP   PALMITOYLATION AT CYS-259 AND CYS-260, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 259-CYS-CYS-260.
RX   PubMed=12021372; DOI=10.1128/JVI.76.12.6382-6386.2002;
RA   van't Hof W., Crystal R.G.;
RT   "Fatty acid modification of the coxsackievirus and adenovirus
RT   receptor.";
RL   J. Virol. 76:6382-6386(2002).
RN   [24]
RP   INTERACTION WITH LNX.
RX   PubMed=12468544; DOI=10.1074/jbc.M205927200;
RA   Sollerbrant K., Raschperger E., Mirza M., Engstroem U., Philipson L.,
RA   Ljungdahl P.O., Pettersson R.F.;
RT   "The Coxsackievirus and adenovirus receptor (CAR) forms a complex with
RT   the PDZ domain-containing protein ligand-of-numb protein-X (LNX).";
RL   J. Biol. Chem. 278:7439-7444(2003).
RN   [25]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY (ISOFORMS 1 AND 2).
RX   PubMed=15533241; DOI=10.1186/1471-2121-5-42;
RA   Shaw C.A., Holland P.C., Sinnreich M., Allen C., Sollerbrant K.,
RA   Karpati G., Nalbantoglu J.;
RT   "Isoform-specific expression of the Coxsackie and adenovirus receptor
RT   (CAR) in neuromuscular junction and cardiac intercalated discs.";
RL   BMC Cell Biol. 5:42-42(2004).
RN   [26]
RP   INTERACTION WITH MPDZ, AND SUBCELLULAR LOCATION.
RX   PubMed=15364909; DOI=10.1074/jbc.M409061200;
RA   Coyne C.B., Voelker T., Pichla S.L., Bergelson J.M.;
RT   "The coxsackievirus and adenovirus receptor interacts with the multi-
RT   PDZ domain protein-1 (MUPP-1) within the tight junction.";
RL   J. Biol. Chem. 279:48079-48084(2004).
RN   [27]
RP   INTERACTION WITH BAIAP1; DLG4 AND PRKCABP.
RX   PubMed=15304526; DOI=10.1242/jcs.01300;
RA   Ashbourne-Excoffon K.J.D., Hruska-Hageman A.M., Klotz M., Traver G.L.,
RA   Zabner J.;
RT   "A role for the PDZ-binding domain of the coxsackie B virus and
RT   adenovirus receptor (CAR) in cell adhesion and growth.";
RL   J. Cell Sci. 117:4401-4409(2004).
RN   [28]
RP   INTERACTION WITH AMICA1, DOMAIN, AND FUNCTION.
RX   PubMed=15800062; DOI=10.1091/mbc.E05-01-0036;
RA   Zen K., Liu Y., McCall I.C., Wu T., Lee W., Babbin B.A., Nusrat A.,
RA   Parkos C.A.;
RT   "Neutrophil migration across tight junctions is mediated by adhesive
RT   interactions between epithelial CAR and a JAM-like protein on
RT   neutrophils.";
RL   Mol. Biol. Cell 16:2694-2703(2005).
RN   [29]
RP   FUNCTION IN LEUKOCYTE MIGRATION, AND INTERACTION WITH AMICA1.
RX   PubMed=19064666; DOI=10.1083/jcb.200805061;
RA   Luissint A.C., Lutz P.G., Calderwood D.A., Couraud P.O.,
RA   Bourdoulous S.;
RT   "JAM-L-mediated leukocyte adhesion to endothelial cells is regulated
RT   in cis by alpha4beta1 integrin activation.";
RL   J. Cell Biol. 183:1159-1173(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-306 AND SER-332, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 21-144 IN COMPLEX WITH HUMAN
RP   ADENOVIRUS 12 FIBER PROTEIN, AND DISULFIDE BONDS.
RX   PubMed=10567268; DOI=10.1126/science.286.5444.1579;
RA   Bewley M.C., Springer K., Zhang Y.-B., Freimuth P., Flanagan J.M.;
RT   "Structural analysis of the mechanism of adenovirus binding to its
RT   human cellular receptor, CAR.";
RL   Science 286:1579-1583(1999).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 15-140, DOMAIN, AND DISULFIDE
RP   BOND.
RX   PubMed=11080637; DOI=10.1016/S0969-2126(00)00528-1;
RA   van Raaij M.J., Chouin E., van der Zandt H., Bergelson J.M.,
RA   Cusack S.;
RT   "Dimeric structure of the coxsackievirus and adenovirus receptor D1
RT   domain at 1.7 A resolution.";
RL   Structure 8:1147-1155(2000).
RN   [36]
RP   STRUCTURE BY NMR OF 21-144, AND DISULFIDE BONDS.
RX   PubMed=14967025; DOI=10.1021/bi035490x;
RA   Jiang S., Jacobs A., Laue T.M., Caffrey M.;
RT   "Solution structure of the coxsackievirus and adenovirus receptor
RT   domain 1.";
RL   Biochemistry 43:1847-1853(2004).
CC   -!- FUNCTION: Component of the epithelial apical junction complex that
CC       may function as an homophilic cell adhesion molecule and is
CC       essential for tight junction integrity. Also involved in
CC       transepithelial migration of leukocytes through adhesive
CC       interactions with AMICA1/JAML a transmembrane protein of the
CC       plasma membrane of leukocytes. The interaction between both
CC       receptors also mediates the activation of gamma-delta T-cells, a
CC       subpopulation of T-cells residing in epithelia and involved in
CC       tissue homeostasis and repair. Upon epithelial CXADR-binding,
CC       AMICA1 induces downstream cell signaling events in gamma-delta T-
CC       cells through PI3-kinase and MAP kinases. It results in
CC       proliferation and production of cytokines and growth factors by T-
CC       cells that in turn stimulate epithelial tissues repair.
CC       {ECO:0000269|PubMed:11734628, ECO:0000269|PubMed:12297051,
CC       ECO:0000269|PubMed:15800062, ECO:0000269|PubMed:19064666,
CC       ECO:0000269|PubMed:9096397}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for adenovirus
CC       type C (PubMed:9733828, PubMed:10666333, PubMed:12297051,
CC       PubMed:10567268). Acts as a receptor for Coxsackievirus B1 to B6
CC       (PubMed:14978041, PubMed:10814575). {ECO:0000269|PubMed:10567268,
CC       ECO:0000269|PubMed:10666333, ECO:0000269|PubMed:10814575,
CC       ECO:0000269|PubMed:12297051, ECO:0000269|PubMed:14978041,
CC       ECO:0000269|PubMed:9733828}.
CC   -!- SUBUNIT: Monomer. May form homodimer. Interacts with LNX, BAIAP1,
CC       DLG4, PRKCABP, TJP1 and CTNNB1. Interacts with MPDZ; recruits MPDZ
CC       to intercellular contact sites. Interacts with AMICA1 (homodimeric
CC       form). Secreted isoform 3, isoform 4 and isoform 5 can interact
CC       with the extracellular domain of the receptor. (Microbial
CC       infection) Interacts with adenovirus subgroups A, C, D, E and F
CC       fiber proteins as well as coxsackievirus B1, B2, B3, B4, B5 and B6
CC       capsid proteins (PubMed:14978041, PubMed:9733828, PubMed:10666333,
CC       PubMed:10814575, PubMed:12297051, PubMed:10567268).
CC       {ECO:0000269|PubMed:10567268, ECO:0000269|PubMed:10666333,
CC       ECO:0000269|PubMed:10814575, ECO:0000269|PubMed:11734628,
CC       ECO:0000269|PubMed:12297051, ECO:0000269|PubMed:12468544,
CC       ECO:0000269|PubMed:14978041, ECO:0000269|PubMed:15304526,
CC       ECO:0000269|PubMed:15364909, ECO:0000269|PubMed:15800062,
CC       ECO:0000269|PubMed:19064666, ECO:0000269|PubMed:9733828}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane
CC       {ECO:0000269|PubMed:15533241}; Single-pass type I membrane protein
CC       {ECO:0000255}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:11316797, ECO:0000269|PubMed:12021372,
CC       ECO:0000269|PubMed:12297051, ECO:0000269|PubMed:15364909}; Single-
CC       pass type I membrane protein {ECO:0000255}. Cell junction, tight
CC       junction {ECO:0000269|PubMed:11734628,
CC       ECO:0000269|PubMed:12297051}. Cell junction, adherens junction
CC       {ECO:0000269|PubMed:12297051}. Note=In epithelial cells localizes
CC       to the apical junction complex composed of tight and adherens
CC       junctions (PubMed:12297051). In airway epithelial cells localized
CC       to basolateral membrane but not to apical surface
CC       (PubMed:11316797). {ECO:0000269|PubMed:11316797,
CC       ECO:0000269|PubMed:12297051}.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted
CC       {ECO:0000269|PubMed:14978041}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Secreted
CC       {ECO:0000269|PubMed:14978041}.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Secreted
CC       {ECO:0000269|PubMed:14978041}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=SIV;
CC         IsoId=P78310-1; Sequence=Displayed;
CC       Name=2; Synonyms=CAR2, HCAR2, TVV;
CC         IsoId=P78310-2; Sequence=VSP_014825, VSP_014826;
CC         Note=Ref.14 (AAD31772) sequence is in conflict in position:
CC         343:P->A. {ECO:0000305};
CC       Name=3; Synonyms=CAR2/7, Gamma;
CC         IsoId=P78310-3; Sequence=VSP_014819, VSP_014820;
CC       Name=4; Synonyms=CAR3/7;
CC         IsoId=P78310-4; Sequence=VSP_014821, VSP_014822;
CC       Name=5; Synonyms=CAR4/7, Beta;
CC         IsoId=P78310-5; Sequence=VSP_014823, VSP_014824;
CC       Name=6;
CC         IsoId=P78310-6; Sequence=VSP_047357;
CC         Note=Gene prediction based on EST data.;
CC       Name=7; Synonyms=CAR 4/6;
CC         IsoId=P78310-7; Sequence=VSP_047729;
CC   -!- TISSUE SPECIFICITY: Expressed in pancreas, brain, heart, small
CC       intestine, testis, prostate and at a lower level in liver and
CC       lung. Isoform 5 is ubiquitously expressed. Isoform 3 is expressed
CC       in heart, lung and pancreas. In skeletal muscle, isoform 1 is
CC       found at the neuromuscular junction and isoform 2 is found in
CC       blood vessels. In cardiac muscle, isoform 1 and isoform 2 are
CC       found at intercalated disks. In heart expressed in subendothelial
CC       layers of the vessel wall but not in the luminal endothelial
CC       surface. Expression is elevated in hearts with dilated
CC       cardiomyopathy. {ECO:0000269|PubMed:10490761,
CC       ECO:0000269|PubMed:11457744, ECO:0000269|PubMed:11549277,
CC       ECO:0000269|PubMed:9096397}.
CC   -!- DOMAIN: The Ig-like C2-type 1 domain mediates homodimerization and
CC       interaction with AMICA1.
CC   -!- DOMAIN: The PDZ-binding motif mediates interaction with MPDZ and
CC       BAIAP1.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: Palmitoylated on Cys-259 and/or Cys-260; required for proper
CC       localization to the plasma membrane.
CC       {ECO:0000269|PubMed:12021372}.
CC   -!- SIMILARITY: Contains 2 Ig-like C2-type (immunoglobulin-like)
CC       domains. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U90716; AAC51234.1; -; mRNA.
DR   EMBL; Y07593; CAA68868.1; -; mRNA.
DR   EMBL; AF169366; AAF05908.1; -; Genomic_DNA.
DR   EMBL; AF169360; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF169361; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF169362; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF169363; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF169364; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF169365; AAF05908.1; JOINED; Genomic_DNA.
DR   EMBL; AF200465; AAF24344.1; -; Genomic_DNA.
DR   EMBL; AY072910; AAL68878.1; -; mRNA.
DR   EMBL; AY072911; AAL68879.1; -; mRNA.
DR   EMBL; AY072912; AAL68880.1; -; mRNA.
DR   EMBL; AF242865; AAG01088.1; -; Genomic_DNA.
DR   EMBL; AF242862; AAG01088.1; JOINED; Genomic_DNA.
DR   EMBL; AF242864; AAG01088.1; JOINED; Genomic_DNA.
DR   EMBL; GU474812; ADC84500.1; -; mRNA.
DR   EMBL; CR617256; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BT019876; AAV38679.1; -; mRNA.
DR   EMBL; AK313526; BAG36305.1; -; mRNA.
DR   EMBL; AP000963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000967; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX10031.1; -; Genomic_DNA.
DR   EMBL; BC003684; AAH03684.1; -; mRNA.
DR   EMBL; BC010536; AAH10536.1; -; mRNA.
DR   EMBL; AF124598; AAD31772.1; -; mRNA.
DR   CCDS; CCDS33519.1; -. [P78310-1]
DR   CCDS; CCDS56204.1; -. [P78310-6]
DR   CCDS; CCDS56205.1; -. [P78310-5]
DR   CCDS; CCDS56206.1; -. [P78310-4]
DR   CCDS; CCDS56207.1; -. [P78310-3]
DR   RefSeq; NP_001193992.1; NM_001207063.1. [P78310-5]
DR   RefSeq; NP_001193993.1; NM_001207064.1. [P78310-4]
DR   RefSeq; NP_001193994.1; NM_001207065.1. [P78310-3]
DR   RefSeq; NP_001193995.1; NM_001207066.1. [P78310-6]
DR   RefSeq; NP_001329.1; NM_001338.4. [P78310-1]
DR   RefSeq; XP_011527781.1; XM_011529479.1. [P78310-5]
DR   UniGene; Hs.627078; -.
DR   PDB; 1EAJ; X-ray; 1.35 A; A/B=15-140.
DR   PDB; 1F5W; X-ray; 1.70 A; A/B=15-140.
DR   PDB; 1JEW; EM; 22.00 A; R=21-140.
DR   PDB; 1KAC; X-ray; 2.60 A; B=22-144.
DR   PDB; 1P69; X-ray; 3.10 A; B=22-144.
DR   PDB; 1P6A; X-ray; 2.90 A; B=22-144.
DR   PDB; 1RSF; NMR; -; A=21-144.
DR   PDB; 2J12; X-ray; 1.50 A; B=15-140.
DR   PDB; 2J1K; X-ray; 2.30 A; A/B/G/J/K/O/P/T/V/X/Y/Z=15-140.
DR   PDB; 2NPL; NMR; -; X=142-235.
DR   PDB; 2W9L; X-ray; 2.91 A; A/B/G/J/K/O/P/T/V/X/Y/Z=16-139.
DR   PDB; 2WBW; X-ray; 1.55 A; B=15-138.
DR   PDB; 3J6L; EM; 9.00 A; B=15-140.
DR   PDB; 3J6M; EM; 9.00 A; B=22-144.
DR   PDB; 3J6N; EM; 9.00 A; K=20-233.
DR   PDB; 3J6O; EM; 9.00 A; S=20-236.
DR   PDBsum; 1EAJ; -.
DR   PDBsum; 1F5W; -.
DR   PDBsum; 1JEW; -.
DR   PDBsum; 1KAC; -.
DR   PDBsum; 1P69; -.
DR   PDBsum; 1P6A; -.
DR   PDBsum; 1RSF; -.
DR   PDBsum; 2J12; -.
DR   PDBsum; 2J1K; -.
DR   PDBsum; 2NPL; -.
DR   PDBsum; 2W9L; -.
DR   PDBsum; 2WBW; -.
DR   PDBsum; 3J6L; -.
DR   PDBsum; 3J6M; -.
DR   PDBsum; 3J6N; -.
DR   PDBsum; 3J6O; -.
DR   ProteinModelPortal; P78310; -.
DR   SMR; P78310; 16-235.
DR   BioGrid; 107905; 14.
DR   IntAct; P78310; 5.
DR   MINT; MINT-111007; -.
DR   STRING; 9606.ENSP00000284878; -.
DR   iPTMnet; P78310; -.
DR   PhosphoSite; P78310; -.
DR   SwissPalm; P78310; -.
DR   BioMuta; CXADR; -.
DR   DMDM; 6685351; -.
DR   MaxQB; P78310; -.
DR   PaxDb; P78310; -.
DR   PRIDE; P78310; -.
DR   DNASU; 1525; -.
DR   Ensembl; ENST00000284878; ENSP00000284878; ENSG00000154639. [P78310-1]
DR   Ensembl; ENST00000356275; ENSP00000348620; ENSG00000154639. [P78310-3]
DR   Ensembl; ENST00000400165; ENSP00000383029; ENSG00000154639. [P78310-4]
DR   Ensembl; ENST00000400166; ENSP00000383030; ENSG00000154639. [P78310-5]
DR   Ensembl; ENST00000400169; ENSP00000383033; ENSG00000154639. [P78310-6]
DR   GeneID; 1525; -.
DR   KEGG; hsa:1525; -.
DR   UCSC; uc002ykh.2; human. [P78310-5]
DR   UCSC; uc002yki.3; human. [P78310-1]
DR   UCSC; uc010gld.2; human. [P78310-4]
DR   UCSC; uc010gle.2; human. [P78310-3]
DR   UCSC; uc021whp.1; human.
DR   CTD; 1525; -.
DR   GeneCards; CXADR; -.
DR   HGNC; HGNC:2559; CXADR.
DR   HPA; CAB005103; -.
DR   HPA; HPA003342; -.
DR   HPA; HPA030411; -.
DR   HPA; HPA030412; -.
DR   MIM; 602621; gene.
DR   neXtProt; NX_P78310; -.
DR   PharmGKB; PA27055; -.
DR   eggNOG; ENOG410IGDG; Eukaryota.
DR   eggNOG; ENOG4110WP1; LUCA.
DR   GeneTree; ENSGT00760000119145; -.
DR   HOGENOM; HOG000111222; -.
DR   HOVERGEN; HBG105787; -.
DR   InParanoid; P78310; -.
DR   KO; K06788; -.
DR   OMA; VGNKKIQ; -.
DR   OrthoDB; EOG7MH0Z1; -.
DR   PhylomeDB; P78310; -.
DR   TreeFam; TF330875; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   ChiTaRS; CXADR; human.
DR   EvolutionaryTrace; P78310; -.
DR   GeneWiki; Coxsackie_virus_and_adenovirus_receptor; -.
DR   GenomeRNAi; 1525; -.
DR   NextBio; 35491112; -.
DR   PRO; PR:P78310; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; P78310; -.
DR   CleanEx; HS_CXADR; -.
DR   Genevisible; P78310; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; ISS:UniProtKB.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016327; C:apicolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB.
DR   GO; GO:0044297; C:cell body; ISS:UniProtKB.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0009986; C:cell surface; IBA:GO_Central.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:CACAO.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:UniProtKB.
DR   GO; GO:0071253; F:connexin binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0086067; P:AV node cell to bundle of His cell communication; ISS:UniProtKB.
DR   GO; GO:0086072; P:AV node cell-bundle of His cell adhesion involved in cell communication; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0048739; P:cardiac muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0045216; P:cell-cell junction organization; ISS:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0010669; P:epithelial structure maintenance; IMP:UniProtKB.
DR   GO; GO:0046629; P:gamma-delta T cell activation; ISS:UniProtKB.
DR   GO; GO:0008354; P:germ cell migration; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:UniProtKB.
DR   GO; GO:0034109; P:homotypic cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0007005; P:mitochondrion organization; ISS:UniProtKB.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0098904; P:regulation of AV node cell action potential; IEA:Ensembl.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0070633; P:transepithelial transport; IMP:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell junction;
KW   Cell membrane; Complete proteome; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction;
KW   Immunoglobulin domain; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Tight junction; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    365       Coxsackievirus and adenovirus receptor.
FT                                /FTId=PRO_0000014739.
FT   TOPO_DOM     20    237       Extracellular. {ECO:0000255}.
FT   TRANSMEM    238    258       Helical. {ECO:0000255}.
FT   TOPO_DOM    259    365       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20    134       Ig-like C2-type 1.
FT   DOMAIN      141    228       Ig-like C2-type 2.
FT   MOTIF       360    365       PDZ-binding.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97792}.
FT   MOD_RES     304    304       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97792}.
FT   MOD_RES     306    306       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     323    323       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97792}.
FT   MOD_RES     332    332       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P97792}.
FT   LIPID       259    259       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:12021372}.
FT   LIPID       260    260       S-palmitoyl cysteine.
FT                                {ECO:0000305|PubMed:12021372}.
FT   CARBOHYD    106    106       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    201    201       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     41    120       {ECO:0000269|PubMed:10567268,
FT                                ECO:0000269|PubMed:11080637,
FT                                ECO:0000269|PubMed:14967025}.
FT   DISULFID    162    212       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:14967025}.
FT   VAR_SEQ      71     89       IILYSGDKIYDDYYPDLKG -> GRCATSKEPYVHCQKLHR
FT                                Q (in isoform 3).
FT                                {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014819.
FT   VAR_SEQ      90    365       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014820.
FT   VAR_SEQ     139    139       V -> GKMCHLQRAVRPLPEATSAVIIHPWGPCLLPTWKDI
FT                                PRLSITKYQVKTLNALLRVRLSHLLR (in isoform
FT                                4). {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014821.
FT   VAR_SEQ     140    365       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014822.
FT   VAR_SEQ     191    232       EMTSSVISVKNASSEYSGTYSCTVRNRVGSDQCLLRLNVVP
FT                                P -> A (in isoform 7).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_047729.
FT   VAR_SEQ     191    191       E -> GKMCHLQRAVRPLPEATSAVIIHPWGPCLLPTWKDI
FT                                PRLSITKYQVKTLNALLRVRLSHLLR (in isoform
FT                                5). {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014823.
FT   VAR_SEQ     192    365       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14978041}.
FT                                /FTId=VSP_014824.
FT   VAR_SEQ     340    365       VAAPNLSRMGAIPVMIPAQSKDGSIV -> FKYPYKTDGIT
FT                                VV (in isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_047357.
FT   VAR_SEQ     340    345       VAAPNL -> FKYPY (in isoform 2).
FT                                {ECO:0000303|Ref.8}.
FT                                /FTId=VSP_014825.
FT   VAR_SEQ     346    365       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.8}.
FT                                /FTId=VSP_014826.
FT   VARIANT     323    323       S -> R (in dbSNP:rs34727960).
FT                                /FTId=VAR_049871.
FT   MUTAGEN      70     72       VII->AID: Abolishes binding to adenovirus
FT                                type 5. {ECO:0000269|PubMed:10666333}.
FT   MUTAGEN     259    260       CC->AA: Loss of palmitoylation and
FT                                altered localization.
FT                                {ECO:0000269|PubMed:12021372}.
FT   MUTAGEN     318    318       Y->A: Affects basolateral localization in
FT                                airway epithelial cells.
FT                                {ECO:0000269|PubMed:11316797}.
FT   MUTAGEN     345    348       LSRM->AAAA: Affects basolateral
FT                                localization in airway epithelial cells.
FT                                {ECO:0000269|PubMed:11316797}.
FT   STRAND       21     32       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       37     39       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       42     44       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       53     61       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       62     65       {ECO:0000244|PDB:1RSF}.
FT   STRAND       68     75       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       78     80       {ECO:0000244|PDB:1EAJ}.
FT   TURN         86     90       {ECO:0000244|PDB:1EAJ}.
FT   STRAND       91     93       {ECO:0000244|PDB:1EAJ}.
FT   HELIX        98    100       {ECO:0000244|PDB:1EAJ}.
FT   STRAND      105    107       {ECO:0000244|PDB:1EAJ}.
FT   HELIX       112    114       {ECO:0000244|PDB:1EAJ}.
FT   STRAND      116    124       {ECO:0000244|PDB:1EAJ}.
FT   STRAND      127    138       {ECO:0000244|PDB:1EAJ}.
FT   STRAND      145    148       {ECO:0000244|PDB:2NPL}.
FT   STRAND      156    163       {ECO:0000244|PDB:2NPL}.
FT   STRAND      166    168       {ECO:0000244|PDB:2NPL}.
FT   STRAND      171    178       {ECO:0000244|PDB:2NPL}.
FT   HELIX       185    192       {ECO:0000244|PDB:2NPL}.
FT   STRAND      195    201       {ECO:0000244|PDB:2NPL}.
FT   STRAND      208    215       {ECO:0000244|PDB:2NPL}.
FT   STRAND      221    227       {ECO:0000244|PDB:2NPL}.
SQ   SEQUENCE   365 AA;  40030 MW;  AB01C6346CB7FE64 CRC64;
     MALLLCFVLL CGVVDFARSL SITTPEEMIE KAKGETAYLP CKFTLSPEDQ GPLDIEWLIS
     PADNQKVDQV IILYSGDKIY DDYYPDLKGR VHFTSNDLKS GDASINVTNL QLSDIGTYQC
     KVKKAPGVAN KKIHLVVLVK PSGARCYVDG SEEIGSDFKI KCEPKEGSLP LQYEWQKLSD
     SQKMPTSWLA EMTSSVISVK NASSEYSGTY SCTVRNRVGS DQCLLRLNVV PPSNKAGLIA
     GAIIGTLLAL ALIGLIIFCC RKKRREEKYE KEVHHDIRED VPPPKSRTST ARSYIGSNHS
     SLGSMSPSNM EGYSKTQYNQ VPSEDFERTP QSPTLPPAKV AAPNLSRMGA IPVMIPAQSK
     DGSIV
//
ID   PDGFB_MOUSE             Reviewed;         241 AA.
AC   P31240; Q6P3C4;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   09-DEC-2015, entry version 137.
DE   RecName: Full=Platelet-derived growth factor subunit B;
DE            Short=PDGF subunit B;
DE   AltName: Full=PDGF-2;
DE   AltName: Full=Platelet-derived growth factor B chain;
DE   AltName: Full=Platelet-derived growth factor beta polypeptide;
DE   AltName: Full=Proto-oncogene c-Sis;
DE   Flags: Precursor;
GN   Name=Pdgfb; Synonyms=Sis;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2045107; DOI=10.1016/0888-7543(91)90515-G;
RA   Bonthron D.T., Sultan P., Collins T.;
RT   "Structure of the murine c-sis proto-oncogene (Sis, PDGFB) encoding
RT   the B chain of platelet-derived growth factor.";
RL   Genomics 10:287-292(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo, and Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=7958863; DOI=10.1101/gad.8.16.1875;
RA   Leveen P., Pekny M., Gebre-Medhin S., Swolin B., Larsson E.,
RA   Betsholtz C.;
RT   "Mice deficient for PDGF B show renal, cardiovascular, and
RT   hematological abnormalities.";
RL   Genes Dev. 8:1875-1887(1994).
RN   [4]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=9211853; DOI=10.1126/science.277.5323.242;
RA   Lindahl P., Johansson B.R., Leveen P., Betsholtz C.;
RT   "Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.";
RL   Science 277:242-245(1997).
RN   [5]
RP   FUNCTION.
RX   PubMed=10734101; DOI=10.1074/jbc.275.13.9527;
RA   Arar M., Xu Y.C., Elshihabi I., Barnes J.L., Choudhury G.G.,
RA   Abboud H.E.;
RT   "Platelet-derived growth factor receptor beta regulates migration and
RT   DNA synthesis in metanephric mesenchymal cells.";
RL   J. Biol. Chem. 275:9527-9533(2000).
RN   [6]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=11264163; DOI=10.1182/blood.V97.7.1990;
RA   Kaminski W.E., Lindahl P., Lin N.L., Broudy V.C., Crosby J.R.,
RA   Hellstrom M., Swolin B., Bowen-Pope D.F., Martin P.J., Ross R.,
RA   Betsholtz C., Raines E.W.;
RT   "Basis of hematopoietic defects in platelet-derived growth factor
RT   (PDGF)-B and PDGF beta-receptor null mice.";
RL   Blood 97:1990-1998(2001).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=14514732; DOI=10.1097/01.ASN.0000089828.73014.C8;
RA   Taneda S., Hudkins K.L., Topouzis S., Gilbertson D.G.,
RA   Ophascharoensuk V., Truong L., Johnson R.J., Alpers C.E.;
RT   "Obstructive uropathy in mice and humans: potential role for PDGF-D in
RT   the progression of tubulointerstitial injury.";
RL   J. Am. Soc. Nephrol. 14:2544-2555(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=14561699; DOI=10.1172/JCI200318549;
RA   Abramsson A., Lindblom P., Betsholtz C.;
RT   "Endothelial and nonendothelial sources of PDGF-B regulate pericyte
RT   recruitment and influence vascular pattern formation in tumors.";
RL   J. Clin. Invest. 112:1142-1151(2003).
RN   [9]
RP   REVIEW.
RX   PubMed=15207812; DOI=10.1016/j.cytogfr.2004.03.003;
RA   Tallquist M., Kazlauskas A.;
RT   "PDGF signaling in cells and mice.";
RL   Cytokine Growth Factor Rev. 15:205-213(2004).
RN   [10]
RP   REVIEW ON FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15207813; DOI=10.1016/j.cytogfr.2004.03.005;
RA   Betsholtz C.;
RT   "Insight into the physiological functions of PDGF through genetic
RT   studies in mice.";
RL   Cytokine Growth Factor Rev. 15:215-228(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=19030102; DOI=10.1371/journal.pone.0003794;
RA   Wu E., Palmer N., Tian Z., Moseman A.P., Galdzicki M., Wang X.,
RA   Berger B., Zhang H., Kohane I.S.;
RT   "Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR
RT   genetically defined cells.";
RL   PLoS ONE 3:E3794-E3794(2008).
CC   -!- FUNCTION: Growth factor that plays an essential role in the
CC       regulation of embryonic development, cell proliferation, cell
CC       migration, survival and chemotaxis. Potent mitogen for cells of
CC       mesenchymal origin. Required for normal proliferation and
CC       recruitment of pericytes and vascular smooth muscle cells in the
CC       central nervous system, skin, lung, heart and placenta. Required
CC       for normal blood vessel development, and for normal development of
CC       kidney glomeruli. Plays an important role in wound healing.
CC       Signaling is modulated by the formation of heterodimers with
CC       PDGFA. {ECO:0000269|PubMed:10734101, ECO:0000269|PubMed:14561699,
CC       ECO:0000269|PubMed:19030102, ECO:0000269|PubMed:7958863}.
CC   -!- SUBUNIT: Homodimer; antiparallel disulfide-linked dimer.
CC       Heterodimer with PDGFA; antiparallel disulfide-linked dimer. The
CC       PDGFB homodimer interacts with PDGFRA and PDGFRB homodimers, and
CC       with heterodimers formed by PDGFRA and PDGFRB. The heterodimer
CC       composed of PDGFA and PDGFB interacts with PDGFRB homodimers, and
CC       with heterodimers formed by PDGFRA and PDGFRB. Interacts with
CC       XLKD1 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted. Note=Released by platelets upon
CC       wounding. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Localized to vascular smooth muscle cells.
CC       Also weakly expressed by cortical interstitial cells but absent in
CC       tubules. Up-regulated in areas of renal fibrosis. In mice with
CC       unilateral ureteral obstruction, an increased expression in
CC       interstitial cells and in some tubules observed after day 4.
CC       {ECO:0000269|PubMed:14514732}.
CC   -!- DISRUPTION PHENOTYPE: Perinatal lethality, due to severe
CC       hemorrhages shortly before birth. Kidney glomerular tufts do not
CC       form, apparently because of absence of mesangial cells. The heart
CC       and some large arteries are dilated in late-stage embryos. Mice
CC       lack microvascular pericytes, which normally form part of the
CC       capillary wall, and develop numerous capillary microaneurysms,
CC       leading to hemorrhages. Mice display erythroblastosis, macrocytic
CC       anemia, and thrombocytopenia. {ECO:0000269|PubMed:11264163,
CC       ECO:0000269|PubMed:15207813, ECO:0000269|PubMed:7958863,
CC       ECO:0000269|PubMed:9211853}.
CC   -!- SIMILARITY: Belongs to the PDGF/VEGF growth factor family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M84453; AAA40113.1; -; Genomic_DNA.
DR   EMBL; M84448; AAA40113.1; JOINED; Genomic_DNA.
DR   EMBL; M84449; AAA40113.1; JOINED; Genomic_DNA.
DR   EMBL; M84450; AAA40113.1; JOINED; Genomic_DNA.
DR   EMBL; M84451; AAA40113.1; JOINED; Genomic_DNA.
DR   EMBL; M84452; AAA40113.1; JOINED; Genomic_DNA.
DR   EMBL; M64849; AAA37485.1; -; Genomic_DNA.
DR   EMBL; M64844; AAA37485.1; JOINED; Genomic_DNA.
DR   EMBL; M64845; AAA37485.1; JOINED; Genomic_DNA.
DR   EMBL; M64846; AAA37485.1; JOINED; Genomic_DNA.
DR   EMBL; M64847; AAA37485.1; JOINED; Genomic_DNA.
DR   EMBL; M64848; AAA37485.1; JOINED; Genomic_DNA.
DR   EMBL; BC053430; AAH53430.1; -; mRNA.
DR   EMBL; BC064056; AAH64056.1; -; mRNA.
DR   CCDS; CCDS27656.1; -.
DR   PIR; A39073; PFMSGB.
DR   RefSeq; NP_035187.2; NM_011057.3.
DR   UniGene; Mm.144089; -.
DR   PDB; 2DZ4; Model; -; A=90-185.
DR   PDB; 2DZ5; Model; -; A=90-185.
DR   PDBsum; 2DZ4; -.
DR   PDBsum; 2DZ5; -.
DR   ProteinModelPortal; P31240; -.
DR   SMR; P31240; 25-182.
DR   IntAct; P31240; 1.
DR   STRING; 10090.ENSMUSP00000000500; -.
DR   PhosphoSite; P31240; -.
DR   MaxQB; P31240; -.
DR   PaxDb; P31240; -.
DR   PRIDE; P31240; -.
DR   GeneID; 18591; -.
DR   KEGG; mmu:18591; -.
DR   UCSC; uc007wuz.1; mouse.
DR   CTD; 5155; -.
DR   MGI; MGI:97528; Pdgfb.
DR   eggNOG; ENOG410IJ45; Eukaryota.
DR   eggNOG; ENOG410XWTB; LUCA.
DR   HOGENOM; HOG000286027; -.
DR   HOVERGEN; HBG053546; -.
DR   InParanoid; P31240; -.
DR   KO; K17386; -.
DR   OrthoDB; EOG78H3VV; -.
DR   PhylomeDB; P31240; -.
DR   TreeFam; TF319554; -.
DR   NextBio; 294476; -.
DR   PRO; PR:P31240; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; P31240; -.
DR   CleanEx; MM_PDGFB; -.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0042056; F:chemoattractant activity; ISO:MGI.
DR   GO; GO:0005518; F:collagen binding; ISO:MGI.
DR   GO; GO:0008083; F:growth factor activity; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; ISO:MGI.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0016176; F:superoxide-generating NADPH oxidase activator activity; ISS:UniProtKB.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:MGI.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; ISS:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; IEP:UniProtKB.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IDA:MGI.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0060947; P:cardiac vascular smooth muscle cell differentiation; TAS:DFLAT.
DR   GO; GO:0060326; P:cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0030031; P:cell projection assembly; IDA:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISO:MGI.
DR   GO; GO:0071506; P:cellular response to mycophenolic acid; ISS:UniProtKB.
DR   GO; GO:0001892; P:embryonic placenta development; IMP:UniProtKB.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IMP:MGI.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IMP:MGI.
DR   GO; GO:0021782; P:glial cell development; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0072264; P:metanephric glomerular endothelium development; IEP:UniProtKB.
DR   GO; GO:0072255; P:metanephric glomerular mesangial cell development; IMP:UniProtKB.
DR   GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; IMP:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IGI:MGI.
DR   GO; GO:0010512; P:negative regulation of phosphatidylinositol biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0010544; P:negative regulation of platelet activation; ISS:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; ISO:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045908; P:negative regulation of vasodilation; TAS:DFLAT.
DR   GO; GO:0016322; P:neuron remodeling; IMP:MGI.
DR   GO; GO:0038001; P:paracrine signaling; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050918; P:positive chemotaxis; ISO:MGI.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IGI:MGI.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0045740; P:positive regulation of DNA replication; ISS:UniProtKB.
DR   GO; GO:0038033; P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IGI:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; IMP:UniProtKB.
DR   GO; GO:0072126; P:positive regulation of glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:1900127; P:positive regulation of hyaluronan biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:2000591; P:positive regulation of metanephric mesenchymal cell migration; ISO:MGI.
DR   GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045977; P:positive regulation of mitotic cell cycle, embryonic; IGI:MGI.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; TAS:DFLAT.
DR   GO; GO:0070528; P:protein kinase C signaling; ISO:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0009611; P:response to wounding; ISS:UniProtKB.
DR   GO; GO:0060041; P:retina development in camera-type eye; IMP:MGI.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; IMP:MGI.
DR   GO; GO:0006929; P:substrate-dependent cell migration; IDA:MGI.
DR   GO; GO:0007416; P:synapse assembly; IMP:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   Gene3D; 2.10.90.10; -; 1.
DR   InterPro; IPR029034; Cystine-knot_cytokine.
DR   InterPro; IPR023581; PD_growth_factor_CS.
DR   InterPro; IPR000072; PDGF/VEGF_dom.
DR   InterPro; IPR006782; PDGF_N.
DR   Pfam; PF00341; PDGF; 1.
DR   Pfam; PF04692; PDGF_N; 1.
DR   SMART; SM00141; PDGF; 1.
DR   SUPFAM; SSF57501; SSF57501; 1.
DR   PROSITE; PS00249; PDGF_1; 1.
DR   PROSITE; PS50278; PDGF_2; 1.
PE   2: Evidence at transcript level;
KW   3D-structure; Cleavage on pair of basic residues; Complete proteome;
KW   Developmental protein; Disulfide bond; Glycoprotein; Growth factor;
KW   Mitogen; Proto-oncogene; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     20       {ECO:0000250}.
FT   PROPEP       21     81       Removed in mature form. {ECO:0000250}.
FT                                /FTId=PRO_0000023374.
FT   CHAIN        82    190       Platelet-derived growth factor subunit B.
FT                                /FTId=PRO_0000023375.
FT   PROPEP      191    241       Removed in mature form. {ECO:0000250}.
FT                                /FTId=PRO_0000023376.
FT   SITE        108    108       Involved in receptor binding.
FT   SITE        111    111       Involved in receptor binding.
FT   CARBOHYD     63     63       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     97    141       {ECO:0000250}.
FT   DISULFID    124    124       Interchain. {ECO:0000250}.
FT   DISULFID    130    178       {ECO:0000250}.
FT   DISULFID    133    133       Interchain. {ECO:0000250}.
FT   DISULFID    134    180       {ECO:0000250}.
FT   CONFLICT    183    183       I -> V (in Ref. 2; AAH53430/AAH64056).
FT                                {ECO:0000305}.
SQ   SEQUENCE   241 AA;  27382 MW;  3C5EB7A2DAD64178 CRC64;
     MNRCWALFLP LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRLLHR DSVDEDGAEL
     DLNMTRAHSG VELESSSRGR RSLGSLAAAE PAVIAECKTR TEVFQISRNL IDRTNANFLV
     WPPCVEVQRC SGCCNNRNVQ CRASQVQMRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC
     ETIVTPRPVT RSPGTSREQR AKTPQARVTI RTVRIRRPPK GKHRKFKHTH DKAALKETLG
     A
//
ID   PLMN_HUMAN              Reviewed;         810 AA.
AC   P00747; Q15146; Q5TEH4; Q6PA00;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 2.
DT   17-FEB-2016, entry version 210.
DE   RecName: Full=Plasminogen;
DE            EC=3.4.21.7;
DE   Contains:
DE     RecName: Full=Plasmin heavy chain A;
DE   Contains:
DE     RecName: Full=Activation peptide;
DE   Contains:
DE     RecName: Full=Angiostatin;
DE   Contains:
DE     RecName: Full=Plasmin heavy chain A, short form;
DE   Contains:
DE     RecName: Full=Plasmin light chain B;
DE   Flags: Precursor;
GN   Name=PLG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASN-472.
RX   PubMed=2318848;
RA   Petersen T.E., Martzen M.R., Ichinose A., Davie E.W.;
RT   "Characterization of the gene for human plasminogen, a key proenzyme
RT   in the fibrinolytic system.";
RL   J. Biol. Chem. 265:6104-6111(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3030813; DOI=10.1016/0014-5793(87)81501-6;
RA   Forsgren M., Raden B., Israelsson M., Larsson K., Heden L.-O.;
RT   "Molecular cloning and characterization of a full-length cDNA clone
RT   for human plasminogen.";
RL   FEBS Lett. 213:254-260(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RA   Browne M.J., Chapman C.G., Dodd I., Carey J.E., Lawrence G.M.P.,
RA   Mitchell D., Robinson J.H.;
RT   "Expression of recombinant human plasminogen and aglycoplasminogen in
RT   HeLa cells.";
RL   Submitted (OCT-1991) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-57; GLN-133;
RP   HIS-261; TRP-408; ASN-472; VAL-494 AND TRP-523.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASP-676.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 20-810, AND VARIANT ASN-472.
RA   Sottrup-Jensen L., Petersen T.E., Magnusson S.;
RL   Submitted (JUL-1977) to the PIR data bank.
RN   [8]
RP   PROTEIN SEQUENCE OF 20-100.
RX   PubMed=122932; DOI=10.1111/j.1432-1033.1975.tb09887.x;
RA   Wiman B., Wallen P.;
RT   "Structural relationship between 'glutamic acid' and 'lysine' forms of
RT   human plasminogen and their interaction with the NH2-terminal
RT   activation peptide as studied by affinity chromatography.";
RL   Eur. J. Biochem. 50:489-494(1975).
RN   [9]
RP   PROTEIN SEQUENCE OF 95-580; 581-626; 657-700 AND 732-810, AND VARIANT
RP   ASN-472.
RA   Sottrup-Jensen L., Claeys H., Zajdel M., Petersen T.E., Magnusson S.;
RT   "The primary structure of human plasminogen.";
RL   (In) Davidson J.F., Rowan R.M., Samama M.M., Desnoyers P.C. (eds.);
RL   Progress in chemical fibrinolysis and thrombolysis, pp.3:191-209,
RL   Raven Press, New York (1978).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-810.
RX   PubMed=6148961; DOI=10.1021/bi00313a035;
RA   Malinowski D.P., Sadler J.E., Davie E.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for
RT   human and bovine plasminogen.";
RL   Biochemistry 23:4243-4250(1984).
RN   [11]
RP   PROTEIN SEQUENCE OF 483-604.
RX   PubMed=126863; DOI=10.1111/j.1432-1033.1975.tb02403.x;
RA   Wiman B., Wallen P.;
RT   "Amino-acid sequence of the cyanogen-bromide fragment from human
RT   plasminogen that forms the linkage between the plasmin chains.";
RL   Eur. J. Biochem. 58:539-547(1975).
RN   [12]
RP   PROTEIN SEQUENCE OF 581-810.
RX   PubMed=142009; DOI=10.1111/j.1432-1033.1977.tb11578.x;
RA   Wiman B.;
RT   "Primary structure of the B-chain of human plasmin.";
RL   Eur. J. Biochem. 76:129-137(1977).
RN   [13]
RP   ACTIVE SITE.
RX   PubMed=4694729;
RA   Robbins K.C., Bernabe P., Arzadon L., Summaria L.;
RT   "The primary structure of human plasminogen. II. The histidine loop of
RT   human plasmin: light (B) chain active center histidine sequence.";
RL   J. Biol. Chem. 248:1631-1633(1973).
RN   [14]
RP   ACTIVE SITE.
RX   PubMed=4240117;
RA   Groskopf W.R., Summaria L., Robbins K.C.;
RT   "Studies on the active center of human plasmin. Partial amino acid
RT   sequence of a peptide containing the active center serine residue.";
RL   J. Biol. Chem. 244:3590-3597(1969).
RN   [15]
RP   OMEGA-AMINOCARBOXYLIC ACID-BINDING SITES.
RX   PubMed=6919539;
RA   Trexler M., Vali Z., Patthy L.;
RT   "Structure of the omega-aminocarboxylic acid-binding sites of human
RT   plasminogen. Arginine 70 and aspartic acid 56 are essential for
RT   binding of ligand by kringle 4.";
RL   J. Biol. Chem. 257:7401-7406(1982).
RN   [16]
RP   FIBRIN AND OMEGA-AMINOCARBOXYLIC ACID BINDING SITES.
RX   PubMed=6094526;
RA   Vali Z., Patthy L.;
RT   "The fibrin-binding site of human plasminogen. Arginines 32 and 34 are
RT   essential for fibrin affinity of the kringle 1 domain.";
RL   J. Biol. Chem. 259:13690-13694(1984).
RN   [17]
RP   PHOSPHORYLATION AT SER-597.
RX   PubMed=9201958; DOI=10.1021/bi970328d;
RA   Wang H., Prorok M., Bretthauer R.K., Castellino F.J.;
RT   "Serine-578 is a major phosphorylation locus in human plasma
RT   plasminogen.";
RL   Biochemistry 36:8100-8106(1997).
RN   [18]
RP   GLYCOSYLATION AT SER-268; ASN-308 AND THR-365, AND STRUCTURE OF
RP   CARBOHYDRATES.
RX   PubMed=3356193; DOI=10.1111/j.1432-1033.1988.tb13966.x;
RA   Marti T., Schaller J., Rickli E.E., Schmid K., Kamerling J.P.,
RA   Gerwig G.J., van Halbeek H., Vliegenthart J.F.G.;
RT   "The N- and O-linked carbohydrate chains of human, bovine and porcine
RT   plasminogen. Species specificity in relation to sialylation and
RT   fucosylation patterns.";
RL   Eur. J. Biochem. 173:57-63(1988).
RN   [19]
RP   INTERACTION WITH HRG.
RX   PubMed=9102401; DOI=10.1074/jbc.272.9.5718;
RA   Borza D.B., Morgan W.T.;
RT   "Acceleration of plasminogen activation by tissue plasminogen
RT   activator on surface-bound histidine-proline-rich glycoprotein.";
RL   J. Biol. Chem. 272:5718-5726(1997).
RN   [20]
RP   GLYCOSYLATION AT SER-268.
RX   PubMed=9054441; DOI=10.1074/jbc.272.11.7408;
RA   Pirie-Shepherd S.R., Stevens R.D., Andon N.L., Enghild J.J.,
RA   Pizzo S.V.;
RT   "Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of
RT   human plasminogen 2.";
RL   J. Biol. Chem. 272:7408-7411(1997).
RN   [21]
RP   CHARACTERIZATION OF ANGIOSTATIN, AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=7525077; DOI=10.1016/0092-8674(94)90200-3;
RA   O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A.,
RA   Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J.;
RT   "Angiostatin: a novel angiogenesis inhibitor that mediates the
RT   suppression of metastases by a Lewis lung carcinoma.";
RL   Cell 79:315-328(1994).
RN   [22]
RP   CHARACTERIZATION OF ANGIOSTATIN.
RX   PubMed=9102221;
RA   Sim B.K., O'Reilly M.S., Liang H., Fortier A.H., He W., Madsen J.W.,
RA   Lapcevich R., Nacy C.A.;
RT   "A recombinant human angiostatin protein inhibits experimental primary
RT   and metastatic cancer.";
RL   Cancer Res. 57:1329-1334(1997).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=9548733; DOI=10.1021/bi9731798;
RA   Lijnen H.R., Ugwu F., Bini A., Collen D.;
RT   "Generation of an angiostatin-like fragment from plasminogen by
RT   stromelysin-1 (MMP-3).";
RL   Biochemistry 37:4699-4702(1998).
RN   [24]
RP   INTERACTION WITH ATP5A1, AND SUBCELLULAR LOCATION.
RX   PubMed=10077593; DOI=10.1073/pnas.96.6.2811;
RA   Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P.,
RA   Everitt L., Hubchak S., Schnaper H.W., Pizzo S.V.;
RT   "Angiostatin binds ATP synthase on the surface of human endothelial
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2811-2816(1999).
RN   [25]
RP   INTERACTION WITH CSPG4, AND DOMAIN.
RX   PubMed=10889192; DOI=10.1074/jbc.M002290200;
RA   Goretzki L., Lombardo C.R., Stallcup W.B.;
RT   "Binding of the NG2 proteoglycan to kringle domains modulates the
RT   functional properties of angiostatin and plasmin(ogen).";
RL   J. Biol. Chem. 275:28625-28633(2000).
RN   [26]
RP   PROTEOLYTIC PROCESSING, ENZYME REGULATION, SUBCELLULAR LOCATION,
RP   FUNCTION OF PLASMIN, AND MUTAGENESIS OF SER-741.
RX   PubMed=14699093; DOI=10.1074/jbc.M310964200;
RA   Rossignol P., Ho-Tin-Noe B., Vranckx R., Bouton M.C., Meilhac O.,
RA   Lijnen H.R., Guillin M.C., Michel J.B., Angles-Cano E.;
RT   "Protease nexin-1 inhibits plasminogen activation-induced apoptosis of
RT   adherent cells.";
RL   J. Biol. Chem. 279:10346-10356(2004).
RN   [27]
RP   INTERACTION WITH AMOT.
RX   PubMed=16043488; DOI=10.1074/jbc.M503915200;
RA   Bratt A., Birot O., Sinha I., Veitonmaeki N., Aase K., Ernkvist M.,
RA   Holmgren L.;
RT   "Angiomotin regulates endothelial cell-cell junctions and cell
RT   motility.";
RL   J. Biol. Chem. 280:34859-34869(2005).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-308.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [29]
RP   CATALYTIC ACTIVITY.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [30]
RP   INTERACTION WITH HRG.
RX   PubMed=19712047; DOI=10.1042/BJ20090794;
RA   Poon I.K., Olsson A.K., Hulett M.D., Parish C.R.;
RT   "Regulation of histidine-rich glycoprotein (HRG) function via plasmin-
RT   mediated proteolytic cleavage.";
RL   Biochem. J. 424:27-37(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 374-461.
RX   PubMed=1657148; DOI=10.1021/bi00107a029;
RA   Mulichak A.M., Tulinsky A., Ravichandran K.G.;
RT   "Crystal and molecular structure of human plasminogen kringle 4
RT   refined at 1.9-A resolution.";
RL   Biochemistry 30:10576-10588(1991).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 374-461.
RX   PubMed=1657149; DOI=10.1021/bi00107a030;
RA   Wu T.-P., Padmanabhan K., Tulinsky A., Mulichak A.M.;
RT   "The refined structure of the epsilon-aminocaproic acid complex of
RT   human plasminogen kringle 4.";
RL   Biochemistry 30:10589-10594(1991).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 101-181.
RX   PubMed=8054447;
RA   Wu T.-P., Padmanabhan K.P., Tulinsky A.;
RT   "The structure of recombinant plasminogen kringle 1 and the fibrin
RT   binding site.";
RL   Blood Coagul. Fibrinolysis 5:157-166(1994).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 102-181.
RX   PubMed=8611560; DOI=10.1021/bi9521351;
RA   Mathews I.I., Vanderhoff-Hanaver P., Castellino F.J., Tulinsky A.;
RT   "Crystal structures of the recombinant kringle 1 domain of human
RT   plasminogen in complexes with the ligands epsilon-aminocaproic acid
RT   and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.";
RL   Biochemistry 35:2567-2576(1996).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 376-454.
RX   PubMed=15299951; DOI=10.1107/S0907444996012267;
RA   Stec B., Yamano A., Whitlow M., Teeter M.M.;
RT   "Structure of human plasminogen kringle 4 at 1.68 Angstrom and 277 K.
RT   A possible structural role of disordered residues.";
RL   Acta Crystallogr. D 53:169-178(1997).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 561-810, AND DISULFIDE
RP   BONDS.
RX   PubMed=9783753; DOI=10.1038/2359;
RA   Parry M.A., Fernandez-Catalan C., Bergner A., Huber R., Hopfner K.P.,
RA   Schlott B., Guehrs K.H., Bode W.;
RT   "The ternary microplasmin-staphylokinase-microplasmin complex is a
RT   proteinase-cofactor-substrate complex in action.";
RL   Nat. Struct. Biol. 5:917-923(1998).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 480-563.
RX   PubMed=9521645; DOI=10.1021/bi972284e;
RA   Chang Y., Mochalkin I., McCance S.G., Cheng B., Tulinsky A.,
RA   Castellino F.J.;
RT   "Structure and ligand binding determinants of the recombinant kringle
RT   5 domain of human plasminogen.";
RL   Biochemistry 37:3258-3271(1998).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 564-810, AND DISULFIDE BONDS.
RX   PubMed=10656799; DOI=10.1006/jmbi.1999.3397;
RA   Wang X., Terzyan S., Tang J., Loy J.A., Lin X., Zhang X.C.;
RT   "Human plasminogen catalytic domain undergoes an unusual
RT   conformational change upon activation.";
RL   J. Mol. Biol. 295:903-914(2000).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 183-262.
RX   PubMed=11350170; DOI=10.1006/jmbi.2001.4646;
RA   Rios-Steiner J.L., Schenone M., Mochalkin I., Tulinsky A.,
RA   Castellino F.J.;
RT   "Structure and binding determinants of the recombinant kringle-2
RT   domain of human plasminogen to an internal peptide from a group A
RT   Streptococcal surface protein.";
RL   J. Mol. Biol. 308:705-719(2001).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 100-352, AND DISULFIDE
RP   BONDS.
RX   PubMed=12054798; DOI=10.1016/S0022-2836(02)00211-5;
RA   Abad M.C., Arni R.K., Grella D.K., Castellino F.J., Tulinsky A.,
RA   Geiger J.H.;
RT   "The X-ray crystallographic structure of the angiogenesis inhibitor
RT   angiostatin.";
RL   J. Mol. Biol. 318:1009-1017(2002).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 562-810.
RX   PubMed=12456874; DOI=10.1093/protein/15.9.753;
RA   Wakeham N., Terzyan S., Zhai P., Loy J.A., Tang J., Zhang X.C.;
RT   "Effects of deletion of streptokinase residues 48-59 on plasminogen
RT   activation.";
RL   Protein Eng. 15:753-761(2002).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 564-810.
RX   PubMed=15211511; DOI=10.1002/prot.20070;
RA   Terzyan S., Wakeham N., Zhai P., Rodgers K., Zhang X.C.;
RT   "Characterization of Lys-698-to-Met substitution in human plasminogen
RT   catalytic domain.";
RL   Proteins 56:277-284(2004).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.78 ANGSTROMS) OF 564-810 IN COMPLEX WITH THE
RP   SNAKE VENOM PROTEASE INHIBITOR TEXTILININ-1, AND DISULFIDE BOND.
RX   PubMed=23335990; DOI=10.1371/journal.pone.0054104;
RA   Millers E.K., Johnson L.A., Birrell G.W., Masci P.P., Lavin M.F.,
RA   de Jersey J., Guddat L.W.;
RT   "The structure of human microplasmin in complex with textilinin-1, an
RT   aprotinin-like inhibitor from the Australian brown snake.";
RL   PLoS ONE 8:E54104-E54104(2013).
RN   [45]
RP   STRUCTURE BY NMR OF 374-461.
RX   PubMed=2157850; DOI=10.1016/0022-2836(90)90330-O;
RA   Atkinson R.A., Williams R.J.P.;
RT   "Solution structure of the kringle 4 domain from human plasminogen by
RT   1H nuclear magnetic resonance spectroscopy and distance geometry.";
RL   J. Mol. Biol. 212:541-552(1990).
RN   [46]
RP   STRUCTURE BY NMR OF 96-184.
RX   PubMed=8181475; DOI=10.1111/j.1432-1033.1994.tb18808.x;
RA   Rejante M.R., Llinas M.;
RT   "1H-NMR assignments and secondary structure of human plasminogen
RT   kringle 1.";
RL   Eur. J. Biochem. 221:927-937(1994).
RN   [47]
RP   STRUCTURE BY NMR OF 96-184.
RX   PubMed=8181476; DOI=10.1111/j.1432-1033.1994.tb18809.x;
RA   Rejante M.R., Llinas M.;
RT   "Solution structure of the epsilon-aminohexanoic acid complex of human
RT   plasminogen kringle 1.";
RL   Eur. J. Biochem. 221:939-949(1994).
RN   [48]
RP   STRUCTURE BY NMR OF 183-354.
RX   PubMed=8652577; DOI=10.1021/bi9520949;
RA   Soehndel S., Hu C.-K., Marti D., Affolter M., Schaller J., Llinas M.,
RA   Rickli E.E.;
RT   "Recombinant gene expression and 1H NMR characteristics of the kringle
RT   (2 + 3) supermodule: spectroscopic/functional individuality of
RT   plasminogen kringle domains.";
RL   Biochemistry 35:2357-2364(1996).
RN   [49]
RP   STRUCTURE BY NMR OF 183-263.
RX   PubMed=9305949; DOI=10.1021/bi971316v;
RA   Marti D.N., Hu C.K., An S.S., von Haller P., Schaller J., Llinas M.;
RT   "Ligand preferences of kringle 2 and homologous domains of human
RT   plasminogen: canvassing weak, intermediate, and high-affinity binding
RT   sites by 1H-NMR.";
RL   Biochemistry 36:11591-11604(1997).
RN   [50]
RP   VARIANTS PLGD PHE-374 AND THR-620.
RX   PubMed=1986355; DOI=10.1073/pnas.88.1.115;
RA   Ichinose A., Espling E.S., Takamatsu J., Saito H., Shinmyozu K.,
RA   Maruyama I., Petersen T.E., Davie E.W.;
RT   "Two types of abnormal genes for plasminogen in families with a
RT   predisposition for thrombosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:115-119(1991).
RN   [51]
RP   ERRATUM.
RA   Ichinose A., Espling E.S., Takamatsu J., Saito H., Shinmyozu K.,
RA   Maruyama I., Petersen T.E., Davie E.W.;
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2067-2067(1991).
RN   [52]
RP   VARIANT PLGD PRO-591.
RX   PubMed=8392398;
RA   Azuma H., Uno Y., Shigekiyo T., Saito S.;
RT   "Congenital plasminogen deficiency caused by a Ser-572 to Pro
RT   mutation.";
RL   Blood 82:475-480(1993).
RN   [53]
RP   VARIANT PLGD THR-620.
RX   PubMed=6216475; DOI=10.1073/pnas.79.20.6132;
RA   Miyata T., Iwanaga S., Sakata Y., Aoki N.;
RT   "Plasminogen Tochigi: inactive plasmin resulting from replacement of
RT   alanine-600 by threonine in the active site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:6132-6136(1982).
RN   [54]
RP   VARIANT PLGD THR-620.
RX   PubMed=6238949;
RA   Miyata T., Iwanaga S., Sakata Y., Aoki N., Takamatsu J., Kamiya T.;
RT   "Plasminogens Tochigi II and Nagoya: two additional molecular defects
RT   with Ala-600-->Thr replacement found in plasmin light chain
RT   variants.";
RL   J. Biochem. 96:277-287(1984).
RN   [55]
RP   VARIANT PLGD THR-620.
RX   PubMed=1427790; DOI=10.1007/BF00210737;
RA   Kikuchi S., Yamanouchi Y., Li L., Kobayashi K., Ijima H., Miyazaki R.,
RA   Tsuchiya S., Hamaguchi H.;
RT   "Plasminogen with type-I mutation is polymorphic in the Japanese
RT   population.";
RL   Hum. Genet. 90:7-11(1992).
RN   [56]
RP   VARIANT PLGD HIS-235.
RX   PubMed=9242524;
RA   Schuster V., Mingers A.-M., Seidenspinner S., Nuessgens Z., Pukrop T.,
RA   Kreth H.W.;
RT   "Homozygous mutations in the plasminogen gene of two unrelated girls
RT   with ligneous conjunctivitis.";
RL   Blood 90:958-966(1997).
RN   [57]
RP   VARIANT PLGD ARG-751.
RX   PubMed=9858247; DOI=10.1046/j.1365-2141.1998.01074.x;
RA   Higuchi Y., Furihata K., Ueno I., Ishikawa S., Okumura N., Tozuka M.,
RA   Sakurai N.;
RT   "Plasminogen Kanagawa-I, a novel missense mutation, is caused by the
RT   amino acid substitution G732R.";
RL   Br. J. Haematol. 103:867-870(1998).
RN   [58]
RP   VARIANTS PLGD GLU-38; PRO-147 AND HIS-532.
RX   PubMed=10233898;
RA   Schuster V., Seidenspinner S., Zeitler P., Escher C., Pleyer U.,
RA   Bernauer W., Stiehm E.R., Isenberg S., Seregard S., Olsson T.,
RA   Mingers A.-M., Schambeck C., Kreth H.W.;
RT   "Compound-heterozygous mutations in the plasminogen gene predispose to
RT   the development of ligneous conjunctivitis.";
RL   Blood 93:3457-3466(1999).
CC   -!- FUNCTION: Plasmin dissolves the fibrin of blood clots and acts as
CC       a proteolytic factor in a variety of other processes including
CC       embryonic development, tissue remodeling, tumor invasion, and
CC       inflammation. In ovulation, weakens the walls of the Graafian
CC       follicle. It activates the urokinase-type plasminogen activator,
CC       collagenases and several complement zymogens, such as C1 and C5.
CC       Cleavage of fibronectin and laminin leads to cell detachment and
CC       apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand
CC       factor. Its role in tissue remodeling and tumor invasion may be
CC       modulated by CSPG4. Binds to cells. {ECO:0000269|PubMed:14699093}.
CC   -!- FUNCTION: Angiostatin is an angiogenesis inhibitor that blocks
CC       neovascularization and growth of experimental primary and
CC       metastatic tumors in vivo. {ECO:0000269|PubMed:14699093}.
CC   -!- CATALYTIC ACTIVITY: Preferential cleavage: Lys-|-Xaa > Arg-|-Xaa;
CC       higher selectivity than trypsin. Converts fibrin into soluble
CC       products. {ECO:0000269|PubMed:2143188}.
CC   -!- ENZYME REGULATION: Converted into plasmin by plasminogen
CC       activators, both plasminogen and its activator being bound to
CC       fibrin. Activated with catalytic amounts of streptokinase. Plasmin
CC       activity inhibited by SERPINE2. {ECO:0000269|PubMed:14699093}.
CC   -!- SUBUNIT: Interacts (both mature PLG and the angiostatin peptide)
CC       with CSPG4 and AMOT. Interacts (via the Kringle domains) with HRG;
CC       the interaction tethers PLG to the cell surface and enhances its
CC       activation (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q6V4L1:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984250;
CC       Q6V4L4:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984286;
CC       Q6V4L5:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984118;
CC       Q6V4L9:- (xeno); NbExp=2; IntAct=EBI-999394, EBI-984197;
CC       P02749:APOH; NbExp=2; IntAct=EBI-999394, EBI-2114682;
CC       Q99SU7:sak (xeno); NbExp=7; IntAct=EBI-999394, EBI-7689378;
CC       P00779:skc (xeno); NbExp=2; IntAct=EBI-999394, EBI-1035089;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10077593,
CC       ECO:0000269|PubMed:14699093}. Note=Locates to the cell surface
CC       where it is proteolytically cleaved to produce the active plasmin.
CC       Interaction with HRG tethers it to the cell surface.
CC   -!- TISSUE SPECIFICITY: Present in plasma and many other extracellular
CC       fluids. It is synthesized in the liver.
CC   -!- DOMAIN: Kringle domains mediate interaction with CSPG4.
CC       {ECO:0000269|PubMed:10889192}.
CC   -!- PTM: N-linked glycan contains N-acetyllactosamine and sialic acid.
CC       O-linked glycans consist of Gal-GalNAc disaccharide modified with
CC       up to 2 sialic acid residues (microheterogeneity).
CC       {ECO:0000269|PubMed:18780401, ECO:0000269|PubMed:3356193,
CC       ECO:0000269|PubMed:9054441}.
CC   -!- PTM: In the presence of the inhibitor, the activation involves
CC       only cleavage after Arg-580, yielding two chains held together by
CC       two disulfide bonds. In the absence of the inhibitor, the
CC       activation involves additionally the removal of the activation
CC       peptide. {ECO:0000269|PubMed:14699093,
CC       ECO:0000269|PubMed:9548733}.
CC   -!- DISEASE: Plasminogen deficiency (PLGD) [MIM:217090]: A disorder
CC       characterized by decreased serum plasminogen activity. Two forms
CC       of the disorder are distinguished: type 1 deficiency is
CC       additionally characterized by decreased plasminogen antigen levels
CC       and clinical symptoms, whereas type 2 deficiency, also known as
CC       dysplasminogenemia, is characterized by normal, or slightly
CC       reduced antigen levels, and absence of clinical manifestations.
CC       Plasminogen deficiency type 1 results in markedly impaired
CC       extracellular fibrinolysis and chronic mucosal pseudomembranous
CC       lesions due to subepithelial fibrin deposition and inflammation.
CC       The most common clinical manifestation of type 1 deficiency is
CC       ligneous conjunctivitis in which pseudomembranes formation on the
CC       palpebral surfaces of the eye progresses to white, yellow-white,
CC       or red thick masses with a wood-like consistency that replace the
CC       normal mucosa. {ECO:0000269|PubMed:10233898,
CC       ECO:0000269|PubMed:1427790, ECO:0000269|PubMed:1986355,
CC       ECO:0000269|PubMed:6216475, ECO:0000269|PubMed:6238949,
CC       ECO:0000269|PubMed:8392398, ECO:0000269|PubMed:9242524,
CC       ECO:0000269|PubMed:9858247}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Plasmin is inactivated by alpha-2-antiplasmin
CC       immediately after dissociation from the clot.
CC   -!- SIMILARITY: Belongs to the peptidase S1 family. Plasminogen
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00274}.
CC   -!- SIMILARITY: Contains 5 kringle domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00121}.
CC   -!- SIMILARITY: Contains 1 PAN domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00315}.
CC   -!- SIMILARITY: Contains 1 peptidase S1 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00274}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Plasmin entry;
CC       URL="https://en.wikipedia.org/wiki/Plasmin";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/plg/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34276; AAA60113.1; -; Genomic_DNA.
DR   EMBL; M33272; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33274; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33275; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33278; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33279; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33280; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33282; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33283; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33284; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33285; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33286; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33287; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33288; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33289; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M33290; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34272; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34273; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; M34275; AAA60113.1; JOINED; Genomic_DNA.
DR   EMBL; X05199; CAA28831.1; -; mRNA.
DR   EMBL; M74220; AAA36451.1; -; mRNA.
DR   EMBL; AY192161; AAN85555.1; -; Genomic_DNA.
DR   EMBL; AL109933; CAI22908.1; -; Genomic_DNA.
DR   EMBL; BC060513; AAH60513.1; -; mRNA.
DR   EMBL; K02922; AAA60124.1; -; mRNA.
DR   CCDS; CCDS5279.1; -.
DR   PIR; A35229; PLHU.
DR   RefSeq; NP_000292.1; NM_000301.3.
DR   UniGene; Hs.143436; -.
DR   PDB; 1B2I; NMR; -; A=181-263.
DR   PDB; 1BML; X-ray; 2.90 A; A/B=561-810.
DR   PDB; 1BUI; X-ray; 2.65 A; A/B=561-810.
DR   PDB; 1CEA; X-ray; 2.06 A; A/B=100-187.
DR   PDB; 1CEB; X-ray; 2.07 A; A/B=100-187.
DR   PDB; 1DDJ; X-ray; 2.00 A; A/B/C/D=564-810.
DR   PDB; 1HPJ; NMR; -; A=103-181.
DR   PDB; 1HPK; NMR; -; A=103-181.
DR   PDB; 1I5K; X-ray; 2.70 A; A/B=184-262.
DR   PDB; 1KI0; X-ray; 1.75 A; A=100-352.
DR   PDB; 1KRN; X-ray; 1.67 A; A=374-461.
DR   PDB; 1L4D; X-ray; 2.30 A; A=562-810.
DR   PDB; 1L4Z; X-ray; 2.80 A; A=563-810.
DR   PDB; 1PK4; X-ray; 1.90 A; A=376-454.
DR   PDB; 1PKR; X-ray; 2.48 A; A=101-181.
DR   PDB; 1PMK; X-ray; 2.25 A; A/B=374-461.
DR   PDB; 1QRZ; X-ray; 2.00 A; A/B/C/D=565-810.
DR   PDB; 1RJX; X-ray; 2.30 A; B=564-810.
DR   PDB; 2DOH; X-ray; 2.30 A; X=100-333.
DR   PDB; 2DOI; X-ray; 3.10 A; A/X=100-333.
DR   PDB; 2KNF; NMR; -; A=480-562.
DR   PDB; 2L0S; NMR; -; A=272-354.
DR   PDB; 2PK4; X-ray; 2.25 A; A=375-454.
DR   PDB; 3UIR; X-ray; 2.78 A; A/B=564-810.
DR   PDB; 4A5T; X-ray; 3.49 A; S=20-810.
DR   PDB; 4CIK; X-ray; 1.78 A; A=101-181.
DR   PDB; 4DCB; X-ray; 2.03 A; F=576-585.
DR   PDB; 4DUR; X-ray; 2.45 A; A/B=20-810.
DR   PDB; 4DUU; X-ray; 5.20 A; A=20-810.
DR   PDB; 5HPG; X-ray; 1.66 A; A/B=480-563.
DR   PDBsum; 1B2I; -.
DR   PDBsum; 1BML; -.
DR   PDBsum; 1BUI; -.
DR   PDBsum; 1CEA; -.
DR   PDBsum; 1CEB; -.
DR   PDBsum; 1DDJ; -.
DR   PDBsum; 1HPJ; -.
DR   PDBsum; 1HPK; -.
DR   PDBsum; 1I5K; -.
DR   PDBsum; 1KI0; -.
DR   PDBsum; 1KRN; -.
DR   PDBsum; 1L4D; -.
DR   PDBsum; 1L4Z; -.
DR   PDBsum; 1PK4; -.
DR   PDBsum; 1PKR; -.
DR   PDBsum; 1PMK; -.
DR   PDBsum; 1QRZ; -.
DR   PDBsum; 1RJX; -.
DR   PDBsum; 2DOH; -.
DR   PDBsum; 2DOI; -.
DR   PDBsum; 2KNF; -.
DR   PDBsum; 2L0S; -.
DR   PDBsum; 2PK4; -.
DR   PDBsum; 3UIR; -.
DR   PDBsum; 4A5T; -.
DR   PDBsum; 4CIK; -.
DR   PDBsum; 4DCB; -.
DR   PDBsum; 4DUR; -.
DR   PDBsum; 4DUU; -.
DR   PDBsum; 5HPG; -.
DR   DisProt; DP00191; -.
DR   ProteinModelPortal; P00747; -.
DR   SMR; P00747; 20-810.
DR   BioGrid; 111356; 35.
DR   IntAct; P00747; 30.
DR   STRING; 9606.ENSP00000308938; -.
DR   BindingDB; P00747; -.
DR   ChEMBL; CHEMBL1801; -.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB00513; Aminocaproic Acid.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB06692; Aprotinin.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00086; Streptokinase.
DR   DrugBank; DB00031; Tenecteplase.
DR   DrugBank; DB00302; Tranexamic Acid.
DR   DrugBank; DB00013; Urokinase.
DR   GuidetoPHARMACOLOGY; 2394; -.
DR   MEROPS; S01.233; -.
DR   iPTMnet; P00747; -.
DR   PhosphoSite; P00747; -.
DR   UniCarbKB; P00747; -.
DR   BioMuta; PLG; -.
DR   DMDM; 130316; -.
DR   SWISS-2DPAGE; P00747; -.
DR   MaxQB; P00747; -.
DR   PaxDb; P00747; -.
DR   PeptideAtlas; P00747; -.
DR   PRIDE; P00747; -.
DR   Ensembl; ENST00000308192; ENSP00000308938; ENSG00000122194.
DR   GeneID; 5340; -.
DR   KEGG; hsa:5340; -.
DR   UCSC; uc003qtm.4; human.
DR   CTD; 5340; -.
DR   GeneCards; PLG; -.
DR   HGNC; HGNC:9071; PLG.
DR   HPA; CAB000668; -.
DR   HPA; CAB016678; -.
DR   HPA; HPA021602; -.
DR   MalaCards; PLG; -.
DR   MIM; 173350; gene.
DR   MIM; 217090; phenotype.
DR   neXtProt; NX_P00747; -.
DR   Orphanet; 722; Hypoplasminogenemia.
DR   Orphanet; 97231; Ligneous conjunctivitis.
DR   PharmGKB; PA33405; -.
DR   eggNOG; ENOG410IDXR; Eukaryota.
DR   eggNOG; COG5640; LUCA.
DR   GeneTree; ENSGT00760000119133; -.
DR   HOGENOM; HOG000112892; -.
DR   HOVERGEN; HBG004381; -.
DR   InParanoid; P00747; -.
DR   KO; K01315; -.
DR   OMA; FPNKNLK; -.
DR   OrthoDB; EOG75B84T; -.
DR   PhylomeDB; P00747; -.
DR   TreeFam; TF329901; -.
DR   BioCyc; MetaCyc:HS04553-MONOMER; -.
DR   BRENDA; 3.4.21.7; 2681.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1592389; Activation of Matrix Metalloproteinases.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-75205; Dissolution of Fibrin Clot.
DR   SABIO-RK; P00747; -.
DR   ChiTaRS; PLG; human.
DR   EvolutionaryTrace; P00747; -.
DR   GeneWiki; Plasmin; -.
DR   GeneWiki; Plasminogen_activator; -.
DR   GenomeRNAi; 5340; -.
DR   NextBio; 20698; -.
DR   PMAP-CutDB; P00747; -.
DR   PRO; PR:P00747; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; P00747; -.
DR   CleanEx; HS_PLG; -.
DR   ExpressionAtlas; P00747; baseline and differential.
DR   Genevisible; P00747; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0031232; C:extrinsic component of external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:AgBase.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:0008236; F:serine-type peptidase activity; TAS:AgBase.
DR   GO; GO:0007596; P:blood coagulation; IMP:HGNC.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0022617; P:extracellular matrix disassembly; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; TAS:Reactome.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; TAS:BHF-UCL.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0051919; P:positive regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0048771; P:tissue remodeling; IEA:UniProtKB-KW.
DR   InterPro; IPR000001; Kringle.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR018056; Kringle_CS.
DR   InterPro; IPR003609; Pan_app.
DR   InterPro; IPR023317; Pept_S1A_plasmin.
DR   InterPro; IPR018114; Peptidase_S1_AS.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001314; Peptidase_S1A.
DR   InterPro; IPR001254; Trypsin_dom.
DR   Pfam; PF00051; Kringle; 5.
DR   Pfam; PF00024; PAN_1; 1.
DR   Pfam; PF00089; Trypsin; 1.
DR   PIRSF; PIRSF001150; Plasmin; 1.
DR   PRINTS; PR00722; CHYMOTRYPSIN.
DR   SMART; SM00130; KR; 5.
DR   SMART; SM00473; PAN_AP; 1.
DR   SMART; SM00020; Tryp_SPc; 1.
DR   SUPFAM; SSF50494; SSF50494; 1.
DR   SUPFAM; SSF57440; SSF57440; 5.
DR   PROSITE; PS00021; KRINGLE_1; 5.
DR   PROSITE; PS50070; KRINGLE_2; 5.
DR   PROSITE; PS50948; PAN; 1.
DR   PROSITE; PS50240; TRYPSIN_DOM; 1.
DR   PROSITE; PS00134; TRYPSIN_HIS; 1.
DR   PROSITE; PS00135; TRYPSIN_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Cleavage on pair of basic residues;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Fibrinolysis; Glycoprotein; Hemostasis; Hydrolase;
KW   Kringle; Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Repeat; Secreted; Serine protease; Signal; Thrombophilia;
KW   Tissue remodeling; Zymogen.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:122932,
FT                                ECO:0000269|Ref.7}.
FT   CHAIN        20    810       Plasminogen.
FT                                /FTId=PRO_0000028053.
FT   CHAIN        20    580       Plasmin heavy chain A.
FT                                /FTId=PRO_0000028054.
FT   PEPTIDE      20     97       Activation peptide.
FT                                /FTId=PRO_0000028055.
FT   CHAIN        79    466       Angiostatin.
FT                                /FTId=PRO_0000028057.
FT   CHAIN        98    580       Plasmin heavy chain A, short form.
FT                                /FTId=PRO_0000028056.
FT   CHAIN       581    810       Plasmin light chain B.
FT                                /FTId=PRO_0000028058.
FT   DOMAIN       20     98       PAN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00315}.
FT   DOMAIN      103    181       Kringle 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      184    262       Kringle 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      275    352       Kringle 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      377    454       Kringle 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      481    560       Kringle 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      581    808       Peptidase S1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00274}.
FT   ACT_SITE    622    622       Charge relay system.
FT   ACT_SITE    665    665       Charge relay system.
FT   ACT_SITE    760    760       Charge relay system.
FT   BINDING     134    134       Fibrin.
FT   BINDING     136    136       Fibrin.
FT   BINDING     136    136       Omega-aminocarboxylic acids.
FT   BINDING     158    158       Omega-aminocarboxylic acids.
FT   BINDING     172    172       Omega-aminocarboxylic acids.
FT   BINDING     432    432       Omega-aminocarboxylic acids.
FT   BINDING     445    445       Omega-aminocarboxylic acids.
FT   SITE         78     79       Cleavage; by stromelysin-1.
FT   SITE        466    467       Cleavage; by stromelysin-19.
FT   SITE        580    581       Cleavage; by plasminogen activator.
FT   MOD_RES     597    597       Phosphoserine.
FT                                {ECO:0000269|PubMed:9201958}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CARBOHYD    268    268       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:3356193,
FT                                ECO:0000269|PubMed:9054441}.
FT                                /FTId=CAR_000016.
FT   CARBOHYD    308    308       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:18780401,
FT                                ECO:0000269|PubMed:3356193}.
FT                                /FTId=CAR_000017.
FT   CARBOHYD    365    365       O-linked (GalNAc...).
FT                                {ECO:0000269|PubMed:3356193}.
FT                                /FTId=CAR_000018.
FT   DISULFID     49     73
FT   DISULFID     53     61
FT   DISULFID    103    181
FT   DISULFID    124    164
FT   DISULFID    152    176
FT   DISULFID    185    262
FT   DISULFID    188    316
FT   DISULFID    206    245
FT   DISULFID    234    257
FT   DISULFID    275    352
FT   DISULFID    296    335
FT   DISULFID    324    347
FT   DISULFID    377    454
FT   DISULFID    398    437
FT   DISULFID    426    449
FT   DISULFID    481    560
FT   DISULFID    502    543
FT   DISULFID    531    555
FT   DISULFID    567    685       Interchain (between A and B chains).
FT   DISULFID    577    585       Interchain (between A and B chains).
FT   DISULFID    607    623
FT   DISULFID    699    766
FT   DISULFID    729    745
FT   DISULFID    756    784
FT   VARIANT      38     38       K -> E (in PLGD; common mutation;
FT                                dbSNP:rs73015965).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018657.
FT   VARIANT      46     46       I -> R (in dbSNP:rs1049573).
FT                                /FTId=VAR_011779.
FT   VARIANT      57     57       E -> K (in dbSNP:rs4252070).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016287.
FT   VARIANT     133    133       H -> Q (in dbSNP:rs4252186).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016288.
FT   VARIANT     134    134       R -> K (in dbSNP:rs2817).
FT                                /FTId=VAR_033653.
FT   VARIANT     147    147       L -> P (in PLGD).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018658.
FT   VARIANT     235    235       R -> H (in PLGD; severe type 1
FT                                deficiency).
FT                                {ECO:0000269|PubMed:9242524}.
FT                                /FTId=VAR_018659.
FT   VARIANT     261    261       R -> H (in dbSNP:rs4252187).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016289.
FT   VARIANT     374    374       V -> F (in PLGD; Nagoya-1;
FT                                dbSNP:rs121918028).
FT                                {ECO:0000269|PubMed:1986355}.
FT                                /FTId=VAR_006627.
FT   VARIANT     408    408       R -> W (in dbSNP:rs4252119).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016290.
FT   VARIANT     453    453       K -> I (in dbSNP:rs1804181).
FT                                /FTId=VAR_011780.
FT   VARIANT     472    472       D -> N (in dbSNP:rs4252125).
FT                                {ECO:0000269|PubMed:2318848,
FT                                ECO:0000269|Ref.4, ECO:0000269|Ref.7,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_016291.
FT   VARIANT     494    494       A -> V (in dbSNP:rs4252128).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016292.
FT   VARIANT     523    523       R -> W (in dbSNP:rs4252129).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016293.
FT   VARIANT     532    532       R -> H (in PLGD).
FT                                {ECO:0000269|PubMed:10233898}.
FT                                /FTId=VAR_018660.
FT   VARIANT     591    591       S -> P (in PLGD; may be associated with
FT                                susceptibility to thrombosis).
FT                                {ECO:0000269|PubMed:8392398}.
FT                                /FTId=VAR_006628.
FT   VARIANT     620    620       A -> T (in PLGD; type 2 plasminogen
FT                                deficiency; decreased activity; Nagoya-2/
FT                                Tochigi/Kagoshima; may be associated with
FT                                susceptibility to thrombosis;
FT                                dbSNP:rs121918027).
FT                                {ECO:0000269|PubMed:1427790,
FT                                ECO:0000269|PubMed:1986355,
FT                                ECO:0000269|PubMed:6216475,
FT                                ECO:0000269|PubMed:6238949}.
FT                                /FTId=VAR_006629.
FT   VARIANT     676    676       V -> D (in dbSNP:rs17857492).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_031213.
FT   VARIANT     751    751       G -> R (in PLGD; Kanagawa-1; 50%
FT                                activity). {ECO:0000269|PubMed:9858247}.
FT                                /FTId=VAR_006630.
FT   MUTAGEN     741    741       S->A: Proteolytically cleaved, but
FT                                abolishes plasmin activity and cell
FT                                detachment.
FT                                {ECO:0000269|PubMed:14699093}.
FT   CONFLICT     50     50       A -> AQ (in Ref. 8; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     72     72       Q -> E (in Ref. 7; AA sequence and 8; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT     86     86       Missing (in Ref. 7; AA sequence and 8; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    361    361       Q -> E (in Ref. 7; AA sequence and 9; AA
FT                                sequence). {ECO:0000305}.
FT   CONFLICT    701    701       I -> V (in Ref. 3; AAA36451).
FT                                {ECO:0000305}.
FT   STRAND       25     33       {ECO:0000244|PDB:4DUR}.
FT   STRAND       36     42       {ECO:0000244|PDB:4DUR}.
FT   HELIX        46     55       {ECO:0000244|PDB:4DUR}.
FT   STRAND       57     59       {ECO:0000244|PDB:4DUR}.
FT   STRAND       63     67       {ECO:0000244|PDB:4DUR}.
FT   TURN         68     71       {ECO:0000244|PDB:4DUR}.
FT   STRAND       72     77       {ECO:0000244|PDB:4DUR}.
FT   TURN         80     82       {ECO:0000244|PDB:4DUR}.
FT   STRAND       85     96       {ECO:0000244|PDB:4DUR}.
FT   HELIX        97     99       {ECO:0000244|PDB:4DUR}.
FT   STRAND      102    104       {ECO:0000244|PDB:1KI0}.
FT   STRAND      105    110       {ECO:0000244|PDB:1HPJ}.
FT   HELIX       113    115       {ECO:0000244|PDB:1HPJ}.
FT   TURN        119    121       {ECO:0000244|PDB:1HPJ}.
FT   STRAND      131    133       {ECO:0000244|PDB:1KI0}.
FT   TURN        139    141       {ECO:0000244|PDB:1KI0}.
FT   TURN        143    146       {ECO:0000244|PDB:4CIK}.
FT   STRAND      148    150       {ECO:0000244|PDB:1HPJ}.
FT   STRAND      155    157       {ECO:0000244|PDB:1HPK}.
FT   STRAND      163    167       {ECO:0000244|PDB:1KI0}.
FT   STRAND      172    175       {ECO:0000244|PDB:1KI0}.
FT   STRAND      180    182       {ECO:0000244|PDB:2DOH}.
FT   STRAND      184    186       {ECO:0000244|PDB:1KI0}.
FT   STRAND      205    207       {ECO:0000244|PDB:1I5K}.
FT   STRAND      209    211       {ECO:0000244|PDB:1B2I}.
FT   STRAND      213    215       {ECO:0000244|PDB:1KI0}.
FT   TURN        221    223       {ECO:0000244|PDB:1KI0}.
FT   HELIX       225    227       {ECO:0000244|PDB:2DOH}.
FT   STRAND      237    239       {ECO:0000244|PDB:1KI0}.
FT   STRAND      244    248       {ECO:0000244|PDB:1KI0}.
FT   STRAND      253    256       {ECO:0000244|PDB:1KI0}.
FT   STRAND      273    276       {ECO:0000244|PDB:1KI0}.
FT   STRAND      281    283       {ECO:0000244|PDB:2L0S}.
FT   STRAND      291    293       {ECO:0000244|PDB:2L0S}.
FT   STRAND      295    297       {ECO:0000244|PDB:4DUR}.
FT   STRAND      303    305       {ECO:0000244|PDB:2L0S}.
FT   TURN        311    313       {ECO:0000244|PDB:1KI0}.
FT   HELIX       315    317       {ECO:0000244|PDB:1KI0}.
FT   STRAND      334    339       {ECO:0000244|PDB:1KI0}.
FT   STRAND      343    346       {ECO:0000244|PDB:1KI0}.
FT   STRAND      377    379       {ECO:0000244|PDB:4DUR}.
FT   STRAND      382    384       {ECO:0000244|PDB:4DUR}.
FT   STRAND      405    407       {ECO:0000244|PDB:1PK4}.
FT   TURN        413    415       {ECO:0000244|PDB:1KRN}.
FT   TURN        417    419       {ECO:0000244|PDB:2PK4}.
FT   STRAND      429    431       {ECO:0000244|PDB:1PMK}.
FT   STRAND      436    441       {ECO:0000244|PDB:1KRN}.
FT   STRAND      446    450       {ECO:0000244|PDB:1KRN}.
FT   STRAND      460    462       {ECO:0000244|PDB:4DUR}.
FT   STRAND      481    483       {ECO:0000244|PDB:2KNF}.
FT   STRAND      487    489       {ECO:0000244|PDB:4DUR}.
FT   STRAND      509    511       {ECO:0000244|PDB:5HPG}.
FT   STRAND      514    516       {ECO:0000244|PDB:5HPG}.
FT   TURN        518    520       {ECO:0000244|PDB:5HPG}.
FT   TURN        522    525       {ECO:0000244|PDB:4DUR}.
FT   STRAND      542    546       {ECO:0000244|PDB:5HPG}.
FT   STRAND      552    554       {ECO:0000244|PDB:5HPG}.
FT   STRAND      582    586       {ECO:0000244|PDB:1BUI}.
FT   STRAND      595    599       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      605    613       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      616    619       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       621    624       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       630    632       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      634    638       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      640    644       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      650    659       {ECO:0000244|PDB:1DDJ}.
FT   TURN        661    663       {ECO:0000244|PDB:1QRZ}.
FT   STRAND      667    673       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      698    703       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      708    710       {ECO:0000244|PDB:1DDJ}.
FT   TURN        711    714       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      717    724       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       726    729       {ECO:0000244|PDB:1DDJ}.
FT   TURN        732    737       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      743    747       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      749    751       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      752    754       {ECO:0000244|PDB:1BML}.
FT   STRAND      763    767       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      769    778       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       780    782       {ECO:0000244|PDB:1DDJ}.
FT   STRAND      791    795       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       796    798       {ECO:0000244|PDB:1DDJ}.
FT   HELIX       800    808       {ECO:0000244|PDB:1DDJ}.
SQ   SEQUENCE   810 AA;  90569 MW;  8B31CB877CCB3AB6 CRC64;
     MEHKEVVLLL LLFLKSGQGE PLDDYVNTQG ASLFSVTKKQ LGAGSIEECA AKCEEDEEFT
     CRAFQYHSKE QQCVIMAENR KSSIIIRMRD VVLFEKKVYL SECKTGNGKN YRGTMSKTKN
     GITCQKWSST SPHRPRFSPA THPSEGLEEN YCRNPDNDPQ GPWCYTTDPE KRYDYCDILE
     CEEECMHCSG ENYDGKISKT MSGLECQAWD SQSPHAHGYI PSKFPNKNLK KNYCRNPDRE
     LRPWCFTTDP NKRWELCDIP RCTTPPPSSG PTYQCLKGTG ENYRGNVAVT VSGHTCQHWS
     AQTPHTHNRT PENFPCKNLD ENYCRNPDGK RAPWCHTTNS QVRWEYCKIP SCDSSPVSTE
     QLAPTAPPEL TPVVQDCYHG DGQSYRGTSS TTTTGKKCQS WSSMTPHRHQ KTPENYPNAG
     LTMNYCRNPD ADKGPWCFTT DPSVRWEYCN LKKCSGTEAS VVAPPPVVLL PDVETPSEED
     CMFGNGKGYR GKRATTVTGT PCQDWAAQEP HRHSIFTPET NPRAGLEKNY CRNPDGDVGG
     PWCYTTNPRK LYDYCDVPQC AAPSFDCGKP QVEPKKCPGR VVGGCVAHPH SWPWQVSLRT
     RFGMHFCGGT LISPEWVLTA AHCLEKSPRP SSYKVILGAH QEVNLEPHVQ EIEVSRLFLE
     PTRKDIALLK LSSPAVITDK VIPACLPSPN YVVADRTECF ITGWGETQGT FGAGLLKEAQ
     LPVIENKVCN RYEFLNGRVQ STELCAGHLA GGTDSCQGDS GGPLVCFEKD KYILQGVTSW
     GLGCARPNKP GVYVRVSRFV TWIEGVMRNN
//
ID   NRX1B_MOUSE             Reviewed;         468 AA.
AC   P0DI97;
DT   21-SEP-2011, integrated into UniProtKB/Swiss-Prot.
DT   21-SEP-2011, sequence version 1.
DT   17-FEB-2016, entry version 42.
DE   RecName: Full=Neurexin-1-beta;
DE   AltName: Full=Neurexin I-beta;
DE   Flags: Precursor;
GN   Name=Nrxn1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
RN   [3]
RP   INTERACTION WITH CBLN1, AND MUTAGENESIS OF ASP-137 AND ASN-238.
RX   PubMed=21410790; DOI=10.1111/j.1460-9568.2011.07638.x;
RA   Matsuda K., Yuzaki M.;
RT   "Cbln family proteins promote synapse formation by regulating distinct
RT   neurexin signaling pathways in various brain regions.";
RL   Eur. J. Neurosci. 33:1447-1461(2011).
RN   [4]
RP   INTERACTION WITH CBLN1; CBLN2 AND CBLN4.
RX   PubMed=22220752; DOI=10.1111/j.1471-4159.2012.07648.x;
RA   Wei P., Pattarini R., Rong Y., Guo H., Bansal P.K., Kusnoor S.V.,
RA   Deutch A.Y., Parris J., Morgan J.I.;
RT   "The Cbln family of proteins interact with multiple signaling
RT   pathways.";
RL   J. Neurochem. 121:717-729(2012).
CC   -!- FUNCTION: Neuronal cell surface protein that may be involved in
CC       cell recognition and cell adhesion by forming intracellular
CC       junctions through binding to neuroligins. May play a role in
CC       formation or maintenance of synaptic junctions. May mediate
CC       intracellular signaling. May play a role in angiogenesis (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: The cytoplasmic C-terminal region binds to CASK. Isoforms
CC       3b and 4b bind neuroligins NLGN1, NLGN2 and NLGN3, alpha-
CC       dystroglycan and alpha-latrotoxin. Binding to neuroligins is
CC       calcium-dependent, and the binding preference ranks as follow:
CC       NLGN1 > NLGN4 >> NLGN3 > NLGN2 (By similarity). Interacts with
CC       CBLN1, CBLN2 and more weakly with CBLN4. CBLN1-binding is calcium-
CC       independent. {ECO:0000250, ECO:0000269|PubMed:21410790,
CC       ECO:0000269|PubMed:22220752}.
CC   -!- INTERACTION:
CC       Q9R171:Cbln1; NbExp=4; IntAct=EBI-2794440, EBI-2794140;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell junction, synapse. Note=Localized on the pre-
CC       synaptic membrane. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=5;
CC         Comment=A number of isoforms, alpha-type and beta-type are
CC         produced by alternative promoter usage. Beta-type isoforms
CC         differ from alpha-type isoforms in their N-terminus.;
CC       Name=1b;
CC         IsoId=P0DI97-1; Sequence=Displayed;
CC       Name=1a;
CC         IsoId=Q9CS84-1; Sequence=External;
CC       Name=2a; Synonyms=Alpha-2B;
CC         IsoId=Q9CS84-2; Sequence=External;
CC       Name=3a; Synonyms=Alpha-2C;
CC         IsoId=Q9CS84-3; Sequence=External;
CC       Name=4a;
CC         IsoId=Q9CS84-4; Sequence=External;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Highly O-glycosylated and minor N-glycosylated.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the neurexin family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 laminin G-like domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00122}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH466537; EDL38657.1; -; Genomic_DNA.
DR   UniGene; Mm.478418; -.
DR   UniGene; Mm.491332; -.
DR   ProteinModelPortal; P0DI97; -.
DR   SMR; P0DI97; 84-288.
DR   IntAct; P0DI97; 2.
DR   STRING; 10090.ENSMUSP00000125407; -.
DR   PaxDb; P0DI97; -.
DR   PRIDE; P0DI97; -.
DR   Ensembl; ENSMUST00000174337; ENSMUSP00000133724; ENSMUSG00000024109. [P0DI97-1]
DR   MGI; MGI:1096391; Nrxn1.
DR   eggNOG; KOG3514; Eukaryota.
DR   eggNOG; ENOG410XNU6; LUCA.
DR   GeneTree; ENSGT00760000118991; -.
DR   TreeFam; TF334142; -.
DR   ChiTaRS; Nrxn1; mouse.
DR   Proteomes; UP000000589; Chromosome 17.
DR   Bgee; P0DI97; -.
DR   ExpressionAtlas; P0DI97; baseline and differential.
DR   Genevisible; P0DI97; MM.
DR   GO; GO:0044295; C:axonal growth cone; IDA:BHF-UCL.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0030139; C:endocytic vesicle; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0060076; C:excitatory synapse; IC:BHF-UCL.
DR   GO; GO:0060077; C:inhibitory synapse; IC:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043025; C:neuronal cell body; IDA:BHF-UCL.
DR   GO; GO:0031965; C:nuclear membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:BHF-UCL.
DR   GO; GO:0043234; C:protein complex; IPI:MGI.
DR   GO; GO:0031982; C:vesicle; IDA:BHF-UCL.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IDA:MGI.
DR   GO; GO:0005246; F:calcium channel regulator activity; IGI:MGI.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IDA:BHF-UCL.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0097109; F:neuroligin family protein binding; IPI:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL.
DR   GO; GO:0030534; P:adult behavior; ISO:MGI.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:BHF-UCL.
DR   GO; GO:0021707; P:cerebellar granule cell differentiation; IGI:BHF-UCL.
DR   GO; GO:0045184; P:establishment of protein localization; IDA:BHF-UCL.
DR   GO; GO:0046847; P:filopodium assembly; IMP:CACAO.
DR   GO; GO:0097112; P:gamma-aminobutyric acid receptor clustering; IDA:BHF-UCL.
DR   GO; GO:0097116; P:gephyrin clustering involved in postsynaptic density assembly; IDA:BHF-UCL.
DR   GO; GO:0097117; P:guanylate kinase-associated protein clustering; IDA:BHF-UCL.
DR   GO; GO:0007157; P:heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; IDA:BHF-UCL.
DR   GO; GO:0007612; P:learning; ISO:MGI.
DR   GO; GO:0051490; P:negative regulation of filopodium assembly; IDA:BHF-UCL.
DR   GO; GO:0097118; P:neuroligin clustering involved in postsynaptic membrane assembly; IDA:BHF-UCL.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0042551; P:neuron maturation; IDA:BHF-UCL.
DR   GO; GO:0007269; P:neurotransmitter secretion; IGI:MGI.
DR   GO; GO:0097114; P:NMDA glutamate receptor clustering; IDA:BHF-UCL.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IDA:BHF-UCL.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IGI:MGI.
DR   GO; GO:0090129; P:positive regulation of synapse maturation; IDA:MGI.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IDA:BHF-UCL.
DR   GO; GO:0097119; P:postsynaptic density protein 95 clustering; IDA:BHF-UCL.
DR   GO; GO:0097104; P:postsynaptic membrane assembly; IDA:BHF-UCL.
DR   GO; GO:0097105; P:presynaptic membrane assembly; IDA:BHF-UCL.
DR   GO; GO:0090126; P:protein complex assembly involved in synapse maturation; IDA:BHF-UCL.
DR   GO; GO:0035418; P:protein localization to synapse; IDA:BHF-UCL.
DR   GO; GO:0097120; P:receptor localization to synapse; IDA:BHF-UCL.
DR   GO; GO:2000311; P:regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity; IDA:BHF-UCL.
DR   GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:MGI.
DR   GO; GO:2000310; P:regulation of N-methyl-D-aspartate selective glutamate receptor activity; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; ISO:MGI.
DR   GO; GO:0007416; P:synapse assembly; IGI:MGI.
DR   GO; GO:0007268; P:synaptic transmission; IGI:MGI.
DR   GO; GO:0097091; P:synaptic vesicle clustering; IDA:BHF-UCL.
DR   GO; GO:0006904; P:vesicle docking involved in exocytosis; ISO:MGI.
DR   GO; GO:0042297; P:vocal learning; ISO:MGI.
DR   GO; GO:0071625; P:vocalization behavior; ISO:MGI.
DR   Gene3D; 2.60.120.200; -; 1.
DR   InterPro; IPR013320; ConA-like_dom.
DR   InterPro; IPR001791; Laminin_G.
DR   InterPro; IPR029824; Neurexin-1.
DR   InterPro; IPR003585; Neurexin-like.
DR   InterPro; IPR027789; Syndecan/Neurexin_dom.
DR   PANTHER; PTHR10127:SF565; PTHR10127:SF565; 2.
DR   Pfam; PF02210; Laminin_G_2; 1.
DR   Pfam; PF01034; Syndecan; 1.
DR   SMART; SM00294; 4.1m; 1.
DR   SMART; SM00282; LamG; 1.
DR   SUPFAM; SSF49899; SSF49899; 2.
DR   PROSITE; PS50025; LAM_G_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Alternative promoter usage; Alternative splicing; Angiogenesis;
KW   Calcium; Cell adhesion; Cell junction; Cell membrane;
KW   Complete proteome; Glycoprotein; Membrane; Metal-binding;
KW   Reference proteome; Signal; Synapse; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     46       {ECO:0000255}.
FT   CHAIN        47    468       Neurexin-1-beta.
FT                                /FTId=PRO_0000412630.
FT   TRANSMEM    393    413       Helical. {ECO:0000255}.
FT   DOMAIN       87    285       Laminin G-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00122}.
FT   COMPBIAS     53     65       His-rich.
FT   COMPBIAS    315    318       Poly-Thr.
FT   COMPBIAS    400    403       Poly-Ala.
FT   METAL       137    137       Calcium. {ECO:0000250}.
FT   METAL       154    154       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       236    236       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       238    238       Calcium. {ECO:0000250}.
FT   MUTAGEN     137    137       D->A: Loss of NLGN1-binding. No effect on
FT                                CBLN1-binding.
FT                                {ECO:0000269|PubMed:21410790}.
FT   MUTAGEN     238    238       N->A: Loss of NLGN1-binding. No effect on
FT                                CBLN1-binding.
FT                                {ECO:0000269|PubMed:21410790}.
SQ   SEQUENCE   468 AA;  50223 MW;  F118A9053BAB4E21 CRC64;
     MYQRMLRCGA DLGSPGGGSG GGAGGRLALI WIVPLTLSGL LGVAWGASSL GAHHIHHFHG
     SSKHHSVPIA IYRSPASLRG GHAGTTYIFS KGGGQITYKW PPNDRPSTRA DRLAIGFSTV
     QKEAVLVRVD SSSGLGDYLE LHIHQGKIGV KFNVGTDDIA IEESNAIIND GKYHVVRFTR
     SGGNATLQVD SWPVIERYPA GNNDNERLAI ARQRIPYRLG RVVDEWLLDK GRQLTIFNSQ
     ATIIIGGKEQ GQPFQGQLSG LYYNGLKVLN MAAENDANIA IVGNVRLVGE VPSSMTTEST
     ATAMQSEMST SIMETTTTLA TSTARRGKPP TKEPISQTTD DILVASAECP SDDEDIDPCE
     PSSGGLANPT RVGGREPYPG SAEVIRESSS TTGMVVGIVA AAALCILILL YAMYKYRNRD
     EGSYHVDESR NYISNSAQSN GAVVKEKQPS SAKSANKNKK NKDKEYYV
//
ID   IFNG_HUMAN              Reviewed;         166 AA.
AC   P01579; B5BU88; Q53ZV4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1988, sequence version 1.
DT   20-JAN-2016, entry version 185.
DE   RecName: Full=Interferon gamma;
DE            Short=IFN-gamma;
DE   AltName: Full=Immune interferon;
DE   Flags: Precursor;
GN   Name=IFNG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6180322; DOI=10.1038/298859a0;
RA   Gray P.W., Goeddel D.V.;
RT   "Structure of the human immune interferon gene.";
RL   Nature 298:859-863(1982).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6173769; DOI=10.1038/295503a0;
RA   Gray P.W., Leung D.W., Pennica D., Yelverton E., Najarian R.,
RA   Simonsen C.C., Derynck R., Sherwood P.J., Wallace D.M., Berger S.L.,
RA   Levinson A.D., Goeddel D.V.;
RT   "Expression of human immune interferon cDNA in E. coli and monkey
RT   cells.";
RL   Nature 295:503-508(1982).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2860101;
RA   Nishi T., Fujita T., Nishi-Takaoka C., Saito A., Matsumoto T.,
RA   Sato M., Oka T., Itoh S., Yip Y.K., Vilcek J., Taniguchi T.;
RT   "Cloning and expression of a novel variant of human interferon-gamma
RT   cDNA.";
RL   J. Biochem. 97:153-159(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6329718;
RA   Taya Y., Devos R., Tavernier J., Cheroutre H., Engler G., Fiers W.;
RT   "Cloning and structure of the human immune interferon-gamma
RT   chromosomal gene.";
RL   EMBO J. 1:953-958(1982).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6176945; DOI=10.1093/nar/10.8.2487;
RA   Devos R., Cheroutre H., Taya Y., Degrave W., van Heuverswyn H.,
RA   Fiers W.;
RT   "Molecular cloning of human immune interferon cDNA and its expression
RT   in eukaryotic cells.";
RL   Nucleic Acids Res. 10:2487-2501(1982).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-160.
RA   Chikara S.K., Jaiswal P., Sharma G.;
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 24-157, PYROGLUTAMATE FORMATION AT GLN-24, AND
RP   GLYCOSYLATION AT ASN-48 AND ASN-120.
RX   PubMed=6427223;
RA   Rinderknecht E., O'Conner B.H., Rodriguez H.;
RT   "Natural human interferon-gamma. Complete amino acid sequence and
RT   determination of sites of glycosylation.";
RL   J. Biol. Chem. 259:6790-6797(1984).
RN   [12]
RP   PROTEIN SEQUENCE OF 24-161, PYROGLUTAMATE FORMATION AT GLN-24, AND
RP   PROTEOLYTIC PROCESSING OF THE C-TERMINUS.
RX   PubMed=3109913; DOI=10.1111/j.1432-1033.1987.tb13494.x;
RA   Pan Y.C.E., Stern A.S., Familletti P.C., Khan F.R., Chizzonite R.;
RT   "Structural characterization of human interferon gamma. Heterogeneity
RT   of the carboxyl terminus.";
RL   Eur. J. Biochem. 166:145-149(1987).
RN   [13]
RP   STRUCTURE OF CARBOHYDRATES.
RX   PubMed=2504704;
RA   Yamamoto S., Hase S., Yamauchi H., Tanimoto T., Ikenaka T.;
RT   "Studies on the sugar chains of interferon-gamma from human
RT   peripheral-blood lymphocytes.";
RL   J. Biochem. 105:1034-1039(1989).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS).
RX   PubMed=1902591; DOI=10.1126/science.1902591;
RA   Ealick S.E., Cook W.J., Vijay-Kumar S., Carson M., Nagabhushan T.L.,
RA   Trotta P.P., Bugg C.E.;
RT   "Three-dimensional structure of recombinant human interferon-gamma.";
RL   Science 252:698-702(1991).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RX   PubMed=7617032; DOI=10.1038/376230a0;
RA   Walter M.R., Windsor W.T., Nagabhushan T.L., Lundell D.J., Lunn C.A.,
RA   Zauodny P.J., Narula S.K.;
RT   "Crystal structure of a complex between interferon-gamma and its
RT   soluble high-affinity receptor.";
RL   Nature 376:230-235(1995).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RX   PubMed=10860730; DOI=10.1006/jmbi.2000.3734;
RA   Landar A., Curry B., Parker M.H., DiGiacomo R., Indelicato S.R.,
RA   Nagabhushan T.L., Rizzi G., Walter M.R.;
RT   "Design, characterization, and structure of a biologically active
RT   single-chain mutant of human IFN-gamma.";
RL   J. Mol. Biol. 299:169-179(2000).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF COMPLEX WITH RECEPTOR.
RX   PubMed=10986460; DOI=10.1016/S0969-2126(00)00184-2;
RA   Thiel D.J., le Du M.-H., Walter R.L., D'Arcy A., Chene C.,
RA   Fountoulakis M., Garotta G., Winkler F.K., Ealick S.E.;
RT   "Observation of an unexpected third receptor molecule in the crystal
RT   structure of human interferon-gamma receptor complex.";
RL   Structure 8:927-936(2000).
RN   [18]
RP   STRUCTURE BY NMR.
RX   PubMed=1525157; DOI=10.1021/bi00150a009;
RA   Grzesiek S., Doebeli H., Gentz R., Garotta G., Labhardt A.M., Bax A.;
RT   "1H, 13C, and 15N NMR backbone assignments and secondary structure of
RT   human interferon-gamma.";
RL   Biochemistry 31:8180-8190(1992).
RN   [19]
RP   ASSOCIATION WITH APLASTIC ANEMIA.
RX   PubMed=15327519; DOI=10.1111/j.1365-2141.2004.05102.x;
RA   Dufour C., Capasso M., Svahn J., Marrone A., Haupt R., Bacigalupo A.,
RA   Giordani L., Longoni D., Pillon M., Pistorio A., Di Michele P.,
RA   Iori A.P., Pongiglione C., Lanciotti M., Iolascon A.;
RT   "Homozygosis for (12) CA repeats in the first intron of the human IFN-
RT   gamma gene is significantly associated with the risk of aplastic
RT   anaemia in Caucasian population.";
RL   Br. J. Haematol. 126:682-685(2004).
CC   -!- FUNCTION: Produced by lymphocytes activated by specific antigens
CC       or mitogens. IFN-gamma, in addition to having antiviral activity,
CC       has important immunoregulatory functions. It is a potent activator
CC       of macrophages, it has antiproliferative effects on transformed
CC       cells and it can potentiate the antiviral and antitumor effects of
CC       the type I interferons.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Released primarily from activated T
CC       lymphocytes.
CC   -!- PTM: Proteolytic processing produces C-terminal heterogeneity,
CC       with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
CC       {ECO:0000269|PubMed:3109913}.
CC   -!- DISEASE: Aplastic anemia (AA) [MIM:609135]: A form of anemia in
CC       which the bone marrow fails to produce adequate numbers of
CC       peripheral blood elements. It is characterized by peripheral
CC       pancytopenia and marrow hypoplasia. {ECO:0000269|PubMed:15327519}.
CC       Note=Disease susceptibility may be associated with variations
CC       affecting the gene represented in this entry.
CC   -!- PHARMACEUTICAL: Available under the name Actimmune (Genentech).
CC       Used for reducing the frequency and severity of serious infections
CC       associated with chronic granulomatous disease (CGD).
CC   -!- SIMILARITY: Belongs to the type II (or gamma) interferon family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Interferon gamma entry;
CC       URL="https://en.wikipedia.org/wiki/Interferon_gamma";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ifng/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13274; CAA31639.1; -; mRNA.
DR   EMBL; J00219; AAB59534.1; -; Genomic_DNA.
DR   EMBL; X01992; CAA26022.1; -; mRNA.
DR   EMBL; V00543; CAA23804.1; -; mRNA.
DR   EMBL; AY255837; AAP20098.1; -; mRNA.
DR   EMBL; AF375790; AAK53058.1; -; Genomic_DNA.
DR   EMBL; AB451324; BAG70138.1; -; mRNA.
DR   EMBL; AB451453; BAG70267.1; -; mRNA.
DR   EMBL; CH471054; EAW97180.1; -; Genomic_DNA.
DR   EMBL; BC070256; AAH70256.1; -; mRNA.
DR   CCDS; CCDS8980.1; -.
DR   PIR; A93284; IVHUG.
DR   RefSeq; NP_000610.2; NM_000619.2.
DR   UniGene; Hs.856; -.
DR   PDB; 1EKU; X-ray; 2.90 A; A/B=26-161.
DR   PDB; 1FG9; X-ray; 2.90 A; A/B=24-156.
DR   PDB; 1FYH; X-ray; 2.04 A; A/D=28-156.
DR   PDB; 1HIG; X-ray; 3.50 A; A/B/C/D=24-161.
DR   PDB; 3BES; X-ray; 2.20 A; L=24-161.
DR   PDBsum; 1EKU; -.
DR   PDBsum; 1FG9; -.
DR   PDBsum; 1FYH; -.
DR   PDBsum; 1HIG; -.
DR   PDBsum; 3BES; -.
DR   ProteinModelPortal; P01579; -.
DR   SMR; P01579; 24-155.
DR   BioGrid; 109680; 5.
DR   DIP; DIP-483N; -.
DR   IntAct; P01579; 2.
DR   MINT; MINT-1508034; -.
DR   STRING; 9606.ENSP00000229135; -.
DR   BindingDB; P01579; -.
DR   ChEMBL; CHEMBL3286073; -.
DR   DrugBank; DB01296; Glucosamine.
DR   DrugBank; DB01250; Olsalazine.
DR   PhosphoSite; P01579; -.
DR   UniCarbKB; P01579; -.
DR   BioMuta; IFNG; -.
DR   DMDM; 124479; -.
DR   PaxDb; P01579; -.
DR   PRIDE; P01579; -.
DR   DNASU; 3458; -.
DR   Ensembl; ENST00000229135; ENSP00000229135; ENSG00000111537.
DR   GeneID; 3458; -.
DR   KEGG; hsa:3458; -.
DR   UCSC; uc001stw.1; human.
DR   CTD; 3458; -.
DR   GeneCards; IFNG; -.
DR   HGNC; HGNC:5438; IFNG.
DR   HPA; CAB010344; -.
DR   MalaCards; IFNG; -.
DR   MIM; 147570; gene.
DR   MIM; 609135; phenotype.
DR   neXtProt; NX_P01579; -.
DR   Orphanet; 88; Idiopathic aplastic anemia.
DR   PharmGKB; PA29674; -.
DR   eggNOG; ENOG410IWSY; Eukaryota.
DR   eggNOG; ENOG410Z8I5; LUCA.
DR   GeneTree; ENSGT00390000007831; -.
DR   HOGENOM; HOG000254784; -.
DR   HOVERGEN; HBG056912; -.
DR   InParanoid; P01579; -.
DR   KO; K04687; -.
DR   OMA; KEYFNAS; -.
DR   OrthoDB; EOG7VHSZM; -.
DR   PhylomeDB; P01579; -.
DR   TreeFam; TF336308; -.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   SignaLink; P01579; -.
DR   EvolutionaryTrace; P01579; -.
DR   GeneWiki; Interferon-gamma; -.
DR   GenomeRNAi; 3458; -.
DR   NextBio; 13624; -.
DR   PMAP-CutDB; P01579; -.
DR   PRO; PR:P01579; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; P01579; -.
DR   CleanEx; HS_IFNG; -.
DR   Genevisible; P01579; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0005622; C:intracellular; IDA:GOC.
DR   GO; GO:0005125; F:cytokine activity; IBA:GO_Central.
DR   GO; GO:0005133; F:interferon-gamma receptor binding; TAS:ProtInc.
DR   GO; GO:0002250; P:adaptive immune response; IBA:GO_Central.
DR   GO; GO:0019882; P:antigen processing and presentation; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IGI:MGI.
DR   GO; GO:0002302; P:CD8-positive, alpha-beta T cell differentiation involved in immune response; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0071351; P:cellular response to interleukin-18; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IDA:BHF-UCL.
DR   GO; GO:0031642; P:negative regulation of myelination; IEA:Ensembl.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0001781; P:neutrophil apoptotic process; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:0060559; P:positive regulation of calcidiol 1-monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0032834; P:positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0045080; P:positive regulation of chemokine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IDA:CACAO.
DR   GO; GO:0060550; P:positive regulation of fructose 1,6-bisphosphate 1-phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0060552; P:positive regulation of fructose 1,6-bisphosphate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; IEA:Ensembl.
DR   GO; GO:0045084; P:positive regulation of interleukin-12 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:UniProtKB.
DR   GO; GO:0032747; P:positive regulation of interleukin-23 production; IDA:BHF-UCL.
DR   GO; GO:0045410; P:positive regulation of interleukin-6 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl.
DR   GO; GO:0051712; P:positive regulation of killing of cells of other organism; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IDA:BHF-UCL.
DR   GO; GO:0033141; P:positive regulation of peptidyl-serine phosphorylation of STAT protein; NAS:BHF-UCL.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0032224; P:positive regulation of synaptic transmission, cholinergic; IEA:Ensembl.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:2000309; P:positive regulation of tumor necrosis factor (ligand) superfamily member 11 production; IDA:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; IDA:BHF-UCL.
DR   GO; GO:0060557; P:positive regulation of vitamin D biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IDA:UniProtKB.
DR   GO; GO:2000345; P:regulation of hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; IDA:BHF-UCL.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0098908; P:regulation of neuronal action potential; IEA:Ensembl.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IDA:MGI.
DR   GO; GO:0050954; P:sensory perception of mechanical stimulus; IEA:Ensembl.
DR   Gene3D; 1.20.1250.10; -; 1.
DR   InterPro; IPR009079; 4_helix_cytokine-like_core.
DR   InterPro; IPR012351; 4_helix_cytokine_core.
DR   InterPro; IPR002069; Interferon_gamma.
DR   PANTHER; PTHR11419; PTHR11419; 1.
DR   Pfam; PF00714; IFN-gamma; 1.
DR   PIRSF; PIRSF001936; IFN-gamma; 1.
DR   ProDom; PD002435; Interferon_gamma; 1.
DR   SUPFAM; SSF47266; SSF47266; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; Cleavage on pair of basic residues;
KW   Complete proteome; Cytokine; Direct protein sequencing; Glycoprotein;
KW   Growth regulation; Pharmaceutical; Polymorphism;
KW   Pyrrolidone carboxylic acid; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:3109913,
FT                                ECO:0000269|PubMed:6427223}.
FT   CHAIN        24    161       Interferon gamma.
FT                                /FTId=PRO_0000016444.
FT   PROPEP      162    166
FT                                /FTId=PRO_0000259481.
FT   MOD_RES      24     24       Pyrrolidone carboxylic acid.
FT                                {ECO:0000269|PubMed:3109913,
FT                                ECO:0000269|PubMed:6427223}.
FT   CARBOHYD     48     48       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:6427223}.
FT   CARBOHYD    120    120       N-linked (GlcNAc...); in dimeric form.
FT                                {ECO:0000269|PubMed:6427223}.
FT   VARIANT      29     29       K -> Q.
FT                                /FTId=VAR_004017.
FT   VARIANT     160    160       R -> Q (in dbSNP:rs201359065).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_004018.
FT   HELIX        28     38       {ECO:0000244|PDB:1FYH}.
FT   HELIX        43     46       {ECO:0000244|PDB:3BES}.
FT   HELIX        53     58       {ECO:0000244|PDB:1FYH}.
FT   HELIX        62     81       {ECO:0000244|PDB:1FYH}.
FT   TURN         82     85       {ECO:0000244|PDB:1FYH}.
FT   TURN         87     89       {ECO:0000244|PDB:1FYH}.
FT   HELIX        90    104       {ECO:0000244|PDB:1FYH}.
FT   HELIX       109    119       {ECO:0000244|PDB:1FYH}.
FT   HELIX       126    140       {ECO:0000244|PDB:1FYH}.
FT   HELIX       146    148       {ECO:0000244|PDB:3BES}.
SQ   SEQUENCE   166 AA;  19348 MW;  1514E8F785FD81AA CRC64;
     MKYTSYILAF QLCIVLGSLG CYCQDPYVKE AENLKKYFNA GHSDVADNGT LFLGILKNWK
     EESDRKIMQS QIVSFYFKLF KNFKDDQSIQ KSVETIKEDM NVKFFNSNKK KRDDFEKLTN
     YSVTDLNVQR KAIHELIQVM AELSPAAKTG KRKRSQMLFR GRRASQ
//
ID   IL4RA_HUMAN             Reviewed;         825 AA.
AC   P24394; B4E076; B9EKU8; H3BSY5; Q96P01; Q9H181; Q9H182; Q9H183;
AC   Q9H184; Q9H185; Q9H186; Q9H187; Q9H188;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   17-FEB-2016, entry version 187.
DE   RecName: Full=Interleukin-4 receptor subunit alpha;
DE            Short=IL-4 receptor subunit alpha;
DE            Short=IL-4R subunit alpha;
DE            Short=IL-4R-alpha;
DE            Short=IL-4RA;
DE   AltName: CD_antigen=CD124;
DE   Contains:
DE     RecName: Full=Soluble interleukin-4 receptor subunit alpha;
DE              Short=Soluble IL-4 receptor subunit alpha;
DE              Short=Soluble IL-4R-alpha;
DE              Short=sIL4Ralpha/prot;
DE     AltName: Full=IL-4-binding protein;
DE              Short=IL4-BP;
DE   Flags: Precursor;
GN   Name=IL4R; Synonyms=IL4RA; ORFNames=582J2.1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Peripheral blood;
RX   PubMed=2307934; DOI=10.1084/jem.171.3.861;
RA   Idzerda R.L., March C.J., Mosley B., Lyman S.D., Bos T.V.,
RA   Gimpel S.D., Din W.S., Grabstein K.H., Widmer M.B., Park L.S.,
RA   Cosman D., Beckmann M.P.;
RT   "Human interleukin 4 receptor confers biological responsiveness and
RT   defines a novel receptor superfamily.";
RL   J. Exp. Med. 171:861-873(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Myeloid leukemia cell;
RX   PubMed=2278997; DOI=10.1093/intimm/2.7.669;
RA   Galizzi J.-P., Zuber C.E., Harada N., Gorman D.M., Djossou O.,
RA   Kastelein R., Banchereau J., Howard M., Miyajima A.;
RT   "Molecular cloning of a cDNA encoding the human interleukin 4
RT   receptor.";
RL   Int. Immunol. 2:669-675(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Blood;
RX   PubMed=10590262; DOI=10.1093/intimm/11.12.1965;
RA   Kruse S., Forster J., Kuehr J., Deichmann K.A.;
RT   "Characterization of the membrane-bound and a soluble form of human
RT   IL-4 receptor alpha produced by alternative splicing.";
RL   Int. Immunol. 11:1965-1970(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10493829; DOI=10.1006/geno.1999.5927;
RA   Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R.,
RA   Fuhrmann J., Mason T., Crosby M.L., Barnstead M., Cronin L.,
RA   Mays A.D., Cao Y., Xu R.X., Kang H.-L., Mitchell S., Eichler E.E.,
RA   Harris P.C., Venter J.C., Adams M.D.;
RT   "Genome duplications and other features in 12 Mb of DNA sequence from
RT   human chromosome 16p and 16q.";
RL   Genomics 60:295-308(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-75; ALA-400;
RP   ARG-431; LEU-436; PRO-503; ARG-576; ILE-579; SER-675 AND ALA-752.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 301-825 (ISOFORM 1), AND VARIANTS
RP   ALA-400; ARG-431; LEU-436; PRO-503; ARG-576 AND ILE-579.
RX   PubMed=11285129; DOI=10.1034/j.1399-0039.2001.057003216.x;
RA   Lozano F., Places L., Vila J.-M., Padilla O., Arman M., Gimferrer I.,
RA   Suarez B., Lopez de la Iglesia A., Miserachs N., Vives J.;
RT   "Identification of a novel single-nucleotide polymorphism (Val554Ile)
RT   and definition of eight common alleles for human IL4RA exon 11.";
RL   Tissue Antigens 57:216-220(2001).
RN   [10]
RP   FUNCTION IN IRS1 ACTIVATION, AND MUTAGENESIS OF TYR-497.
RX   PubMed=8124718; DOI=10.1016/0092-8674(94)90356-5;
RA   Keegan A.D., Nelms K., White M., Wang L.-M., Pierce J.H., Paul W.E.;
RT   "An IL-4 receptor region containing an insulin receptor motif is
RT   important for IL-4-mediated IRS-1 phosphorylation and cell growth.";
RL   Cell 76:811-820(1994).
RN   [11]
RP   DOMAIN JAK3 ACTIVATION.
RX   PubMed=7721895; DOI=10.1074/jbc.270.16.9630;
RA   Malabarba M.G., Kirken R.A., Rui H., Koettnitz K., Kawamura M.,
RA   O'Shea J.J., Kalthoff F.S., Farrar W.L.;
RT   "Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4)
RT   stimulated proliferation and requires a membrane-proximal region of
RT   IL4 receptor alpha.";
RL   J. Biol. Chem. 270:9630-9637(1995).
RN   [12]
RP   INTERACTION WITH IL13RA1.
RX   PubMed=7775445; DOI=10.1074/jbc.270.23.13869;
RA   Zurawski S.M., Chomarat P., Djossou O., Bidaud C., McKenzie A.N.,
RA   Miossec P., Banchereau J., Zurawski G.;
RT   "The primary binding subunit of the human interleukin-4 receptor is
RT   also a component of the interleukin-13 receptor.";
RL   J. Biol. Chem. 270:13869-13878(1995).
RN   [13]
RP   INTERACTION WITH JAK3.
RX   PubMed=7538655;
RA   Rolling C., Treton D., Beckmann P., Galanaud P., Richard Y.;
RT   "JAK3 associates with the human interleukin 4 receptor and is tyrosine
RT   phosphorylated following receptor triggering.";
RL   Oncogene 10:1757-1761(1995).
RN   [14]
RP   INTERACTION WITH IL13RA1, AND PHOSPHORYLATION.
RX   PubMed=8804422; DOI=10.1016/0014-5793(96)00835-6;
RA   Rolling C., Treton D., Pellegrini S., Galanaud P., Richard Y.;
RT   "IL4 and IL13 receptors share the gamma c chain and activate STAT6,
RT   STAT3 and STAT5 proteins in normal human B cells.";
RL   FEBS Lett. 393:53-56(1996).
RN   [15]
RP   DOMAIN STAT6 ACTIVATION, AND MUTAGENESIS OF TYR-575; TYR-603 AND
RP   TYR-631.
RX   PubMed=8624803; DOI=10.1016/S1074-7613(00)80677-9;
RA   Ryan J.J., McReynolds L.J., Keegan A., Wang L.-H., Garfein E.,
RA   Rothman P., Nelms K., Paul W.E.;
RT   "Growth and gene expression are predominantly controlled by distinct
RT   regions of the human IL-4 receptor.";
RL   Immunity 4:123-132(1996).
RN   [16]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10341317; DOI=10.1159/000024171;
RA   Jung T., Schrader N., Hellwig M., Enssle K.H., Neumann C.;
RT   "Soluble human interleukin-4 receptor is produced by activated T cells
RT   under the control of metalloproteinases.";
RL   Int. Arch. Allergy Immunol. 119:23-30(1999).
RN   [17]
RP   INTERACTION WITH PTPN6; PTPN11 AND INPP5D, STAT6 ACTIVATION, AND
RP   MUTAGENESIS OF TYR-713.
RX   PubMed=11714803; DOI=10.4049/jimmunol.167.11.6382;
RA   Kashiwada M., Giallourakis C.C., Pan P.-Y., Rothman P.B.;
RT   "Immunoreceptor tyrosine-based inhibitory motif of the IL-4 receptor
RT   associates with SH2-containing phosphatases and regulates IL-4-induced
RT   proliferation.";
RL   J. Immunol. 167:6382-6387(2001).
RN   [18]
RP   LIGAND-BINDING SITES, AND MUTAGENESIS OF TYR-38; MET-39; SER-40;
RP   LEU-64; PHE-66; LEU-67; LEU-68; ASP-91; ASP-92; VAL-93; VAL-94;
RP   SER-95; ASP-97; ASN-98; TYR-99; LYS-116; PRO-117; SER-118; GLU-119;
RP   ASP-150; ASN-151; TYR-152; LEU-153; TYR-154 AND TYR-208.
RX   PubMed=11786020; DOI=10.1006/jmbi.2001.5243;
RA   Zhang J.-L., Simeonowa I., Wang Y., Sebald W.;
RT   "The high-affinity interaction of human IL-4 and the receptor alpha
RT   chain is constituted by two independent binding clusters.";
RL   J. Mol. Biol. 315:399-407(2002).
RN   [19]
RP   STAT6 ACTIVATION, AND INHIBITION BY TYROSINE PHOSPHATASE SHP1.
RX   PubMed=12459556; DOI=10.1074/jbc.M211747200;
RA   Hanson E.M., Dickensheets H., Qu C.K., Donnelly R.P., Keegan A.D.;
RT   "Regulation of the dephosphorylation of Stat6. Participation of Tyr-
RT   713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-
RT   1, and the proteasome.";
RL   J. Biol. Chem. 278:3903-3911(2003).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-232 IN COMPLEX WITH IL4.
RX   PubMed=10219247; DOI=10.1016/S0092-8674(00)80736-9;
RA   Hage T., Sebald W., Reinemer P.;
RT   "Crystal structure of the interleukin-4/receptor alpha chain complex
RT   reveals a mosaic binding interface.";
RL   Cell 97:271-281(1999).
RN   [21]
RP   VARIANTS VAL-75; ALA-400; ARG-431; LEU-436 AND PRO-786.
RX   PubMed=9070874; DOI=10.1006/bbrc.1997.6115;
RA   Deichmann K., Bardutzky J., Forster J., Heinzmann A., Kuehr J.;
RT   "Common polymorphisms in the coding part of the IL4-receptor gene.";
RL   Biochem. Biophys. Res. Commun. 231:696-697(1997).
RN   [22]
RP   VARIANT ARG-576.
RX   PubMed=9392697; DOI=10.1056/NEJM199712113372403;
RA   Hershey G.K.K., Friedrich M.F., Esswein L.A., Thomas M.L.,
RA   Chatila T.A.;
RT   "The association of atopy with a gain-of-function mutation in the
RT   alpha subunit of the interleukin-4 receptor.";
RL   N. Engl. J. Med. 337:1720-1725(1997).
RN   [23]
RP   VARIANT VAL-75.
RX   PubMed=9620765; DOI=10.1038/472;
RA   Mitsuyasu H., Izuhara K., Mao X.-Q., Gao P.S., Arinobu Y., Enomoto T.,
RA   Kawai M., Sasaki S., Dake Y., Hamasaki N., Shirakawa T., Hopkin J.M.;
RT   "Ile50Val variant of IL4R alpha upregulates IgE synthesis and
RT   associates with atopic asthma.";
RL   Nat. Genet. 19:119-120(1998).
RN   [24]
RP   VARIANT VAL-75.
RX   PubMed=10390422; DOI=10.1164/ajrccm.160.1.9807130;
RA   Noguchi E., Shibasaki M., Arinami T., Takeda K., Yokouchi Y.,
RA   Kobayashi K., Imoto N., Nakahara S., Matsui A., Hamaguchi H.;
RT   "No association between atopy/asthma and the Ile50Val polymorphism of
RT   IL-4 receptor.";
RL   Am. J. Respir. Crit. Care Med. 160:342-345(1999).
RN   [25]
RP   VARIANTS PRO-503 AND ARG-576.
RX   PubMed=10233717; DOI=10.1046/j.1365-2567.1999.00705.x;
RA   Kruse S., Japha T., Tedner M., Sparholt S.H., Forster J., Kuehr J.,
RA   Deichmann K.A.;
RT   "The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha
RT   gene are associated with atopy and influence the signal
RT   transduction.";
RL   Immunology 96:365-371(1999).
RN   [26]
RP   CHARACTERIZATION OF VARIANT ARG-576, AND MUTAGENESIS OF TYR-575.
RX   PubMed=10201973;
RA   Wang H.Y., Shelburne C.P., Zamorano J., Kelly A.E., Ryan J.J.,
RA   Keegan A.D.;
RT   "Effects of an allergy-associated mutation in the human IL-4R alpha
RT   (Q576R) on human IL-4-induced signal transduction.";
RL   J. Immunol. 162:4385-4389(1999).
RN   [27]
RP   VARIANT ALA-752.
RX   PubMed=10677312; DOI=10.1086/302781;
RA   Ober C., Leavitt S.A., Tsalenko A., Howard T.D., Hoki D.M., Daniel R.,
RA   Newman D.L., Wu X., Parry R., Lester L.A., Solway J., Blumenthal M.,
RA   King R.A., Xu J., Meyers D.A., Bleecker E.R., Cox N.J.;
RT   "Variation in the interleukin 4-receptor alpha gene confers
RT   susceptibility to asthma and atopy in ethnically diverse
RT   populations.";
RL   Am. J. Hum. Genet. 66:517-526(2000).
RN   [28]
RP   VARIANT ARG-576.
RX   PubMed=10809862; DOI=10.1046/j.1365-2133.2000.03485.x;
RA   Oiso N., Fukai K., Ishii M.;
RT   "Interleukin 4 receptor alpha chain polymorphism Gln551Arg is
RT   associated with adult atopic dermatitis in Japan.";
RL   Br. J. Dermatol. 142:1003-1006(2000).
RN   [29]
RP   VARIANT PRO-786.
RX   PubMed=11513543; DOI=10.1006/clim.2001.5082;
RA   Andrews R.P., Burrell L., Rosa-Rosa L., Cunningham C.M.,
RA   Brzezinski J.L., Bernstein J.A., Khurana Hershey G.K.;
RT   "Analysis of the Ser786Pro interleukin-4 receptor alpha allelic
RT   variant in allergic and nonallergic asthma and its functional
RT   consequences.";
RL   Clin. Immunol. 100:298-304(2001).
RN   [30]
RP   VARIANTS VAL-75 AND ALA-400, AND POLYMORPHISM.
RX   PubMed=14657871; DOI=10.1016/j.jaci.2003.08.051;
RA   Nakamura H., Miyagawa K., Ogino K., Endo T., Imai T., Ozasa K.,
RA   Motohashi Y., Matsuzaki I., Sasahara S., Hatta K., Eboshida A.;
RT   "High contribution contrast between the genes of eosinophil peroxidase
RT   and IL-4 receptor alpha-chain in Japanese cedar pollinosis.";
RL   J. Allergy Clin. Immunol. 112:1127-1131(2003).
CC   -!- FUNCTION: Receptor for both interleukin 4 and interleukin 13.
CC       Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is
CC       involved in promoting Th2 differentiation. The IL4/IL13 responses
CC       are involved in regulating IgE production and, chemokine and mucus
CC       production at sites of allergic inflammation. In certain cell
CC       types, can signal through activation of insulin receptor
CC       substrates, IRS1/IRS2. {ECO:0000269|PubMed:8124718}.
CC   -!- FUNCTION: Soluble IL4R (sIL4R) inhibits IL4-mediated cell
CC       proliferation and IL5 up-regulation by T-cells.
CC       {ECO:0000269|PubMed:8124718}.
CC   -!- SUBUNIT: The functional IL4 receptor is formed by initial binding
CC       of IL4 to IL4R. Subsequent recruitment to the complex of the
CC       common gamma chain, in immune cells, creates a type I receptor
CC       and, in non-immune cells, of IL13RA1 forms a type II receptor.
CC       IL4R can also interact with the IL13/IL13RA1 complex to form a
CC       similar type II receptor. Interacts with PIK3C3 (By similarity).
CC       Interacts with the SH2-containing phosphatases, PTPN6/SHIP1,
CC       PTPN11/SHIP2 and INPP5D/SHIP (By similarity). Interacts with JAK1
CC       through a Box 1-containing region; inhibited by SOCS5. Interacts
CC       with SOCS5; inhibits IL4 signaling (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P05112:IL4; NbExp=7; IntAct=EBI-367009, EBI-367025;
CC       P42226:STAT6; NbExp=4; IntAct=EBI-367009, EBI-1186478;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Membrane-bound form;
CC         IsoId=P24394-1; Sequence=Displayed;
CC       Name=2; Synonyms=Soluble form, sIL4Ralpha/splice;
CC         IsoId=P24394-2; Sequence=VSP_011116, VSP_011117;
CC       Name=3;
CC         IsoId=P24394-3; Sequence=VSP_053738;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are highly expressed
CC       in activated T-cells.
CC   -!- DOMAIN: The extracellular domain represents the IL4 binding
CC       protein (IL4BP).
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-
CC       surface receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- DOMAIN: Contains 1 copy of a cytoplasmic motif that is referred to
CC       as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This
CC       motif is involved in modulation of cellular responses. The
CC       phosphorylated ITIM motif can bind the SH2 domain of several SH2-
CC       containing phosphatases.
CC   -!- PTM: On IL4 binding, phosphorylated on C-terminal tyrosine
CC       residues. Phosphorylation on any one of tyrosine residues, Tyr-
CC       575, Tyr-603 or Tyr-631, is required for STAT6-induced gene
CC       induction. {ECO:0000269|PubMed:8804422}.
CC   -!- PTM: The soluble form (sIL4R/IL4BP) can also be produced by
CC       proteolytic cleavage at the cell surface (shedding) by a
CC       metalloproteinase. {ECO:0000269|PubMed:10341317}.
CC   -!- POLYMORPHISM: Allelic variants in IL4RA are associated with a
CC       susceptibility to atopy, an immunological condition that can lead
CC       to clinical symptoms such as allergic rhinitis, sinusitis, asthma
CC       and eczema.
CC   -!- POLYMORPHISM: Allelic variants in IL4RA are associated with cedar
CC       pollen sensitization. Individuals develop Japanese cedar
CC       pollinosis with increased exposure to cedar pollen. Japanese cedar
CC       pollinosis is a type I allergic disease with ocular and nasal
CC       symptoms that develop paroxysmally on contact with Japanese cedar
CC       pollen. These symptoms, which occur seasonally each year, are
CC       typical features of allergic rhinitis, such as sneezing, excessive
CC       nasal secretion, nasal congestion, and conjunctival itching.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 4
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 fibronectin type-III domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il4r/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL4R";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52425; CAA36672.1; -; mRNA.
DR   EMBL; AC004525; AAC23495.1; -; Genomic_DNA.
DR   EMBL; AF421855; AAL12163.1; -; Genomic_DNA.
DR   EMBL; AJ293647; CAC20445.1; -; Genomic_DNA.
DR   EMBL; AJ293648; CAC20446.1; -; Genomic_DNA.
DR   EMBL; AJ293649; CAC20447.1; -; Genomic_DNA.
DR   EMBL; AJ293650; CAC20448.1; -; Genomic_DNA.
DR   EMBL; AJ293651; CAC20449.1; -; Genomic_DNA.
DR   EMBL; AJ293652; CAC20450.1; -; Genomic_DNA.
DR   EMBL; AJ293653; CAC20451.1; -; Genomic_DNA.
DR   EMBL; AK303255; BAG64338.1; -; mRNA.
DR   EMBL; AC106739; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC151131; AAI51132.1; -; mRNA.
DR   EMBL; AJ293654; CAC20452.1; -; Genomic_DNA.
DR   CCDS; CCDS10629.1; -. [P24394-1]
DR   CCDS; CCDS58441.1; -. [P24394-3]
DR   PIR; A60386; A60386.
DR   RefSeq; NP_000409.1; NM_000418.3. [P24394-1]
DR   RefSeq; NP_001244335.1; NM_001257406.1. [P24394-1]
DR   RefSeq; NP_001244336.1; NM_001257407.1. [P24394-3]
DR   RefSeq; XP_011544127.1; XM_011545825.1. [P24394-1]
DR   RefSeq; XP_011544128.1; XM_011545826.1. [P24394-1]
DR   RefSeq; XP_011544129.1; XM_011545827.1. [P24394-1]
DR   UniGene; Hs.513457; -.
DR   UniGene; Hs.742121; -.
DR   PDB; 1IAR; X-ray; 2.30 A; B=26-232.
DR   PDB; 1IRS; NMR; -; B=489-499.
DR   PDB; 1ITE; Model; -; C=26-232.
DR   PDB; 3BPL; X-ray; 2.93 A; B=27-227.
DR   PDB; 3BPN; X-ray; 3.02 A; B=27-227.
DR   PDB; 3BPO; X-ray; 3.00 A; B=27-227.
DR   PDB; 5E4E; X-ray; 3.00 A; B=26-228.
DR   PDBsum; 1IAR; -.
DR   PDBsum; 1IRS; -.
DR   PDBsum; 1ITE; -.
DR   PDBsum; 3BPL; -.
DR   PDBsum; 3BPN; -.
DR   PDBsum; 3BPO; -.
DR   PDBsum; 5E4E; -.
DR   ProteinModelPortal; P24394; -.
DR   SMR; P24394; 27-224.
DR   BioGrid; 109780; 38.
DR   DIP; DIP-3223N; -.
DR   IntAct; P24394; 11.
DR   MINT; MINT-90363; -.
DR   STRING; 9606.ENSP00000170630; -.
DR   GuidetoPHARMACOLOGY; 1697; -.
DR   iPTMnet; P24394; -.
DR   PhosphoSite; P24394; -.
DR   BioMuta; IL4R; -.
DR   DMDM; 124335; -.
DR   MaxQB; P24394; -.
DR   PaxDb; P24394; -.
DR   PRIDE; P24394; -.
DR   Ensembl; ENST00000170630; ENSP00000170630; ENSG00000077238. [P24394-3]
DR   Ensembl; ENST00000395762; ENSP00000379111; ENSG00000077238. [P24394-1]
DR   Ensembl; ENST00000543915; ENSP00000441667; ENSG00000077238. [P24394-1]
DR   GeneID; 3566; -.
DR   KEGG; hsa:3566; -.
DR   UCSC; uc002don.4; human. [P24394-1]
DR   UCSC; uc002dop.5; human.
DR   CTD; 3566; -.
DR   GeneCards; IL4R; -.
DR   HGNC; HGNC:6015; IL4R.
DR   HPA; CAB004451; -.
DR   HPA; HPA050124; -.
DR   MalaCards; IL4R; -.
DR   MIM; 147781; gene.
DR   neXtProt; NX_P24394; -.
DR   PharmGKB; PA29832; -.
DR   eggNOG; ENOG410IGBQ; Eukaryota.
DR   eggNOG; ENOG41124QC; LUCA.
DR   GeneTree; ENSGT00510000049182; -.
DR   HOVERGEN; HBG052116; -.
DR   InParanoid; P24394; -.
DR   KO; K05071; -.
DR   OMA; SPCCGCC; -.
DR   OrthoDB; EOG73RBCJ; -.
DR   PhylomeDB; P24394; -.
DR   TreeFam; TF337996; -.
DR   SignaLink; P24394; -.
DR   ChiTaRS; IL4R; human.
DR   EvolutionaryTrace; P24394; -.
DR   GeneWiki; Interleukin-4_receptor; -.
DR   GenomeRNAi; 3566; -.
DR   NextBio; 13926; -.
DR   PRO; PR:P24394; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; P24394; -.
DR   ExpressionAtlas; P24394; baseline and differential.
DR   Genevisible; P24394; HS.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; TAS:GOC.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0004913; F:interleukin-4 receptor activity; TAS:ProtInc.
DR   GO; GO:0005057; F:receptor signaling protein activity; TAS:ProtInc.
DR   GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0016064; P:immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0035771; P:interleukin-4-mediated signaling pathway; TAS:GOC.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:GOC.
DR   GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; IEA:Ensembl.
DR   GO; GO:0030728; P:ovulation; IEA:Ensembl.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IEA:Ensembl.
DR   GO; GO:0002639; P:positive regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; IEA:Ensembl.
DR   GO; GO:0043306; P:positive regulation of mast cell degranulation; IEA:Ensembl.
DR   GO; GO:1901741; P:positive regulation of myoblast fusion; IEA:Ensembl.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IEA:Ensembl.
DR   GO; GO:0002532; P:production of molecular mediator involved in inflammatory response; IEA:InterPro.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR003531; Hempt_rcpt_S_F1_CS.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR015319; IL-4_rcpt-alpha_N.
DR   Pfam; PF09238; IL4Ra_N; 1.
DR   SMART; SM00060; FN3; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS01355; HEMATOPO_REC_S_F1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Immunity; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Secreted; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     25       {ECO:0000250}.
FT   CHAIN        26    825       Interleukin-4 receptor subunit alpha.
FT                                /FTId=PRO_0000010887.
FT   CHAIN        26      ?       Soluble interleukin-4 receptor subunit
FT                                alpha.
FT                                /FTId=PRO_0000010888.
FT   TOPO_DOM     26    232       Extracellular. {ECO:0000255}.
FT   TRANSMEM    233    256       Helical. {ECO:0000255}.
FT   TOPO_DOM    257    825       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      125    224       Fibronectin type-III.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   REGION      437    557       Required for IRS1 activation and IL4-
FT                                induced cell growth.
FT   REGION      558    657       Required for IL4-induced gene expression.
FT   MOTIF       212    216       WSXWS motif.
FT   MOTIF       262    270       Box 1 motif.
FT   MOTIF       711    716       ITIM motif.
FT   COMPBIAS    370    380       Poly-Glu.
FT   COMPBIAS    563    566       Poly-Ala.
FT   COMPBIAS    789    794       Poly-Ser.
FT   SITE         38     38       Major IL4 binding determinant.
FT   SITE         64     64       Minor IL4 binding determinant.
FT   SITE         66     66       Minor IL4 binding determinant.
FT   SITE         92     92       Minor IL4 binding determinant.
FT   SITE         94     94       Minor IL4 binding determinant.
FT   SITE         97     97       Major IL4 binding determinant.
FT   SITE        152    152       Minor IL4 binding determinant.
FT   SITE        208    208       Major IL4 binding determinant.
FT   MOD_RES     497    497       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:8804422}.
FT   MOD_RES     575    575       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:8804422}.
FT   MOD_RES     603    603       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:8804422}.
FT   MOD_RES     631    631       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:8804422}.
FT   CARBOHYD     53     53       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    128    128       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    134    134       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    176    176       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    209    209       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     34     44       {ECO:0000250}.
FT   DISULFID     74     86       {ECO:0000250}.
FT   VAR_SEQ       1     23       MGWLCSGLLFPVSCLVLLQVASS -> MQKDARRE (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_053738.
FT   VAR_SEQ     225    227       YRE -> NIC (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_011116.
FT   VAR_SEQ     228    825       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_011117.
FT   VARIANT      75     75       I -> F (in dbSNP:rs1805010).
FT                                /FTId=VAR_059302.
FT   VARIANT      75     75       I -> L (in dbSNP:rs1805010).
FT                                /FTId=VAR_059303.
FT   VARIANT      75     75       I -> V (associated with atopic asthma and
FT                                cedar pollen sensitization;
FT                                dbSNP:rs1805010).
FT                                {ECO:0000269|PubMed:10390422,
FT                                ECO:0000269|PubMed:14657871,
FT                                ECO:0000269|PubMed:9070874,
FT                                ECO:0000269|PubMed:9620765,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_008034.
FT   VARIANT     387    387       S -> L (in dbSNP:rs6413500).
FT                                /FTId=VAR_019999.
FT   VARIANT     400    400       E -> A (associated with cedar pollen
FT                                sensitization; dbSNP:rs1805011).
FT                                {ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|PubMed:14657871,
FT                                ECO:0000269|PubMed:9070874,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011657.
FT   VARIANT     431    431       C -> R (in dbSNP:rs1805012).
FT                                {ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|PubMed:9070874,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011658.
FT   VARIANT     436    436       S -> L (in dbSNP:rs1805013).
FT                                {ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|PubMed:9070874,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011659.
FT   VARIANT     492    492       A -> T (in dbSNP:rs35606110).
FT                                /FTId=VAR_049164.
FT   VARIANT     492    492       A -> V (in dbSNP:rs34727572).
FT                                /FTId=VAR_049165.
FT   VARIANT     503    503       S -> P (lowered total IgE concentration;
FT                                dbSNP:rs1805015).
FT                                {ECO:0000269|PubMed:10233717,
FT                                ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011660.
FT   VARIANT     576    576       Q -> R (associated with atopic
FT                                dermatitis; lowered total IgE
FT                                concentration; no effect on IL4-induced
FT                                signal transduction; dbSNP:rs1801275).
FT                                {ECO:0000269|PubMed:10201973,
FT                                ECO:0000269|PubMed:10233717,
FT                                ECO:0000269|PubMed:10809862,
FT                                ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|PubMed:9392697,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_008035.
FT   VARIANT     579    579       V -> I (in dbSNP:rs3024677).
FT                                {ECO:0000269|PubMed:11285129,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011661.
FT   VARIANT     675    675       P -> S (in dbSNP:rs3024678).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_020000.
FT   VARIANT     752    752       S -> A (in dbSNP:rs1805016).
FT                                {ECO:0000269|PubMed:10677312,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011662.
FT   VARIANT     786    786       S -> P (in 1.8% of the population;
FT                                dbSNP:rs1805014).
FT                                {ECO:0000269|PubMed:11513543,
FT                                ECO:0000269|PubMed:9070874}.
FT                                /FTId=VAR_011663.
FT   MUTAGEN      38     38       Y->A: 700-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      38     38       Y->F: 25-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      39     39       M->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      40     40       S->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      64     64       L->A: 100-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      66     66       F->A: 45-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      67     67       L->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      68     68       L->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      91     91       D->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      92     92       D->A: 50-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      93     93       V->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      94     94       V->A: 35-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      95     95       S->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      97     97       D->A,N: >150-fold reduction in IL4
FT                                binding. {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      98     98       N->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN      99     99       Y->A: 10-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     116    116       K->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     117    117       P->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     118    118       S->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     119    119       E->A: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     150    150       D->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     151    151       N->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     152    152       Y->A: 40-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     152    152       Y->F: No effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     153    153       L->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     154    154       Y->A: Little effect on IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     208    208       Y->A: 500-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     208    208       Y->F: 200-fold reduction in IL4 binding.
FT                                {ECO:0000269|PubMed:11786020}.
FT   MUTAGEN     497    497       Y->F: Abolishes IRS1 tyrosine
FT                                phosphorylation. No cell proliferation.
FT                                {ECO:0000269|PubMed:8124718}.
FT   MUTAGEN     575    575       Y->F: Loss of CD23 gene induction; when
FT                                associated with F-603 and F-631.
FT                                {ECO:0000269|PubMed:10201973,
FT                                ECO:0000269|PubMed:8624803}.
FT   MUTAGEN     603    603       Y->F: Loss of CD23 gene induction; when
FT                                associated with F-575 and F-631.
FT                                {ECO:0000269|PubMed:8624803}.
FT   MUTAGEN     631    631       Y->F: Loss of CD23 gene induction; when
FT                                associated with F-575 and F-603.
FT                                {ECO:0000269|PubMed:8624803}.
FT   MUTAGEN     713    713       Y->F: Increased IL4-induced cell
FT                                proliferation and STAT6 activation.
FT                                {ECO:0000269|PubMed:11714803}.
FT   STRAND       28     36       {ECO:0000244|PDB:1IAR}.
FT   STRAND       38     50       {ECO:0000244|PDB:1IAR}.
FT   HELIX        54     57       {ECO:0000244|PDB:1IAR}.
FT   STRAND       58     68       {ECO:0000244|PDB:1IAR}.
FT   STRAND       72     74       {ECO:0000244|PDB:1IAR}.
FT   STRAND       77     89       {ECO:0000244|PDB:1IAR}.
FT   STRAND       99    105       {ECO:0000244|PDB:1IAR}.
FT   STRAND      108    115       {ECO:0000244|PDB:1IAR}.
FT   HELIX       117    119       {ECO:0000244|PDB:1IAR}.
FT   STRAND      127    132       {ECO:0000244|PDB:1IAR}.
FT   TURN        135    137       {ECO:0000244|PDB:3BPO}.
FT   STRAND      139    144       {ECO:0000244|PDB:1IAR}.
FT   HELIX       154    156       {ECO:0000244|PDB:1IAR}.
FT   STRAND      158    168       {ECO:0000244|PDB:1IAR}.
FT   STRAND      172    177       {ECO:0000244|PDB:1IAR}.
FT   STRAND      183    186       {ECO:0000244|PDB:1IAR}.
FT   HELIX       188    190       {ECO:0000244|PDB:3BPL}.
FT   STRAND      193    195       {ECO:0000244|PDB:3BPO}.
FT   STRAND      197    204       {ECO:0000244|PDB:1IAR}.
FT   HELIX       206    208       {ECO:0000244|PDB:1IAR}.
FT   STRAND      219    221       {ECO:0000244|PDB:1IAR}.
FT   HELIX       495    497       {ECO:0000244|PDB:1IRS}.
SQ   SEQUENCE   825 AA;  89658 MW;  9F886DF5612297F8 CRC64;
     MGWLCSGLLF PVSCLVLLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMNG PTNCSTELRL
     LYQLVFLLSE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSFKPSEH
     VKPRAPGNLT VHTNVSDTLL LTWSNPYPPD NYLYNHLTYA VNIWSENDPA DFRIYNVTYL
     EPSLRIAAST LKSGISYRAR VRAWAQCYNT TWSEWSPSTK WHNSYREPFE QHLLLGVSVS
     CIVILAVCLL CYVSITKIKK EWWDQIPNPA RSRLVAIIIQ DAQGSQWEKR SRGQEPAKCP
     HWKNCLTKLL PCFLEHNMKR DEDPHKAAKE MPFQGSGKSA WCPVEISKTV LWPESISVVR
     CVELFEAPVE CEEEEEVEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG
     GFCQQDMGES CLLPPSGSTS AHMPWDEFPS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD
     NLTCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT
     TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE
     AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE
     PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGSG IVYSALTCHL
     CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL
     APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVS
//
ID   PAI1_HUMAN              Reviewed;         402 AA.
AC   P05121; B7Z4S0; F8WD53;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   17-FEB-2016, entry version 196.
DE   RecName: Full=Plasminogen activator inhibitor 1;
DE            Short=PAI;
DE            Short=PAI-1;
DE   AltName: Full=Endothelial plasminogen activator inhibitor;
DE   AltName: Full=Serpin E1;
DE   Flags: Precursor;
GN   Name=SERPINE1; Synonyms=PAI1, PLANH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2430793;
RA   Pannekoek H., Veerman H., Lambers H., Diergaarde P., Verweij C.L.,
RA   van Zonneveld A.-J., van Mourik J.A.;
RT   "Endothelial plasminogen activator inhibitor (PAI): a new member of
RT   the Serpin gene family.";
RL   EMBO J. 5:2539-2544(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2820474; DOI=10.1021/bi00387a004;
RA   Loskutoff D.J., Linders M., Keijer J., Veerman H.,
RA   van Heerikhuizen H., Pannekoek H.;
RT   "Structure of the human plasminogen activator inhibitor 1 gene:
RT   nonrandom distribution of introns.";
RL   Biochemistry 26:3763-3768(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3097076; DOI=10.1172/JCI112761;
RA   Ginsburg D., Zeheb R., Yang A.Y., Rafferty U.M., Andreasen P.A.,
RA   Nielsen L., Dano K., Lebo R.V., Gelehrter T.D.;
RT   "cDNA cloning of human plasminogen activator-inhibitor from
RT   endothelial cells.";
RL   J. Clin. Invest. 78:1673-1680(1986).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2612914; DOI=10.1016/0378-1119(89)90519-2;
RA   Follo M., Ginsburg D.;
RT   "Structure and expression of the human gene encoding plasminogen
RT   activator inhibitor, PAI-1.";
RL   Gene 84:447-453(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3262512; DOI=10.1111/j.1432-1033.1988.tb14320.x;
RA   Strandberg L., Lawrence D., Ny T.;
RT   "The organization of the human-plasminogen-activator-inhibitor-1 gene.
RT   Implications on the evolution of the serine-protease inhibitor
RT   family.";
RL   Eur. J. Biochem. 176:609-616(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3132455;
RA   Bosma P.J., van den Berg E.A., Kooistra T., Siemieniak D.R.,
RA   Slightom J.L.;
RT   "Human plasminogen activator inhibitor-1 gene. Promoter and structural
RT   gene nucleotide sequences.";
RL   J. Biol. Chem. 263:9129-9141(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Pannekoek H.;
RL   Submitted (FEB-1992) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-15; ILE-17;
RP   PRO-25; HIS-209 AND ASN-255.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-402 (ISOFORM 1).
RX   PubMed=3092219; DOI=10.1073/pnas.83.18.6776;
RA   Ny T., Sawdey M., Lawrence D., Millan J.L., Loskutoff D.J.;
RT   "Cloning and sequence of a cDNA coding for the human beta-migrating
RT   endothelial-cell-type plasminogen activator inhibitor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6776-6780(1986).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-47 AND 364-402 (ISOFORM 1).
RX   PubMed=3025016; DOI=10.1016/0014-5793(86)81113-9;
RA   Andreasen P.A., Riccio A., Welinder K.G., Douglas R., Sartorio R.,
RA   Nielsen L.S., Oppenheimer C., Blasi F., Danoe K.;
RT   "Plasminogen activator inhibitor type-1: reactive center and amino-
RT   terminal heterogeneity determined by protein and cDNA sequencing.";
RL   FEBS Lett. 209:213-218(1986).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-402 (ISOFORM 1), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Placenta;
RX   PubMed=3026837; DOI=10.1016/0014-5793(87)81288-7;
RA   Wun T.C., Kretzmer K.K.;
RT   "cDNA cloning and expression in E. coli of a plasminogen activator
RT   inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell.";
RL   FEBS Lett. 210:11-16(1987).
RN   [15]
RP   INTERACTION WITH VTN.
RX   PubMed=7522053; DOI=10.1016/0167-4838(94)90166-X;
RA   Sigurdardottir O., Wiman B.;
RT   "Identification of a PAI-1 binding site in vitronectin.";
RL   Biochim. Biophys. Acta 1208:104-110(1994).
RN   [16]
RP   INVOLVEMENT IN PAI-1D.
RX   PubMed=9207454;
RA   Fay W.P., Parker A.C., Condrey L.R., Shapiro A.D.;
RT   "Human plasminogen activator inhibitor-1 (PAI-1) deficiency:
RT   characterization of a large kindred with a null mutation in the PAI-1
RT   gene.";
RL   Blood 90:204-208(1997).
RN   [17]
RP   INTERACTION WITH LRP1B.
RX   PubMed=11384978; DOI=10.1074/jbc.M102727200;
RA   Liu C.-X., Li Y., Obermoeller-McCormick L.M., Schwartz A.L., Bu G.;
RT   "The putative tumor suppressor LRP1B, a novel member of the low
RT   density lipoprotein (LDL) receptor family, exhibits both overlapping
RT   and distinct properties with the LDL receptor-related protein.";
RL   J. Biol. Chem. 276:28889-28896(2001).
RN   [18]
RP   FUNCTION IN MEMBRANE-ANCHORED SERINE PROTEASE TMPRSS7 INHIBITION, AND
RP   HETERODIMER WITH TMPRSS7.
RX   PubMed=15853774; DOI=10.1042/BJ20050299;
RA   Szabo R., Netzel-Arnett S., Hobson J.P., Antalis T.M., Bugge T.H.;
RT   "Matriptase-3 is a novel phylogenetically preserved membrane-anchored
RT   serine protease with broad serpin reactivity.";
RL   Biochem. J. 390:231-242(2005).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=1731226; DOI=10.1038/355270a0;
RA   Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E.,
RA   Geoghegan K.F., Gerard R.D., Goldsmith E.J.;
RT   "Structural basis of latency in plasminogen activator inhibitor-1.";
RL   Nature 355:270-273(1992).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RX   PubMed=7552714; DOI=10.1038/nsb1095-891;
RA   Aertgeerts K., de Bondt H.L., de Ranter C.J., Declerck P.J.;
RT   "Mechanisms contributing to the conformational and functional
RT   flexibility of plasminogen activator inhibitor-1.";
RL   Nat. Struct. Biol. 2:891-897(1995).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS).
RX   PubMed=9634700; DOI=10.1016/S0969-2126(98)00064-1;
RA   Xue Y., Bjoerquist P., Inghardt T., Linschoten M., Musil D.,
RA   Sjoelin L., Deinum J.;
RT   "Interfering with the inhibitory mechanism of serpins: crystal
RT   structure of a complex formed between cleaved plasminogen activator
RT   inhibitor type 1 and a reactive-centre loop peptide.";
RL   Structure 6:627-636(1998).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.99 ANGSTROMS).
RX   PubMed=10368279; DOI=10.1016/S0969-2126(99)80018-5;
RA   Sharp A.M., Stein P.E., Pannu N.S., Carrell R.W., Berkenpas M.B.,
RA   Ginsburg D., Lawrence D.A., Read R.J.;
RT   "The active conformation of plasminogen activator inhibitor 1, a
RT   target for drugs to control fibrinolysis and cell adhesion.";
RL   Structure 7:111-118(1999).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RX   PubMed=10731421; DOI=10.1006/jmbi.2000.3604;
RA   Nar H., Bauer M., Stassen J.M., Lang D., Gils A., Declerck P.J.;
RT   "Plasminogen activator inhibitor 1. Structure of the native serpin,
RT   comparison to its other conformers and implications for serpin
RT   inactivation.";
RL   J. Mol. Biol. 297:683-695(2000).
RN   [25]
RP   VARIANT THR-15.
RX   PubMed=9194591; DOI=10.1002/elps.1150180505;
RA   Turkmen B., Schmitt M., Schmalfeldt B., Trommler P., Hell W.,
RA   Creutzburg S., Graeff H., Magdolen V.;
RT   "Mutational analysis of the genes encoding urokinase-type plasminogen
RT   activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.";
RL   Electrophoresis 18:686-689(1997).
RN   [26]
RP   VARIANTS THR-15 AND ILE-17.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [27]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: Serine protease inhibitor. This inhibitor acts as 'bait'
CC       for tissue plasminogen activator, urokinase, protein C and
CC       matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function
CC       as a major control point in the regulation of fibrinolysis.
CC       {ECO:0000269|PubMed:15853774}.
CC   -!- SUBUNIT: Forms protease inhibiting heterodimer with TMPRSS7.
CC       Interacts with VTN. Binds LRP1B; binding is followed by
CC       internalization and degradation. {ECO:0000269|PubMed:11384978,
CC       ECO:0000269|PubMed:7522053}.
CC   -!- INTERACTION:
CC       P02763:ORM1; NbExp=4; IntAct=EBI-953978, EBI-976767;
CC       O43765:SGTA; NbExp=3; IntAct=EBI-953978, EBI-347996;
CC       Q96EQ0:SGTB; NbExp=3; IntAct=EBI-953978, EBI-744081;
CC       Q9UMX0:UBQLN1; NbExp=3; IntAct=EBI-953978, EBI-741480;
CC       Q9UMX0-2:UBQLN1; NbExp=3; IntAct=EBI-953978, EBI-10173939;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P05121-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P05121-2; Sequence=VSP_045493;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Found in plasma and platelets and in
CC       endothelial, hepatoma and fibrosarcoma cells.
CC   -!- PTM: Inactivated by proteolytic attack of the urokinase-type (u-
CC       PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370
CC       bond.
CC   -!- DISEASE: Plasminogen activator inhibitor-1 deficiency (PAI-1D)
CC       [MIM:613329]: A hematologic disorder characterized by increased
CC       bleeding after trauma, injury, or surgery. Affected females have
CC       menorrhagia. The bleeding defect is due to increased fibrinolysis
CC       of fibrin blood clots due to deficiency of plasminogen activator
CC       inhibitor-1, which inhibits tissue and urinary activators of
CC       plasminogen. {ECO:0000269|PubMed:9207454}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=High concentrations of SERPINE1 seem to contribute
CC       to the development of venous but not arterial occlusions.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Plasminogen activator
CC       inhibitor-1 entry;
CC       URL="https://en.wikipedia.org/wiki/Plasminogen_activator_inhibitor-1";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/serpine1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04429; CAA28025.1; -; mRNA.
DR   EMBL; M14083; AAA60008.1; -; mRNA.
DR   EMBL; X04729; CAA28438.1; -; mRNA.
DR   EMBL; X04731; CAA28442.1; -; mRNA.
DR   EMBL; M16006; AAA60003.1; -; mRNA.
DR   EMBL; M22321; AAA60009.1; -; Genomic_DNA.
DR   EMBL; M22314; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22315; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22316; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22317; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22318; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22319; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; M22320; AAA60009.1; JOINED; Genomic_DNA.
DR   EMBL; X13323; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X13338; CAA31722.1; -; Genomic_DNA.
DR   EMBL; X13339; CAB51639.1; -; Genomic_DNA.
DR   EMBL; X13340; CAB51737.1; -; Genomic_DNA.
DR   EMBL; X13341; CAB51606.1; -; Genomic_DNA.
DR   EMBL; X13342; CAB51607.1; -; Genomic_DNA.
DR   EMBL; X13343; CAB51738.1; -; Genomic_DNA.
DR   EMBL; X13344; CAB51739.1; -; Genomic_DNA.
DR   EMBL; X13345; CAA31729.1; -; Genomic_DNA.
DR   EMBL; J03764; AAA60007.1; -; Genomic_DNA.
DR   EMBL; X12701; CAA31208.1; -; mRNA.
DR   EMBL; AF386492; AAK60338.1; -; Genomic_DNA.
DR   EMBL; AK297728; BAH12656.1; -; mRNA.
DR   EMBL; AC004876; AAD45828.1; -; Genomic_DNA.
DR   EMBL; BC010860; AAH10860.1; -; mRNA.
DR   EMBL; X04744; CAA28444.1; -; mRNA.
DR   CCDS; CCDS5711.1; -. [P05121-1]
DR   PIR; A28107; ITHUP1.
DR   RefSeq; NP_000593.1; NM_000602.4. [P05121-1]
DR   UniGene; Hs.414795; -.
DR   UniGene; Hs.713079; -.
DR   UniGene; Hs.741440; -.
DR   PDB; 1A7C; X-ray; 1.95 A; A=24-402.
DR   PDB; 1B3K; X-ray; 2.99 A; A/B/C/D=24-402.
DR   PDB; 1C5G; X-ray; 2.60 A; A=1-402.
DR   PDB; 1DB2; X-ray; 2.70 A; A/B=26-402.
DR   PDB; 1DVM; X-ray; 2.40 A; A/B/C/D=24-402.
DR   PDB; 1DVN; X-ray; 2.10 A; A=24-402.
DR   PDB; 1LJ5; X-ray; 1.80 A; A=24-402.
DR   PDB; 1OC0; X-ray; 2.28 A; A=24-402.
DR   PDB; 3CVM; X-ray; 2.02 A; A/B=21-402.
DR   PDB; 3EOX; X-ray; 2.61 A; A=24-402.
DR   PDB; 3PB1; X-ray; 2.30 A; I=24-402.
DR   PDB; 3Q02; X-ray; 2.30 A; A/B=24-402.
DR   PDB; 3Q03; X-ray; 2.64 A; A/B=24-402.
DR   PDB; 3R4L; X-ray; 2.70 A; A=24-402.
DR   PDB; 3UT3; X-ray; 2.42 A; A/B/C/D=28-402.
DR   PDB; 4AQH; X-ray; 2.40 A; A/B/C=24-402.
DR   PDB; 4G8O; X-ray; 2.71 A; A/B/C/D=28-402.
DR   PDB; 4G8R; X-ray; 2.19 A; A/B=28-402.
DR   PDB; 4IC0; X-ray; 2.32 A; A/B/C/D=24-402.
DR   PDB; 5BRR; X-ray; 3.16 A; I=24-402.
DR   PDB; 9PAI; X-ray; 2.70 A; A=24-369, B=370-402.
DR   PDBsum; 1A7C; -.
DR   PDBsum; 1B3K; -.
DR   PDBsum; 1C5G; -.
DR   PDBsum; 1DB2; -.
DR   PDBsum; 1DVM; -.
DR   PDBsum; 1DVN; -.
DR   PDBsum; 1LJ5; -.
DR   PDBsum; 1OC0; -.
DR   PDBsum; 3CVM; -.
DR   PDBsum; 3EOX; -.
DR   PDBsum; 3PB1; -.
DR   PDBsum; 3Q02; -.
DR   PDBsum; 3Q03; -.
DR   PDBsum; 3R4L; -.
DR   PDBsum; 3UT3; -.
DR   PDBsum; 4AQH; -.
DR   PDBsum; 4G8O; -.
DR   PDBsum; 4G8R; -.
DR   PDBsum; 4IC0; -.
DR   PDBsum; 5BRR; -.
DR   PDBsum; 9PAI; -.
DR   DisProt; DP00320; -.
DR   ProteinModelPortal; P05121; -.
DR   SMR; P05121; 24-402.
DR   BioGrid; 111091; 16.
DR   IntAct; P05121; 9.
DR   MINT; MINT-202409; -.
DR   STRING; 9606.ENSP00000223095; -.
DR   BindingDB; P05121; -.
DR   ChEMBL; CHEMBL3475; -.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB00055; Drotrecogin alfa.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00031; Tenecteplase.
DR   DrugBank; DB00013; Urokinase.
DR   MEROPS; I04.020; -.
DR   PhosphoSite; P05121; -.
DR   UniCarbKB; P05121; -.
DR   BioMuta; SERPINE1; -.
DR   DMDM; 129576; -.
DR   OGP; P05121; -.
DR   SWISS-2DPAGE; P05121; -.
DR   MaxQB; P05121; -.
DR   PaxDb; P05121; -.
DR   PRIDE; P05121; -.
DR   DNASU; 5054; -.
DR   Ensembl; ENST00000223095; ENSP00000223095; ENSG00000106366. [P05121-1]
DR   GeneID; 5054; -.
DR   KEGG; hsa:5054; -.
DR   UCSC; uc003uxt.4; human. [P05121-1]
DR   CTD; 5054; -.
DR   GeneCards; SERPINE1; -.
DR   HGNC; HGNC:8583; SERPINE1.
DR   HPA; HPA050039; -.
DR   MalaCards; SERPINE1; -.
DR   MIM; 173360; gene.
DR   MIM; 613329; phenotype.
DR   neXtProt; NX_P05121; -.
DR   Orphanet; 465; Congenital plasminogen activator inhibitor type 1 deficiency.
DR   PharmGKB; PA261; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00760000118789; -.
DR   HOGENOM; HOG000238519; -.
DR   HOVERGEN; HBG106493; -.
DR   InParanoid; P05121; -.
DR   KO; K03982; -.
DR   OMA; IVNDWVK; -.
DR   OrthoDB; EOG7327PB; -.
DR   PhylomeDB; P05121; -.
DR   TreeFam; TF352620; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-75205; Dissolution of Fibrin Clot.
DR   ChiTaRS; SERPINE1; human.
DR   EvolutionaryTrace; P05121; -.
DR   GeneWiki; Plasminogen_activator_inhibitor-1; -.
DR   GenomeRNAi; 5054; -.
DR   NextBio; 19480; -.
DR   PMAP-CutDB; P05121; -.
DR   PRO; PR:P05121; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; P05121; -.
DR   CleanEx; HS_SERPINE1; -.
DR   ExpressionAtlas; P05121; baseline and differential.
DR   Genevisible; P05121; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IMP:BHF-UCL.
DR   GO; GO:0001300; P:chronological cell aging; IEP:BHF-UCL.
DR   GO; GO:0007623; P:circadian rhythm; TAS:Reactome.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IGI:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0030195; P:negative regulation of blood coagulation; IC:BHF-UCL.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IDA:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IDA:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IMP:BHF-UCL.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; IDA:BHF-UCL.
DR   GO; GO:0010757; P:negative regulation of plasminogen activation; IDA:BHF-UCL.
DR   GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IDA:BHF-UCL.
DR   GO; GO:2000098; P:negative regulation of smooth muscle cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0061044; P:negative regulation of vascular wound healing; IGI:BHF-UCL.
DR   GO; GO:0061045; P:negative regulation of wound healing; IC:BHF-UCL.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IMP:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IGI:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IMP:BHF-UCL.
DR   GO; GO:0035491; P:positive regulation of leukotriene production involved in inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010469; P:regulation of receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; TAS:Reactome.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Glycoprotein; Polymorphism;
KW   Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     23
FT   CHAIN        24    402       Plasminogen activator inhibitor 1.
FT                                /FTId=PRO_0000032499.
FT   SITE        369    370       Reactive bond.
FT   CARBOHYD    232    232       N-linked (GlcNAc...).
FT   CARBOHYD    288    288       N-linked (GlcNAc...).
FT   CARBOHYD    352    352       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ      31     45       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045493.
FT   VARIANT      15     15       A -> T (in dbSNP:rs6092).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:9194591,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_007099.
FT   VARIANT      17     17       V -> I (in dbSNP:rs6090).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_011750.
FT   VARIANT      25     25       H -> P (in dbSNP:rs2227647).
FT                                {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_013086.
FT   VARIANT     209    209       R -> H (in dbSNP:rs2227669).
FT                                {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_013087.
FT   VARIANT     255    255       T -> N (in dbSNP:rs2227685).
FT                                {ECO:0000269|Ref.8}.
FT                                /FTId=VAR_013088.
FT   CONFLICT     53     53       R -> A (in Ref. 7; CAA31208).
FT                                {ECO:0000305}.
FT   CONFLICT     55     55       V -> L (in Ref. 2; AAA60009).
FT                                {ECO:0000305}.
FT   CONFLICT     75     75       G -> V (in Ref. 7; CAA31208).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       R -> K (in Ref. 7; CAA31208).
FT                                {ECO:0000305}.
FT   CONFLICT    226    226       A -> V (in Ref. 9; BAH12656).
FT                                {ECO:0000305}.
FT   CONFLICT    280    282       QLI -> HVM (in Ref. 7; CAA31208).
FT                                {ECO:0000305}.
FT   HELIX        27     49       {ECO:0000244|PDB:1LJ5}.
FT   STRAND       51     53       {ECO:0000244|PDB:4IC0}.
FT   STRAND       55     57       {ECO:0000244|PDB:1LJ5}.
FT   HELIX        59     72       {ECO:0000244|PDB:1LJ5}.
FT   HELIX        75     85       {ECO:0000244|PDB:1LJ5}.
FT   HELIX        94    106       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       108    110       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      111    123       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       132    140       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      145    147       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       149    151       {ECO:0000244|PDB:3UT3}.
FT   HELIX       152    165       {ECO:0000244|PDB:1LJ5}.
FT   TURN        166    169       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      170    172       {ECO:0000244|PDB:9PAI}.
FT   HELIX       176    179       {ECO:0000244|PDB:4G8R}.
FT   STRAND      186    200       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       204    206       {ECO:0000244|PDB:3CVM}.
FT   STRAND      209    213       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      216    218       {ECO:0000244|PDB:1C5G}.
FT   STRAND      219    237       {ECO:0000244|PDB:1LJ5}.
FT   TURN        239    241       {ECO:0000244|PDB:1C5G}.
FT   STRAND      243    251       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      254    265       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       271    274       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       279    288       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      290    299       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      301    308       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       310    315       {ECO:0000244|PDB:1LJ5}.
FT   HELIX       320    322       {ECO:0000244|PDB:1LJ5}.
FT   TURN        324    326       {ECO:0000244|PDB:1LJ5}.
FT   TURN        330    332       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      334    336       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      340    351       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      353    368       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      374    376       {ECO:0000244|PDB:3CVM}.
FT   STRAND      380    387       {ECO:0000244|PDB:1LJ5}.
FT   TURN        388    391       {ECO:0000244|PDB:1LJ5}.
FT   STRAND      392    400       {ECO:0000244|PDB:1LJ5}.
SQ   SEQUENCE   402 AA;  45060 MW;  A2E181ED28DD6082 CRC64;
     MQMSPALTCL VLGLALVFGE GSAVHHPPSY VAHLASDFGV RVFQQVAQAS KDRNVVFSPY
     GVASVLAMLQ LTTGGETQQQ IQAAMGFKID DKGMAPALRH LYKELMGPWN KDEISTTDAI
     FVQRDLKLVQ GFMPHFFRLF RSTVKQVDFS EVERARFIIN DWVKTHTKGM ISNLLGKGAV
     DQLTRLVLVN ALYFNGQWKT PFPDSSTHRR LFHKSDGSTV SVPMMAQTNK FNYTEFTTPD
     GHYYDILELP YHGDTLSMFI AAPYEKEVPL SALTNILSAQ LISHWKGNMT RLPRLLVLPK
     FSLETEVDLR KPLENLGMTD MFRQFQADFT SLSDQEPLHV AQALQKVKIE VNESGTVASS
     STAVIVSARM APEEIIMDRP FLFVVRHNPT GTVLFMGQVM EP
//
ID   SORL_HUMAN              Reviewed;        2214 AA.
AC   Q92673; B2RNX7; Q92856;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   20-JAN-2016, entry version 163.
DE   RecName: Full=Sortilin-related receptor;
DE   AltName: Full=Low-density lipoprotein receptor relative with 11 ligand-binding repeats;
DE            Short=LDLR relative with 11 ligand-binding repeats;
DE            Short=LR11;
DE   AltName: Full=SorLA-1;
DE   AltName: Full=Sorting protein-related receptor containing LDLR class A repeats;
DE            Short=SorLA;
DE   Flags: Precursor;
GN   Name=SORL1; Synonyms=C11orf32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLU-1074 AND ILE-1967.
RC   TISSUE=Brain;
RX   PubMed=9157966; DOI=10.1161/01.ATV.17.5.996;
RA   Morwald S., Yamazaki H., Bujo H., Kusunoki J., Kanaki T., Seimiya K.,
RA   Morisaki N., Nimpf J., Schneider W.J., Saito Y.;
RT   "A novel mosaic protein containing LDL receptor elements is highly
RT   conserved in humans and chickens.";
RL   Arterioscler. Thromb. Vasc. Biol. 17:996-1002(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF N-TERMINUS, PARTIAL
RP   PROTEIN SEQUENCE, AND VARIANTS GLU-1074 AND ILE-1967.
RC   TISSUE=Brain, and T-cell;
RX   PubMed=8940146; DOI=10.1074/jbc.271.49.31379;
RA   Jacobsen L., Madsen P., Moestrup S.K., Lund A.H., Tommerup N.,
RA   Nykjaer A., Sottrup-Jensen L., Gliemann J., Petersen C.M.;
RT   "Molecular characterization of a novel human hybrid-type receptor that
RT   binds the alpha2-macroglobulin receptor-associated protein.";
RL   J. Biol. Chem. 271:31379-31383(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS GLU-1074
RP   AND ILE-1967.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS GLU-1074 AND
RP   ILE-1967.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PLAUR.
RX   PubMed=14764453; DOI=10.1161/01.RES.0000120862.79154.0F;
RA   Zhu Y., Bujo H., Yamazaki H., Ohwaki K., Jiang M., Hirayama S.,
RA   Kanaki T., Shibasaki M., Takahashi K., Schneider W.J., Saito Y.;
RT   "LR11, an LDL receptor gene family member, is a novel regulator of
RT   smooth muscle cell migration.";
RL   Circ. Res. 94:752-758(2004).
RN   [7]
RP   FUNCTION IN APP TRAFFICKING, SUBCELLULAR LOCATION, INTERACTION WITH
RP   APP, AND TISSUE SPECIFICITY.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R.,
RA   Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X.,
RA   Bales K.R., Cappai R., Masters C.L., Gliemann J., Mufson E.J.,
RA   Hyman B.T., Paul S.M., Nykjaer A., Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates
RT   processing of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [8]
RP   LACK OF ASSOCIATION WITH SUSCEPTIBILITY TO LATE-ONSET ALZHEIMER
RP   DISEASE.
RX   PubMed=18562096; DOI=10.1016/j.neulet.2008.05.082;
RA   Minster R.L., DeKosky S.T., Kamboh M.I.;
RT   "No association of SORL1 SNPs with Alzheimer's disease.";
RL   Neurosci. Lett. 440:190-192(2008).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-99; ASN-1733; ASN-2010;
RP   ASN-2076 AND ASN-2092.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-114, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   INVOLVEMENT IN AD.
RX   PubMed=21220680; DOI=10.1001/archneurol.2010.346;
RG   Genetic and Environmental Risk in Alzheimer Disease 1 Consortium;
RA   Reitz C., Cheng R., Rogaeva E., Lee J.H., Tokuhiro S., Zou F.,
RA   Bettens K., Sleegers K., Tan E.K., Kimura R., Shibata N., Arai H.,
RA   Kamboh M.I., Prince J.A., Maier W., Riemenschneider M., Owen M.,
RA   Harold D., Hollingworth P., Cellini E., Sorbi S., Nacmias B.,
RA   Takeda M., Pericak-Vance M.A., Haines J.L., Younkin S., Williams J.,
RA   van Broeckhoven C., Farrer L.A., St George-Hyslop P.H., Mayeux R.;
RT   "Meta-analysis of the association between variants in SORL1 and
RT   Alzheimer disease.";
RL   Arch. Neurol. 68:99-106(2011).
RN   [12]
RP   PHOSPHORYLATION AT SER-2206, AND INTERACTION WITH ROCK2.
RX   PubMed=21147781; DOI=10.1074/jbc.M110.167239;
RA   Herskowitz J.H., Seyfried N.T., Gearing M., Kahn R.A., Peng J.,
RA   Levey A.I., Lah J.J.;
RT   "Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA
RT   alters amyloid-beta production.";
RL   J. Biol. Chem. 286:6117-6127(2011).
RN   [13]
RP   INVOLVEMENT IN AD.
RX   PubMed=23565137; DOI=10.1371/journal.pone.0058618;
RG   Alzheimer Disease Genetics Consortium;
RA   Miyashita A., Koike A., Jun G., Wang L.S., Takahashi S., Matsubara E.,
RA   Kawarabayashi T., Shoji M., Tomita N., Arai H., Asada T., Harigaya Y.,
RA   Ikeda M., Amari M., Hanyu H., Higuchi S., Ikeuchi T., Nishizawa M.,
RA   Suga M., Kawase Y., Akatsu H., Kosaka K., Yamamoto T., Imagawa M.,
RA   Hamaguchi T., Yamada M., Moriaha T., Takeda M., Takao T., Nakata K.,
RA   Fujisawa Y., Sasaki K., Watanabe K., Nakashima K., Urakami K.,
RA   Ooya T., Takahashi M., Yuzuriha T., Serikawa K., Yoshimoto S.,
RA   Nakagawa R., Kim J.W., Ki C.S., Won H.H., Na D.L., Seo S.W.,
RA   Mook-Jung I., St George-Hyslop P., Mayeux R., Haines J.L.,
RA   Pericak-Vance M.A., Yoshida M., Nishida N., Tokunaga K., Yamamoto K.,
RA   Tsuji S., Kanazawa I., Ihara Y., Schellenberg G.D., Farrer L.A.,
RA   Kuwano R.;
RT   "SORL1 is genetically associated with late-onset Alzheimer's disease
RT   in Japanese, Koreans and Caucasians.";
RL   PLoS ONE 8:E58618-E58618(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   STRUCTURE BY NMR OF 1651-1745.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second FN3 domain of human SORLA/LR11.";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 2202-2214 IN COMPLEX WITH
RP   GGA1, AND INTERACTION WITH GGA1.
RX   PubMed=20015111; DOI=10.1111/j.1600-0854.2009.01017.x;
RA   Cramer J.F., Gustafsen C., Behrens M.A., Oliveira C.L., Pedersen J.S.,
RA   Madsen P., Petersen C.M., Thirup S.S.;
RT   "GGA autoinhibition revisited.";
RL   Traffic 11:259-273(2010).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-120; LEU-1581 AND VAL-1972.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [18]
RP   POSSIBLE ASSOCIATION WITH SUSCEPTIBILITY TO LATE-ONSET ALZHEIMER
RP   DISEASE, AND VARIANT THR-528.
RX   PubMed=18407551; DOI=10.1002/humu.20725;
RA   Bettens K., Brouwers N., Engelborghs S., De Deyn P.P.,
RA   Van Broeckhoven C., Sleegers K.;
RT   "SORL1 is genetically associated with increased risk for late-onset
RT   Alzheimer disease in the Belgian population.";
RL   Hum. Mutat. 29:769-770(2008).
RN   [19]
RP   VARIANTS AD CYS-141; ARG-511; SER-924; SER-1358 AND ASP-1681.
RX   PubMed=22472873; DOI=10.1038/mp.2012.15;
RG   PHRC GMAJ Collaborators;
RA   Pottier C., Hannequin D., Coutant S., Rovelet-Lecrux A., Wallon D.,
RA   Rousseau S., Legallic S., Paquet C., Bombois S., Pariente J.,
RA   Thomas-Anterion C., Michon A., Croisile B., Etcharry-Bouyx F.,
RA   Berr C., Dartigues J.F., Amouyel P., Dauchel H.,
RA   Boutoleau-Bretonniere C., Thauvin C., Frebourg T., Lambert J.C.,
RA   Campion D.;
RT   "High frequency of potentially pathogenic SORL1 mutations in autosomal
RT   dominant early-onset Alzheimer disease.";
RL   Mol. Psychiatry 17:875-879(2012).
CC   -!- FUNCTION: Likely to be a multifunctional endocytic receptor, that
CC       may be implicated in the uptake of lipoproteins and of proteases.
CC       Binds LDL, the major cholesterol-carrying lipoprotein of plasma,
CC       and transports it into cells by endocytosis. Binds the receptor-
CC       associated protein (RAP). Could play a role in cell-cell
CC       interaction. Involved in APP trafficking to and from the Golgi
CC       apparatus. It probably acts as a sorting receptor that protects
CC       APP from trafficking to late endosome and from processing into
CC       amyloid beta, thereby reducing the burden of amyloidogenic peptide
CC       formation. Involved in the regulation of smooth muscle cells
CC       migration, probably through PLAUR binding and decreased
CC       internalization. {ECO:0000269|PubMed:14764453,
CC       ECO:0000269|PubMed:16174740}.
CC   -!- SUBUNIT: Interacts with GGA1 and ROCK2. Interacts with PLAUR.
CC       Interacts with APP. {ECO:0000269|PubMed:14764453,
CC       ECO:0000269|PubMed:16174740, ECO:0000269|PubMed:20015111,
CC       ECO:0000269|PubMed:21147781}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}. Golgi apparatus. Endosome.
CC       Secreted.
CC   -!- TISSUE SPECIFICITY: Expressed mainly in brain, where it is most
CC       abundant in the cerebellum, cerebral cortex and the occipital
CC       pole; low expression in the putamen and the thalamus. Expression
CC       is significantly reduced in the frontal cortex of patients
CC       suffering from Alzheimer disease. According to PubMed:9157966,
CC       found in spinal cord, testis, liver, kidney and pancreas with
CC       detectable levels in placenta, lung and heart. According to
CC       PubMed:8940146, expressed in the prostate, ovary, thyroid and
CC       spleen, but not found in kidney, liver, lung, skeletal muscle,
CC       bone marrow and adrenals. {ECO:0000269|PubMed:16174740}.
CC   -!- PTM: The propeptide removed in the N-terminus may be cleaved by
CC       furin or homologous proteases.
CC   -!- DISEASE: Alzheimer disease (AD) [MIM:104300]: Alzheimer disease is
CC       a neurodegenerative disorder characterized by progressive
CC       dementia, loss of cognitive abilities, and deposition of fibrillar
CC       amyloid proteins as intraneuronal neurofibrillary tangles,
CC       extracellular amyloid plaques and vascular amyloid deposits. The
CC       major constituent of these plaques is the neurotoxic amyloid-beta-
CC       APP 40-42 peptide (s), derived proteolytically from the
CC       transmembrane precursor protein APP by sequential secretase
CC       processing. The cytotoxic C-terminal fragments (CTFs) and the
CC       caspase-cleaved products such as C31 derived from APP, are also
CC       implicated in neuronal death. {ECO:0000269|PubMed:21220680,
CC       ECO:0000269|PubMed:22472873, ECO:0000269|PubMed:23565137}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- SIMILARITY: Belongs to the VPS10-related sortilin family. SORL1
CC       subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 5 BNR repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 EGF-like domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 6 fibronectin type-III domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00316}.
CC   -!- SIMILARITY: Contains 11 LDL-receptor class A domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00124}.
CC   -!- SIMILARITY: Contains 5 LDL-receptor class B repeats.
CC       {ECO:0000255|PROSITE-ProRule:PRU00461}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y08110; CAA69325.1; -; mRNA.
DR   EMBL; U60975; AAC50891.2; -; mRNA.
DR   EMBL; AP000664; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000977; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67525.1; -; Genomic_DNA.
DR   EMBL; BC137171; AAI37172.1; -; mRNA.
DR   CCDS; CCDS8436.1; -.
DR   RefSeq; NP_003096.1; NM_003105.5.
DR   UniGene; Hs.368592; -.
DR   PDB; 2DM4; NMR; -; A=1651-1745.
DR   PDB; 3G2S; X-ray; 1.70 A; C/D=2202-2214.
DR   PDB; 3G2T; X-ray; 2.00 A; C/D=2202-2214.
DR   PDB; 3WSX; X-ray; 2.35 A; A=29-753.
DR   PDB; 3WSY; X-ray; 3.11 A; A=86-753, C=42-56.
DR   PDB; 3WSZ; X-ray; 3.20 A; A=86-753.
DR   PDBsum; 2DM4; -.
DR   PDBsum; 3G2S; -.
DR   PDBsum; 3G2T; -.
DR   PDBsum; 3WSX; -.
DR   PDBsum; 3WSY; -.
DR   PDBsum; 3WSZ; -.
DR   ProteinModelPortal; Q92673; -.
DR   SMR; Q92673; 86-753, 1156-1193, 1651-1745.
DR   BioGrid; 112536; 48.
DR   DIP; DIP-41229N; -.
DR   IntAct; Q92673; 11.
DR   MINT; MINT-231252; -.
DR   STRING; 9606.ENSP00000260197; -.
DR   iPTMnet; Q92673; -.
DR   PhosphoSite; Q92673; -.
DR   BioMuta; SORL1; -.
DR   DMDM; 296452912; -.
DR   MaxQB; Q92673; -.
DR   PaxDb; Q92673; -.
DR   PRIDE; Q92673; -.
DR   Ensembl; ENST00000260197; ENSP00000260197; ENSG00000137642.
DR   GeneID; 6653; -.
DR   KEGG; hsa:6653; -.
DR   UCSC; uc001pxx.3; human.
DR   CTD; 6653; -.
DR   GeneCards; SORL1; -.
DR   HGNC; HGNC:11185; SORL1.
DR   HPA; CAB011500; -.
DR   HPA; HPA031321; -.
DR   MalaCards; SORL1; -.
DR   MIM; 104300; phenotype.
DR   MIM; 602005; gene.
DR   neXtProt; NX_Q92673; -.
DR   Orphanet; 1020; Early-onset autosomal dominant Alzheimer disease.
DR   PharmGKB; PA36022; -.
DR   eggNOG; KOG1215; Eukaryota.
DR   eggNOG; KOG3511; Eukaryota.
DR   eggNOG; ENOG410Y3W5; LUCA.
DR   GeneTree; ENSGT00510000046443; -.
DR   HOGENOM; HOG000007009; -.
DR   HOVERGEN; HBG017830; -.
DR   InParanoid; Q92673; -.
DR   OMA; ESDEKAC; -.
DR   OrthoDB; EOG7FV3PK; -.
DR   PhylomeDB; Q92673; -.
DR   TreeFam; TF324918; -.
DR   ChiTaRS; SORL1; human.
DR   EvolutionaryTrace; Q92673; -.
DR   GenomeRNAi; 6653; -.
DR   NextBio; 25935; -.
DR   PRO; PR:Q92673; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; Q92673; -.
DR   CleanEx; HS_SORL1; -.
DR   ExpressionAtlas; Q92673; baseline and differential.
DR   Genevisible; Q92673; HS.
DR   GO; GO:0005769; C:early endosome; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0031985; C:Golgi cisterna; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005641; C:nuclear envelope lumen; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0055037; C:recycling endosome; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030306; F:ADP-ribosylation factor binding; IPI:Alzheimers_University_of_Toronto.
DR   GO; GO:0001540; F:beta-amyloid binding; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; IPI:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0008203; P:cholesterol metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:1902960; P:negative regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902430; P:negative regulation of beta-amyloid formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:1902963; P:negative regulation of metalloendopeptidase activity involved in amyloid precursor protein catabolic process; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1902997; P:negative regulation of neurofibrillary tangle assembly; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:1901215; P:negative regulation of neuron death; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032460; P:negative regulation of protein oligomerization; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1902948; P:negative regulation of tau-protein kinase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:1902771; P:positive regulation of choline O-acetyltransferase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:1902955; P:positive regulation of early endosome to recycling endosome transport; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:2001137; P:positive regulation of endocytic recycling; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1902953; P:positive regulation of ER to Golgi vesicle-mediated transport; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0070863; P:positive regulation of protein exit from endoplasmic reticulum; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1902966; P:positive regulation of protein localization to early endosome; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0006892; P:post-Golgi vesicle-mediated transport; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0051604; P:protein maturation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0045053; P:protein retention in Golgi apparatus; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006605; P:protein targeting; IMP:UniProtKB.
DR   GO; GO:0000042; P:protein targeting to Golgi; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006622; P:protein targeting to lysosome; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:ProtInc.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:GOC.
DR   Gene3D; 2.120.10.30; -; 1.
DR   Gene3D; 2.60.40.10; -; 4.
DR   Gene3D; 4.10.400.10; -; 10.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR000033; LDLR_classB_rpt.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR031777; Sortilin_C.
DR   InterPro; IPR031778; Sortilin_N.
DR   InterPro; IPR006581; VPS10.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF00057; Ldl_recept_a; 10.
DR   Pfam; PF00058; Ldl_recept_b; 2.
DR   Pfam; PF15902; Sortilin-Vps10; 1.
DR   Pfam; PF15901; Sortilin_C; 1.
DR   PRINTS; PR00261; LDLRECEPTOR.
DR   SMART; SM00181; EGF; 1.
DR   SMART; SM00060; FN3; 6.
DR   SMART; SM00192; LDLa; 11.
DR   SMART; SM00135; LY; 5.
DR   SMART; SM00602; VPS10; 1.
DR   SUPFAM; SSF49265; SSF49265; 3.
DR   SUPFAM; SSF57424; SSF57424; 11.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS01209; LDLRA_1; 10.
DR   PROSITE; PS50068; LDLRA_2; 11.
DR   PROSITE; PS51120; LDLRB; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alzheimer disease; Amyloidosis; Cholesterol metabolism;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   EGF-like domain; Endocytosis; Endosome; Glycoprotein; Golgi apparatus;
KW   LDL; Lipid metabolism; Lipid transport; Membrane; Neurodegeneration;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Steroid metabolism; Sterol metabolism;
KW   Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   PROPEP       29     81       Removed in mature form.
FT                                {ECO:0000269|PubMed:8940146}.
FT                                /FTId=PRO_0000033164.
FT   CHAIN        82   2214       Sortilin-related receptor.
FT                                /FTId=PRO_0000033165.
FT   TOPO_DOM     82   2137       Extracellular. {ECO:0000255}.
FT   TRANSMEM   2138   2158       Helical. {ECO:0000255}.
FT   TOPO_DOM   2159   2214       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      136    147       BNR 1.
FT   REPEAT      232    243       BNR 2.
FT   REPEAT      441    452       BNR 3.
FT   REPEAT      521    532       BNR 4.
FT   REPEAT      562    573       BNR 5.
FT   REPEAT      800    843       LDL-receptor class B 1.
FT   REPEAT      844    887       LDL-receptor class B 2.
FT   REPEAT      888    932       LDL-receptor class B 3.
FT   REPEAT      933    970       LDL-receptor class B 4.
FT   REPEAT      971   1013       LDL-receptor class B 5.
FT   DOMAIN     1026   1072       EGF-like.
FT   DOMAIN     1076   1114       LDL-receptor class A 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1115   1155       LDL-receptor class A 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1156   1194       LDL-receptor class A 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1198   1236       LDL-receptor class A 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1238   1272       LDL-receptor class A 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1273   1317       LDL-receptor class A 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1323   1361       LDL-receptor class A 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1366   1405       LDL-receptor class A 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1417   1455       LDL-receptor class A 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1469   1508       LDL-receptor class A 10.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1512   1551       LDL-receptor class A 11.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DOMAIN     1557   1649       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1653   1745       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1749   1844       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1843   1927       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1934   2029       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     2030   2118       Fibronectin type-III 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   MOTIF        63     65       Cell attachment site. {ECO:0000255}.
FT   MOTIF      2172   2177       Endocytosis signal. {ECO:0000255}.
FT   MOD_RES     114    114       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    2206   2206       Phosphoserine; by ROCK2.
FT                                {ECO:0000269|PubMed:21147781}.
FT   CARBOHYD     99     99       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    368    368       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    430    430       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    616    616       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    674    674       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    818    818       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    871    871       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1035   1035       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1068   1068       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1164   1164       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1191   1191       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1246   1246       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1367   1367       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1458   1458       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1608   1608       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1706   1706       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1733   1733       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   1809   1809       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1854   1854       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1894   1894       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1986   1986       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2010   2010       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2054   2054       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2069   2069       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   2076   2076       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD   2092   2092       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   DISULFID   1078   1090       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1085   1103       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1097   1112       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1117   1131       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1125   1144       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1138   1153       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1158   1170       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1165   1183       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1177   1192       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1199   1211       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1206   1224       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1218   1235       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1239   1249       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1244   1262       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1256   1271       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1275   1289       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1283   1302       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1296   1315       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1325   1337       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1332   1350       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1344   1359       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1368   1381       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1376   1394       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1388   1403       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1419   1431       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1426   1444       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1438   1453       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1471   1484       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1478   1497       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1491   1506       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1514   1527       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1521   1540       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   DISULFID   1534   1549       {ECO:0000255|PROSITE-ProRule:PRU00124}.
FT   VARIANT     120    120       L -> S (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036371.
FT   VARIANT     141    141       Y -> C (in AD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22472873}.
FT                                /FTId=VAR_070012.
FT   VARIANT     511    511       G -> R (in AD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22472873}.
FT                                /FTId=VAR_070013.
FT   VARIANT     528    528       A -> T (in dbSNP:rs2298813).
FT                                {ECO:0000269|PubMed:18407551}.
FT                                /FTId=VAR_020360.
FT   VARIANT     924    924       N -> S (in AD; unknown pathological
FT                                significance; dbSNP:rs377498269).
FT                                {ECO:0000269|PubMed:22472873}.
FT                                /FTId=VAR_070014.
FT   VARIANT    1074   1074       Q -> E (in dbSNP:rs1699107).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8940146,
FT                                ECO:0000269|PubMed:9157966,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034508.
FT   VARIANT    1358   1358       N -> S (in AD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22472873}.
FT                                /FTId=VAR_070015.
FT   VARIANT    1581   1581       M -> L (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036372.
FT   VARIANT    1681   1681       G -> D (in AD; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22472873}.
FT                                /FTId=VAR_070016.
FT   VARIANT    1967   1967       V -> I (in dbSNP:rs1792120).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8940146,
FT                                ECO:0000269|PubMed:9157966,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034509.
FT   VARIANT    1972   1972       L -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036373.
FT   STRAND       48     51       {ECO:0000244|PDB:3WSY}.
FT   STRAND       91     98       {ECO:0000244|PDB:3WSX}.
FT   STRAND      103    109       {ECO:0000244|PDB:3WSX}.
FT   STRAND      117    122       {ECO:0000244|PDB:3WSX}.
FT   STRAND      125    128       {ECO:0000244|PDB:3WSY}.
FT   STRAND      133    140       {ECO:0000244|PDB:3WSX}.
FT   STRAND      145    147       {ECO:0000244|PDB:3WSY}.
FT   HELIX       149    151       {ECO:0000244|PDB:3WSX}.
FT   STRAND      164    169       {ECO:0000244|PDB:3WSX}.
FT   STRAND      177    192       {ECO:0000244|PDB:3WSX}.
FT   STRAND      198    201       {ECO:0000244|PDB:3WSX}.
FT   STRAND      207    211       {ECO:0000244|PDB:3WSX}.
FT   STRAND      219    223       {ECO:0000244|PDB:3WSX}.
FT   STRAND      230    236       {ECO:0000244|PDB:3WSX}.
FT   STRAND      242    253       {ECO:0000244|PDB:3WSX}.
FT   TURN        256    258       {ECO:0000244|PDB:3WSX}.
FT   STRAND      264    268       {ECO:0000244|PDB:3WSX}.
FT   STRAND      271    273       {ECO:0000244|PDB:3WSY}.
FT   STRAND      275    282       {ECO:0000244|PDB:3WSX}.
FT   HELIX       287    289       {ECO:0000244|PDB:3WSX}.
FT   STRAND      290    298       {ECO:0000244|PDB:3WSX}.
FT   STRAND      300    303       {ECO:0000244|PDB:3WSX}.
FT   STRAND      306    313       {ECO:0000244|PDB:3WSX}.
FT   STRAND      318    320       {ECO:0000244|PDB:3WSY}.
FT   STRAND      323    330       {ECO:0000244|PDB:3WSX}.
FT   STRAND      333    337       {ECO:0000244|PDB:3WSZ}.
FT   STRAND      349    353       {ECO:0000244|PDB:3WSX}.
FT   STRAND      355    358       {ECO:0000244|PDB:3WSX}.
FT   STRAND      360    363       {ECO:0000244|PDB:3WSX}.
FT   HELIX       366    368       {ECO:0000244|PDB:3WSX}.
FT   STRAND      369    374       {ECO:0000244|PDB:3WSX}.
FT   STRAND      383    391       {ECO:0000244|PDB:3WSX}.
FT   STRAND      394    396       {ECO:0000244|PDB:3WSY}.
FT   TURN        397    400       {ECO:0000244|PDB:3WSY}.
FT   HELIX       402    405       {ECO:0000244|PDB:3WSY}.
FT   STRAND      411    416       {ECO:0000244|PDB:3WSX}.
FT   STRAND      420    422       {ECO:0000244|PDB:3WSX}.
FT   STRAND      424    428       {ECO:0000244|PDB:3WSX}.
FT   STRAND      431    434       {ECO:0000244|PDB:3WSY}.
FT   HELIX       435    437       {ECO:0000244|PDB:3WSY}.
FT   STRAND      439    445       {ECO:0000244|PDB:3WSX}.
FT   STRAND      451    453       {ECO:0000244|PDB:3WSY}.
FT   STRAND      460    462       {ECO:0000244|PDB:3WSY}.
FT   HELIX       469    471       {ECO:0000244|PDB:3WSY}.
FT   STRAND      473    479       {ECO:0000244|PDB:3WSX}.
FT   HELIX       480    485       {ECO:0000244|PDB:3WSY}.
FT   STRAND      492    495       {ECO:0000244|PDB:3WSX}.
FT   STRAND      504    510       {ECO:0000244|PDB:3WSX}.
FT   STRAND      519    525       {ECO:0000244|PDB:3WSX}.
FT   STRAND      531    536       {ECO:0000244|PDB:3WSX}.
FT   STRAND      538    543       {ECO:0000244|PDB:3WSX}.
FT   HELIX       544    546       {ECO:0000244|PDB:3WSX}.
FT   STRAND      548    553       {ECO:0000244|PDB:3WSX}.
FT   STRAND      560    566       {ECO:0000244|PDB:3WSX}.
FT   STRAND      572    575       {ECO:0000244|PDB:3WSX}.
FT   STRAND      577    579       {ECO:0000244|PDB:3WSY}.
FT   STRAND      581    588       {ECO:0000244|PDB:3WSX}.
FT   STRAND      596    602       {ECO:0000244|PDB:3WSX}.
FT   TURN        604    607       {ECO:0000244|PDB:3WSZ}.
FT   STRAND      610    616       {ECO:0000244|PDB:3WSX}.
FT   HELIX       618    621       {ECO:0000244|PDB:3WSX}.
FT   HELIX       627    629       {ECO:0000244|PDB:3WSX}.
FT   STRAND      630    633       {ECO:0000244|PDB:3WSX}.
FT   HELIX       635    637       {ECO:0000244|PDB:3WSY}.
FT   TURN        638    641       {ECO:0000244|PDB:3WSY}.
FT   STRAND      647    654       {ECO:0000244|PDB:3WSX}.
FT   STRAND      670    674       {ECO:0000244|PDB:3WSX}.
FT   HELIX       679    681       {ECO:0000244|PDB:3WSX}.
FT   STRAND      682    684       {ECO:0000244|PDB:3WSX}.
FT   STRAND      688    690       {ECO:0000244|PDB:3WSX}.
FT   HELIX       694    696       {ECO:0000244|PDB:3WSX}.
FT   STRAND      699    701       {ECO:0000244|PDB:3WSX}.
FT   HELIX       703    705       {ECO:0000244|PDB:3WSX}.
FT   STRAND      722    724       {ECO:0000244|PDB:3WSX}.
FT   STRAND      727    730       {ECO:0000244|PDB:3WSX}.
FT   TURN        740    745       {ECO:0000244|PDB:3WSX}.
FT   STRAND      748    750       {ECO:0000244|PDB:3WSX}.
FT   STRAND     1655   1660       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1669   1674       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1683   1692       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1699   1710       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1718   1729       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1731   1734       {ECO:0000244|PDB:2DM4}.
FT   STRAND     1738   1741       {ECO:0000244|PDB:2DM4}.
SQ   SEQUENCE   2214 AA;  248426 MW;  4C215BB33E65C0B2 CRC64;
     MATRSSRRES RLPFLFTLVA LLPPGALCEV WTQRLHGGSA PLPQDRGFLV VQGDPRELRL
     WARGDARGAS RADEKPLRRK RSAALQPEPI KVYGQVSLND SHNQMVVHWA GEKSNVIVAL
     ARDSLALARP KSSDVYVSYD YGKSFKKISD KLNFGLGNRS EAVIAQFYHS PADNKRYIFA
     DAYAQYLWIT FDFCNTLQGF SIPFRAADLL LHSKASNLLL GFDRSHPNKQ LWKSDDFGQT
     WIMIQEHVKS FSWGIDPYDK PNTIYIERHE PSGYSTVFRS TDFFQSRENQ EVILEEVRDF
     QLRDKYMFAT KVVHLLGSEQ QSSVQLWVSF GRKPMRAAQF VTRHPINEYY IADASEDQVF
     VCVSHSNNRT NLYISEAEGL KFSLSLENVL YYSPGGAGSD TLVRYFANEP FADFHRVEGL
     QGVYIATLIN GSMNEENMRS VITFDKGGTW EFLQAPAFTG YGEKINCELS QGCSLHLAQR
     LSQLLNLQLR RMPILSKESA PGLIIATGSV GKNLASKTNV YISSSAGARW REALPGPHYY
     TWGDHGGIIT AIAQGMETNE LKYSTNEGET WKTFIFSEKP VFVYGLLTEP GEKSTVFTIF
     GSNKENVHSW LILQVNATDA LGVPCTENDY KLWSPSDERG NECLLGHKTV FKRRTPHATC
     FNGEDFDRPV VVSNCSCTRE DYECDFGFKM SEDLSLEVCV PDPEFSGKSY SPPVPCPVGS
     TYRRTRGYRK ISGDTCSGGD VEARLEGELV PCPLAEENEF ILYAVRKSIY RYDLASGATE
     QLPLTGLRAA VALDFDYEHN CLYWSDLALD VIQRLCLNGS TGQEVIINSG LETVEALAFE
     PLSQLLYWVD AGFKKIEVAN PDGDFRLTIV NSSVLDRPRA LVLVPQEGVM FWTDWGDLKP
     GIYRSNMDGS AAYHLVSEDV KWPNGISVDD QWIYWTDAYL ECIERITFSG QQRSVILDNL
     PHPYAIAVFK NEIYWDDWSQ LSIFRASKYS GSQMEILANQ LTGLMDMKIF YKGKNTGSNA
     CVPRPCSLLC LPKANNSRSC RCPEDVSSSV LPSGDLMCDC PQGYQLKNNT CVKQENTCLR
     NQYRCSNGNC INSIWWCDFD NDCGDMSDER NCPTTICDLD TQFRCQESGT CIPLSYKCDL
     EDDCGDNSDE SHCEMHQCRS DEYNCSSGMC IRSSWVCDGD NDCRDWSDEA NCTAIYHTCE
     ASNFQCRNGH CIPQRWACDG DTDCQDGSDE DPVNCEKKCN GFRCPNGTCI PSSKHCDGLR
     DCSDGSDEQH CEPLCTHFMD FVCKNRQQCL FHSMVCDGII QCRDGSDEDA AFAGCSQDPE
     FHKVCDEFGF QCQNGVCISL IWKCDGMDDC GDYSDEANCE NPTEAPNCSR YFQFRCENGH
     CIPNRWKCDR ENDCGDWSDE KDCGDSHILP FSTPGPSTCL PNYYRCSSGT CVMDTWVCDG
     YRDCADGSDE EACPLLANVT AASTPTQLGR CDRFEFECHQ PKTCIPNWKR CDGHQDCQDG
     RDEANCPTHS TLTCMSREFQ CEDGEACIVL SERCDGFLDC SDESDEKACS DELTVYKVQN
     LQWTADFSGD VTLTWMRPKK MPSASCVYNV YYRVVGESIW KTLETHSNKT NTVLKVLKPD
     TTYQVKVQVQ CLSKAHNTND FVTLRTPEGL PDAPRNLQLS LPREAEGVIV GHWAPPIHTH
     GLIREYIVEY SRSGSKMWAS QRAASNFTEI KNLLVNTLYT VRVAAVTSRG IGNWSDSKSI
     TTIKGKVIPP PDIHIDSYGE NYLSFTLTME SDIKVNGYVV NLFWAFDTHK QERRTLNFRG
     SILSHKVGNL TAHTSYEISA WAKTDLGDSP LAFEHVMTRG VRPPAPSLKA KAINQTAVEC
     TWTGPRNVVY GIFYATSFLD LYRNPKSLTT SLHNKTVIVS KDEQYLFLVR VVVPYQGPSS
     DYVVVKMIPD SRLPPRHLHV VHTGKTSVVI KWESPYDSPD QDLLYAVAVK DLIRKTDRSY
     KVKSRNSTVE YTLNKLEPGG KYHIIVQLGN MSKDSSIKIT TVSLSAPDAL KIITENDHVL
     LFWKSLALKE KHFNESRGYE IHMFDSAMNI TAYLGNTTDN FFKISNLKMG HNYTFTVQAR
     CLFGNQICGE PAILLYDELG SGADASATQA ARSTDVAAVV VPILFLILLS LGVGFAILYT
     KHRRLQSSFT AFANSHYSSR LGSAIFSSGD DLGEDDEDAP MITGFSDDVP MVIA
//
ID   FLT3_HUMAN              Reviewed;         993 AA.
AC   P36888; A0AVG9; B7ZLT7; B7ZLT8; F5H0A0; Q13414;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 2.
DT   17-FEB-2016, entry version 163.
DE   RecName: Full=Receptor-type tyrosine-protein kinase FLT3;
DE            EC=2.7.10.1;
DE   AltName: Full=FL cytokine receptor;
DE   AltName: Full=Fetal liver kinase-2;
DE            Short=FLK-2;
DE   AltName: Full=Fms-like tyrosine kinase 3;
DE            Short=FLT-3;
DE   AltName: Full=Stem cell tyrosine kinase 1;
DE            Short=STK-1;
DE   AltName: CD_antigen=CD135;
DE   Flags: Precursor;
GN   Name=FLT3; Synonyms=CD135, FLK2, STK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=7507245; DOI=10.1073/pnas.91.2.459;
RA   Small D., Levenstein M., Kim E., Carow C., Amin S., Rockwell P.,
RA   Witte L., Burrow C., Ratajczak M.Z., Gewirtz A.M., Civin C.I.;
RT   "STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in
RT   CD34+ human bone marrow cells and is involved in the proliferation of
RT   early progenitor/stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:459-463(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT MET-227.
RC   TISSUE=Lymphocyte;
RX   PubMed=8394751;
RA   Rosnet O., Schiff C., Pebusque M.J., Marchetto S., Tonnelle C.,
RA   Toiron Y., Birg F., Birnbaum D.;
RT   "Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic
RT   cells.";
RL   Blood 82:1110-1119(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-227.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   MET-227.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 783-942 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2004790; DOI=10.1016/0888-7543(91)90270-O;
RA   Rosnet O., Mattei M.-G., Marchetto S., Birnbaum D.;
RT   "Isolation and chromosomal localization of a novel FMS-like tyrosine
RT   kinase gene.";
RL   Genomics 9:380-385(1991).
RN   [7]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=8637232;
RA   Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C.,
RA   Sainty D., Arnoulet C., Chabannon C., Kanz L., Hannum C., Birnbaum D.;
RT   "Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface
RT   of normal and malignant hematopoietic cells.";
RL   Leukemia 10:238-248(1996).
RN   [8]
RP   INVOLVEMENT IN AML.
RX   PubMed=8946930;
RA   Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K.,
RA   Sonoda Y., Fujimoto T., Misawa S.;
RT   "Internal tandem duplication of the flt3 gene found in acute myeloid
RT   leukemia.";
RL   Leukemia 10:1911-1918(1996).
RN   [9]
RP   INVOLVEMENT IN AML, SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF
RP   TYR-589 AND TYR-591.
RX   PubMed=9737679; DOI=10.1038/sj.leu.2401130;
RA   Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H.,
RA   Naoe T.;
RT   "Internal tandem duplication of the FLT3 gene is a novel modality of
RT   elongation mutation which causes constitutive activation of the
RT   product.";
RL   Leukemia 12:1333-1337(1998).
RN   [10]
RP   FUNCTION IN PROMOTING PHOSPHORYLATION OF SHC1; PTPN6/SHP;
RP   PTPN11/SHP-2; MAPK1/ERK2; MAPK3/ERK1, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH GRB2.
RX   PubMed=10080542;
RA   Zhang S., Mantel C., Broxmeyer H.E.;
RT   "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and
RT   their association with Grb2 and Shc in Baf3/Flt3 cells.";
RL   J. Leukoc. Biol. 65:372-380(1999).
RN   [11]
RP   FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1; STAT5A AND
RP   STAT5B, PHOSPHORYLATION, FUNCTION IN ACTIVATION OF THE RAS PATHWAY,
RP   AND INVOLVEMENT IN AML.
RX   PubMed=11090077;
RA   Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C.,
RA   Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T.,
RA   Kienast J., Kanakura Y., Berdel W.E., Serve H.;
RT   "Flt3 mutations from patients with acute myeloid leukemia induce
RT   transformation of 32D cells mediated by the Ras and STAT5 pathways.";
RL   Blood 96:3907-3914(2000).
RN   [12]
RP   FUNCTION IN ACTIVATION OF AKT1, AND INVOLVEMENT IN AML.
RX   PubMed=16266983; DOI=10.1158/0008-5472.CAN-05-0422;
RA   Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B.,
RA   Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M.,
RA   Berdel W.E., Serve H.;
RT   "Constitutive activation of Akt by Flt3 internal tandem duplications
RT   is necessary for increased survival, proliferation, and myeloid
RT   transformation.";
RL   Cancer Res. 65:9643-9650(2005).
RN   [13]
RP   SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-591,
RP   DEPHOSPHORYLATION BY PTPN1; PTPN6/SHP-1 AND PTPN12, PROTEASOMAL
RP   DEGRADATION, GLYCOSYLATION, AND MUTAGENESIS OF LYS-644.
RX   PubMed=15831474; DOI=10.1128/MCB.25.9.3690-3703.2005;
RA   Schmidt-Arras D.E., Bohmer A., Markova B., Choudhary C., Serve H.,
RA   Bohmer F.D.;
RT   "Tyrosine phosphorylation regulates maturation of receptor tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 25:3690-3703(2005).
RN   [14]
RP   FUNCTION IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION AT
RP   TYR-591; TYR-726; TYR-842; TYR-955 AND TYR-969, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF TYR-589 AND TYR-591.
RX   PubMed=16627759; DOI=10.1182/blood-2005-11-011429;
RA   Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P.,
RA   Gilliland D.G.;
RT   "Roles of tyrosine 589 and 591 in STAT5 activation and transformation
RT   mediated by FLT3-ITD.";
RL   Blood 108:1339-1345(2006).
RN   [15]
RP   INTERACTION WITH PTPN11/SHP2; LYN; FGR; HCK AND SRC,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-589 AND TYR-599, AND
RP   PHOSPHORYLATION AT TYR-572; SER-574; TYR-589; TYR-591 AND TYR-599.
RX   PubMed=16684964; DOI=10.1182/blood-2005-07-008896;
RA   Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S.,
RA   Ronnstrand L.;
RT   "Identification of Y589 and Y599 in the juxtamembrane domain of Flt3
RT   as ligand-induced autophosphorylation sites involved in binding of Src
RT   family kinases and the protein tyrosine phosphatase SHP2.";
RL   Blood 108:1542-1550(2006).
RN   [16]
RP   REGION INVOLVED IN REGULATION OF KINASE ACTIVITY, AUTOREGULATORY
RP   DOMAIN, AND INVOLVEMENT IN AML.
RX   PubMed=18305215; DOI=10.1182/blood-2008-01-117770;
RA   Meshinchi S., Stirewalt D.L., Alonzo T.A., Boggon T.J., Gerbing R.B.,
RA   Rocnik J.L., Lange B.J., Gilliland D.G., Radich J.P.;
RT   "Structural and numerical variation of FLT3/ITD in pediatric AML.";
RL   Blood 111:4930-4933(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18490735; DOI=10.4049/jimmunol.180.11.7358;
RA   Kikushige Y., Yoshimoto G., Miyamoto T., Iino T., Mori Y., Iwasaki H.,
RA   Niiro H., Takenaka K., Nagafuji K., Harada M., Ishikawa F., Akashi K.;
RT   "Human Flt3 is expressed at the hematopoietic stem cell and the
RT   granulocyte/macrophage progenitor stages to maintain cell survival.";
RL   J. Immunol. 180:7358-7367(2008).
RN   [18]
RP   PHOSPHORYLATION AT TYR-589; TYR-591; TYR-599; TYR-726; TYR-768;
RP   TYR-793; TYR-842 AND TYR-955.
RX   PubMed=19477218; DOI=10.1016/j.exphem.2009.05.008;
RA   Razumovskaya E., Masson K., Khan R., Bengtsson S., Ronnstrand L.;
RT   "Oncogenic Flt3 receptors display different specificity and kinetics
RT   of autophosphorylation.";
RL   Exp. Hematol. 37:979-989(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-759 AND SER-993, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN ACTIVATION OF FES AND FER, AND INTERACTION WITH FES AND
RP   FER.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=20508617; DOI=10.1038/leu.2010.114;
RA   Buchwald M., Pietschmann K., Muller J.P., Bohmer F.D., Heinzel T.,
RA   Kramer O.H.;
RT   "Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3
RT   for proteasomal degradation.";
RL   Leukemia 24:1412-1421(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=21067588; DOI=10.1186/1476-4598-9-292;
RA   Chen W., Drakos E., Grammatikakis I., Schlette E.J., Li J.,
RA   Leventaki V., Staikou-Drakopoulou E., Patsouris E., Panayiotidis P.,
RA   Medeiros L.J., Rassidakis G.Z.;
RT   "mTOR signaling is activated by FLT3 kinase and promotes survival of
RT   FLT3-mutated acute myeloid leukemia cells.";
RL   Mol. Cancer 9:292-292(2010).
RN   [23]
RP   INTERACTION WITH PTPRJ/DEP1, FUNCTION IN ACTIVATION OF MAPK1/ERK2;
RP   MAPK3/ERK1; PLCG1; STAT5A AND/OR STAT5B, GLYCOSYLATION,
RP   UBIQUITINATION, AND PHOSPHORYLATION AT TYR-572; TYR-589; TYR-591;
RP   TYR-599; TYR-768; TYR-793; TYR-842 AND TYR-955.
RX   PubMed=21262971; DOI=10.1074/jbc.M110.205021;
RA   Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K.,
RA   Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D.,
RA   Muller J.P.;
RT   "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase
RT   FLT3 signaling.";
RL   J. Biol. Chem. 286:10918-10929(2011).
RN   [24]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=21516120; DOI=10.1038/onc.2011.110;
RA   Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M.,
RA   Small D.;
RT   "Further activation of FLT3 mutants by FLT3 ligand.";
RL   Oncogene 30:4004-4014(2011).
RN   [25]
RP   REVIEW.
RX   PubMed=12951584; DOI=10.1038/nrc1169;
RA   Stirewalt D.L., Radich J.P.;
RT   "The role of FLT3 in haematopoietic malignancies.";
RL   Nat. Rev. Cancer 3:650-665(2003).
RN   [26]
RP   REVIEW.
RX   PubMed=19549778; DOI=10.1158/1078-0432.CCR-08-1123;
RA   Meshinchi S., Appelbaum F.R.;
RT   "Structural and functional alterations of FLT3 in acute myeloid
RT   leukemia.";
RL   Clin. Cancer Res. 15:4263-4269(2009).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 564-958, AND ENZYME
RP   REGULATION.
RX   PubMed=14759363; DOI=10.1016/S1097-2765(03)00505-7;
RA   Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F.,
RA   Lippke J., Saxena K.;
RT   "The structural basis for autoinhibition of FLT3 by the juxtamembrane
RT   domain.";
RL   Mol. Cell 13:169-178(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 27-436 IN COMPLEX WITH
RP   FLT3LG, SUBUNIT, INTERACTION WITH FLT3LG, GLYCOSYLATION AT ASN-43;
RP   ASN-100; ASN-151; ASN-306; ASN-323; ASN-351 AND ASN-354,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND DISULFIDE BONDS.
RX   PubMed=21389326; DOI=10.1182/blood-2011-01-329532;
RA   Verstraete K., Vandriessche G., Januar M., Elegheert J.,
RA   Shkumatov A.V., Desfosses A., Van Craenenbroeck K., Svergun D.I.,
RA   Gutsche I., Vergauwen B., Savvides S.N.;
RT   "Structural insights into the extracellular assembly of the
RT   hematopoietic Flt3 signaling complex.";
RL   Blood 118:60-68(2011).
RN   [29]
RP   VARIANTS TYR-835 DEL; HIS-835 AND TYR-835, AND INVOLVEMENT IN AML.
RX   PubMed=11442493; DOI=10.1046/j.1365-2141.2001.02850.x;
RA   Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R.,
RA   Reilly J.T.;
RT   "Identification of novel FLT-3 Asp835 mutations in adult acute myeloid
RT   leukaemia.";
RL   Br. J. Haematol. 113:983-988(2001).
RN   [30]
RP   VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND TYR-835,
RP   CHARACTERIZATION OF VARIANTS ASN-835; GLU-835; HIS-835; VAL-835 AND
RP   TYR-835, PHOSPHORYLATION, AND INVOLVEMENT IN AML.
RX   PubMed=11290608; DOI=10.1182/blood.V97.8.2434;
RA   Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S.,
RA   Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K.,
RA   Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H.,
RA   Ueda R., Ohno R., Naoe T.;
RT   "Activating mutation of D835 within the activation loop of FLT3 in
RT   human hematologic malignancies.";
RL   Blood 97:2434-2439(2001).
RN   [31]
RP   VARIANTS GLU-835; HIS-835; TYR-835; ILE-836 DEL AND MET-836, FUNCTION
RP   IN ACTIVATION OF STAT5A AND/OR STAT5B, PHOSPHORYLATION, AND
RP   INVOLVEMENT IN AML.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-158; MET-227; ASN-324; VAL-358 AND
RP   ILE-557.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-194.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for the cytokine FLT3LG and regulates differentiation,
CC       proliferation and survival of hematopoietic progenitor cells and
CC       of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and
CC       activation of the downstream effector MTOR. Promotes activation of
CC       RAS signaling and phosphorylation of downstream kinases, including
CC       MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES,
CC       FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B.
CC       Activation of wild-type FLT3 causes only marginal activation of
CC       STAT5A or STAT5B. Mutations that cause constitutive kinase
CC       activity promote cell proliferation and resistance to apoptosis
CC       via the activation of multiple signaling pathways.
CC       {ECO:0000269|PubMed:10080542, ECO:0000269|PubMed:11090077,
CC       ECO:0000269|PubMed:14504097, ECO:0000269|PubMed:16266983,
CC       ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:18490735,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:21067588,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21516120,
CC       ECO:0000269|PubMed:7507245}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15831474}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. FLT3LG binding leads to dimerization and
CC       activation by autophosphorylation. {ECO:0000269|PubMed:14759363,
CC       ECO:0000269|PubMed:21516120}.
CC   -!- SUBUNIT: Monomer in the absence of bound FLT3LG. Homodimer in the
CC       presence of bound FLT3LG. Interacts with FIZ1 following ligand
CC       activation (By similarity). Interacts with FES, FER, LYN, FGR,
CC       HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2.
CC       Interacts with RNF115 and RNF126 (By similarity).
CC       {ECO:0000250|UniProtKB:Q00342, ECO:0000269|PubMed:10080542,
CC       ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:21262971, ECO:0000269|PubMed:21389326,
CC       ECO:0000269|PubMed:9737679}.
CC   -!- INTERACTION:
CC       Q9Y6K9:IKBKG; NbExp=2; IntAct=EBI-3946257, EBI-81279;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-3946257, EBI-79464;
CC       Q12913:PTPRJ; NbExp=3; IntAct=EBI-3946257, EBI-2264500;
CC       P43405:SYK; NbExp=21; IntAct=EBI-3946257, EBI-78302;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein. Endoplasmic reticulum lumen. Note=Constitutively
CC       activated mutant forms with internal tandem duplications are less
CC       efficiently transported to the cell surface and a significant
CC       proportion is retained in an immature form in the endoplasmic
CC       reticulum lumen. The activated kinase is rapidly targeted for
CC       degradation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P36888-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36888-2; Sequence=VSP_041796;
CC   -!- TISSUE SPECIFICITY: Detected in bone marrow, in hematopoietic stem
CC       cells, in myeloid progenitor cells and in granulocyte/macrophage
CC       progenitor cells (at protein level). Detected in bone marrow,
CC       liver, thymus, spleen and lymph node, and at low levels in kidney
CC       and pancreas. Highly expressed in T-cell leukemia.
CC       {ECO:0000269|PubMed:18490735, ECO:0000269|PubMed:7507245,
CC       ECO:0000269|PubMed:8394751, ECO:0000269|PubMed:8637232}.
CC   -!- DOMAIN: The juxtamembrane autoregulatory region is important for
CC       normal regulation of the kinase activity and for maintaining the
CC       kinase in an inactive state in the absence of bound ligand. Upon
CC       tyrosine phosphorylation, it mediates interaction with the SH2
CC       domains of numerous signaling partners. In-frame internal tandem
CC       duplications (ITDs) result in constitutive activation of the
CC       kinase. The activity of the mutant kinase can be stimulated
CC       further by FLT3LG binding.
CC   -!- PTM: N-glycosylated, contains complex N-glycans with sialic acid.
CC       {ECO:0000269|PubMed:15831474, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:21389326}.
CC   -!- PTM: Autophosphorylated on several tyrosine residues in response
CC       to FLT3LG binding. FLT3LG binding also increases phosphorylation
CC       of mutant kinases that are constitutively activated.
CC       Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a
CC       lesser degree by PTPN12. Dephosphorylation is important for export
CC       from the endoplasmic reticulum and location at the cell membrane.
CC   -!- PTM: Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein
CC       ligase SIAH1 after autophosphorylation, leading to its proteasomal
CC       degradation. {ECO:0000269|PubMed:20508617,
CC       ECO:0000269|PubMed:21262971}.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:11090077, ECO:0000269|PubMed:11290608,
CC       ECO:0000269|PubMed:11442493, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:16266983, ECO:0000269|PubMed:18305215,
CC       ECO:0000269|PubMed:8946930, ECO:0000269|PubMed:9737679}. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis. Somatic mutations that lead to constitutive
CC       activation of FLT3 are frequent in AML patients. These mutations
CC       fall into two classes, the most common being in-frame internal
CC       tandem duplications of variable length in the juxtamembrane region
CC       that disrupt the normal regulation of the kinase activity.
CC       Likewise, point mutations in the activation loop of the kinase
CC       domain can result in a constitutively activated kinase.
CC   -!- MISCELLANEOUS: Can be used as diagnostic tool to establish the
CC       exact cause of acute myeloid leukemia, and to determine the
CC       optimal therapy.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 Ig-like C2-type (immunoglobulin-like)
CC       domain. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FLT3ID144.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U02687; AAA18947.1; -; mRNA.
DR   EMBL; Z26652; CAA81393.1; -; mRNA.
DR   EMBL; AL356915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08424.1; -; Genomic_DNA.
DR   EMBL; BC126350; AAI26351.1; -; mRNA.
DR   EMBL; BC144039; AAI44040.1; -; mRNA.
DR   EMBL; BC144040; AAI44041.1; -; mRNA.
DR   EMBL; L36162; AAA35487.1; -; mRNA.
DR   CCDS; CCDS31953.1; -. [P36888-1]
DR   PIR; A36873; A36873.
DR   PIR; A39061; A39061.
DR   RefSeq; NP_004110.2; NM_004119.2. [P36888-1]
DR   UniGene; Hs.507590; -.
DR   PDB; 1RJB; X-ray; 2.10 A; A=564-907.
DR   PDB; 3QS7; X-ray; 4.30 A; E/F/G/H=27-436.
DR   PDB; 3QS9; X-ray; 7.80 A; E/F/G/H=27-540.
DR   PDB; 4RT7; X-ray; 3.10 A; A=564-958.
DR   PDB; 4XUF; X-ray; 3.20 A; A/B=600-947.
DR   PDBsum; 1RJB; -.
DR   PDBsum; 3QS7; -.
DR   PDBsum; 3QS9; -.
DR   PDBsum; 4RT7; -.
DR   PDBsum; 4XUF; -.
DR   DisProt; DP00312; -.
DR   ProteinModelPortal; P36888; -.
DR   SMR; P36888; 79-529, 572-975.
DR   BioGrid; 108610; 11.
DR   DIP; DIP-59769N; -.
DR   IntAct; P36888; 5.
DR   MINT; MINT-7103562; -.
DR   STRING; 9606.ENSP00000241453; -.
DR   BindingDB; P36888; -.
DR   ChEMBL; CHEMBL1974; -.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   GuidetoPHARMACOLOGY; 1807; -.
DR   iPTMnet; P36888; -.
DR   PhosphoSite; P36888; -.
DR   BioMuta; FLT3; -.
DR   DMDM; 156630887; -.
DR   PaxDb; P36888; -.
DR   PRIDE; P36888; -.
DR   Ensembl; ENST00000241453; ENSP00000241453; ENSG00000122025. [P36888-1]
DR   GeneID; 2322; -.
DR   KEGG; hsa:2322; -.
DR   UCSC; uc001urw.3; human. [P36888-1]
DR   UCSC; uc010tdn.2; human. [P36888-2]
DR   CTD; 2322; -.
DR   GeneCards; FLT3; -.
DR   H-InvDB; HIX0037338; -.
DR   HGNC; HGNC:3765; FLT3.
DR   HPA; CAB018358; -.
DR   MalaCards; FLT3; -.
DR   MIM; 136351; gene.
DR   MIM; 601626; phenotype.
DR   neXtProt; NX_P36888; -.
DR   Orphanet; 98829; 'Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)'.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   Orphanet; 98837; Acute biphenotypic leukemia.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 98832; Minimally differentiated acute myeloblastic leukemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA28181; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOVERGEN; HBG005735; -.
DR   InParanoid; P36888; -.
DR   KO; K05092; -.
DR   OMA; GPIYLIF; -.
DR   OrthoDB; EOG7H792D; -.
DR   PhylomeDB; P36888; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   SignaLink; P36888; -.
DR   EvolutionaryTrace; P36888; -.
DR   GeneWiki; CD135; -.
DR   GenomeRNAi; 2322; -.
DR   NextBio; 9425; -.
DR   PRO; PR:P36888; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; P36888; -.
DR   CleanEx; HS_FLT3; -.
DR   ExpressionAtlas; P36888; baseline and differential.
DR   Genevisible; P36888; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004896; F:cytokine receptor activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; TAS:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005021; F:vascular endothelial growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISS:UniProtKB.
DR   GO; GO:0071385; P:cellular response to glucocorticoid stimulus; IEA:Ensembl.
DR   GO; GO:0035726; P:common myeloid progenitor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0001776; P:leukocyte homeostasis; ISS:UniProtKB.
DR   GO; GO:0046651; P:lymphocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045578; P:negative regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0031100; P:organ regeneration; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; TAS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; TAS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; TAS:UniProtKB.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0002328; P:pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0002572; P:pro-T cell differentiation; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:ProtInc.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; TAS:GOC.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR030118; FLT3.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   PANTHER; PTHR24416:SF356; PTHR24416:SF356; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27    993       Receptor-type tyrosine-protein kinase
FT                                FLT3.
FT                                /FTId=PRO_0000016778.
FT   TOPO_DOM     27    543       Extracellular. {ECO:0000255}.
FT   TRANSMEM    544    563       Helical. {ECO:0000255}.
FT   TOPO_DOM    564    993       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      253    343       Ig-like C2-type.
FT   DOMAIN      610    943       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     616    624       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      591    597       Important for normal regulation of the
FT                                kinase activity and for maintaining the
FT                                kinase in an inactive state in the
FT                                absence of bound ligand.
FT   ACT_SITE    811    811       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     644    644       ATP. {ECO:0000305}.
FT   MOD_RES     572    572       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     574    574       Phosphoserine.
FT                                {ECO:0000269|PubMed:16684964}.
FT   MOD_RES     589    589       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     591    591       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15831474,
FT                                ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     599    599       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     726    726       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218}.
FT   MOD_RES     759    759       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     768    768       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     793    793       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     842    842       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     955    955       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:19477218,
FT                                ECO:0000269|PubMed:21262971}.
FT   MOD_RES     969    969       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16627759}.
FT   MOD_RES     993    993       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    151    151       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    354    354       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:21389326}.
FT   CARBOHYD    473    473       N-linked (GlcNAc...).
FT   CARBOHYD    502    502       N-linked (GlcNAc...).
FT   CARBOHYD    541    541       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     35     65       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    103    114       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    199    206       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    232    241       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    272    330       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    368    407       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   DISULFID    381    392       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:21389326}.
FT   VAR_SEQ     807    847       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041796.
FT   VARIANT       7      7       D -> G (in dbSNP:rs12872889).
FT                                /FTId=VAR_034677.
FT   VARIANT     158    158       V -> A (in dbSNP:rs56321896).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042069.
FT   VARIANT     194    194       V -> M. {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054149.
FT   VARIANT     227    227       T -> M (in dbSNP:rs1933437).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8394751,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_034678.
FT   VARIANT     324    324       D -> N (in dbSNP:rs35602083).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042070.
FT   VARIANT     358    358       D -> V (in dbSNP:rs34172843).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042071.
FT   VARIANT     417    417       I -> L (in dbSNP:rs56090538).
FT                                /FTId=VAR_061291.
FT   VARIANT     557    557       V -> I (in dbSNP:rs35958982).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042072.
FT   VARIANT     835    835       D -> E (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065679.
FT   VARIANT     835    835       D -> H (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:11442493,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065680.
FT   VARIANT     835    835       D -> N (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated).
FT                                {ECO:0000269|PubMed:11290608}.
FT                                /FTId=VAR_065681.
FT   VARIANT     835    835       D -> V (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated).
FT                                {ECO:0000269|PubMed:11290608}.
FT                                /FTId=VAR_065682.
FT   VARIANT     835    835       D -> Y (in acute lymphoblastic leukemia
FT                                patients and in acute myelogenous
FT                                leukemia patients; somatic mutation;
FT                                constitutively activated).
FT                                {ECO:0000269|PubMed:11290608,
FT                                ECO:0000269|PubMed:11442493,
FT                                ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065683.
FT   VARIANT     836    836       I -> M (in acute lymphoblastic leukemia
FT                                patients; somatic mutation).
FT                                {ECO:0000269|PubMed:14504097}.
FT                                /FTId=VAR_065684.
FT   MUTAGEN     589    589       Y->F: Reduced phosphorylation of the
FT                                wild-type kinase in response to ligand
FT                                binding. No effect on the phosphorylation
FT                                of the constitutively activated mutant
FT                                kinase variants. Abolishes activation of
FT                                STAT5A. {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:16684964,
FT                                ECO:0000269|PubMed:9737679}.
FT   MUTAGEN     591    591       Y->F: No significant effect on tyrosine
FT                                phosphorylation. Abolishes activation of
FT                                STAT5A. {ECO:0000269|PubMed:16627759,
FT                                ECO:0000269|PubMed:9737679}.
FT   MUTAGEN     599    599       Y->F: Abolishes interaction with
FT                                PTPN11/SHP2 and phosphorylation of
FT                                PTPN11/SHP2.
FT                                {ECO:0000269|PubMed:16684964}.
FT   MUTAGEN     644    644       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15831474}.
FT   CONFLICT      8      8       G -> A (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT     10     11       QL -> TV (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT     71     71       S -> N (in Ref. 5; AAI44040).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       A -> R (in Ref. 2; CAA81393).
FT                                {ECO:0000305}.
FT   CONFLICT    346    346       E -> G (in Ref. 1; AAA18947).
FT                                {ECO:0000305}.
FT   CONFLICT    940    940       T -> H (in Ref. 6; AAA35487).
FT                                {ECO:0000305}.
FT   STRAND      575    581       {ECO:0000244|PDB:1RJB}.
FT   STRAND      583    585       {ECO:0000244|PDB:1RJB}.
FT   STRAND      589    591       {ECO:0000244|PDB:1RJB}.
FT   HELIX       594    596       {ECO:0000244|PDB:1RJB}.
FT   HELIX       601    603       {ECO:0000244|PDB:1RJB}.
FT   HELIX       607    609       {ECO:0000244|PDB:1RJB}.
FT   STRAND      610    618       {ECO:0000244|PDB:1RJB}.
FT   STRAND      620    631       {ECO:0000244|PDB:1RJB}.
FT   STRAND      633    636       {ECO:0000244|PDB:1RJB}.
FT   STRAND      638    646       {ECO:0000244|PDB:1RJB}.
FT   HELIX       656    668       {ECO:0000244|PDB:1RJB}.
FT   STRAND      677    681       {ECO:0000244|PDB:1RJB}.
FT   STRAND      683    686       {ECO:0000244|PDB:1RJB}.
FT   STRAND      688    692       {ECO:0000244|PDB:1RJB}.
FT   HELIX       699    704       {ECO:0000244|PDB:1RJB}.
FT   TURN        705    708       {ECO:0000244|PDB:1RJB}.
FT   HELIX       785    804       {ECO:0000244|PDB:1RJB}.
FT   STRAND      807    809       {ECO:0000244|PDB:1RJB}.
FT   HELIX       814    816       {ECO:0000244|PDB:1RJB}.
FT   STRAND      817    820       {ECO:0000244|PDB:1RJB}.
FT   TURN        821    823       {ECO:0000244|PDB:1RJB}.
FT   STRAND      824    827       {ECO:0000244|PDB:1RJB}.
FT   HELIX       831    833       {ECO:0000244|PDB:1RJB}.
FT   HELIX       836    838       {ECO:0000244|PDB:1RJB}.
FT   STRAND      842    845       {ECO:0000244|PDB:1RJB}.
FT   STRAND      848    850       {ECO:0000244|PDB:1RJB}.
FT   HELIX       852    854       {ECO:0000244|PDB:1RJB}.
FT   HELIX       857    862       {ECO:0000244|PDB:1RJB}.
FT   HELIX       867    881       {ECO:0000244|PDB:1RJB}.
FT   TURN        882    884       {ECO:0000244|PDB:1RJB}.
FT   HELIX       896    903       {ECO:0000244|PDB:1RJB}.
FT   HELIX       916    924       {ECO:0000244|PDB:4RT7}.
FT   HELIX       930    932       {ECO:0000244|PDB:4RT7}.
FT   HELIX       936    949       {ECO:0000244|PDB:4RT7}.
SQ   SEQUENCE   993 AA;  112903 MW;  6C1995718F352ECE CRC64;
     MPALARDGGQ LPLLVVFSAM IFGTITNQDL PVIKCVLINH KNNDSSVGKS SSYPMVSESP
     EDLGCALRPQ SSGTVYEAAA VEVDVSASIT LQVLVDAPGN ISCLWVFKHS SLNCQPHFDL
     QNRGVVSMVI LKMTETQAGE YLLFIQSEAT NYTILFTVSI RNTLLYTLRR PYFRKMENQD
     ALVCISESVP EPIVEWVLCD SQGESCKEES PAVVKKEEKV LHELFGTDIR CCARNELGRE
     CTRLFTIDLN QTPQTTLPQL FLKVGEPLWI RCKAVHVNHG FGLTWELENK ALEEGNYFEM
     STYSTNRTMI RILFAFVSSV ARNDTGYYTC SSSKHPSQSA LVTIVEKGFI NATNSSEDYE
     IDQYEEFCFS VRFKAYPQIR CTWTFSRKSF PCEQKGLDNG YSISKFCNHK HQPGEYIFHA
     ENDDAQFTKM FTLNIRRKPQ VLAEASASQA SCFSDGYPLP SWTWKKCSDK SPNCTEEITE
     GVWNRKANRK VFGQWVSSST LNMSEAIKGF LVKCCAYNSL GTSCETILLN SPGPFPFIQD
     NISFYATIGV CLLFIVVLTL LICHKYKKQF RYESQLQMVQ VTGSSDNEYF YVDFREYEYD
     LKWEFPRENL EFGKVLGSGA FGKVMNATAY GISKTGVSIQ VAVKMLKEKA DSSEREALMS
     ELKMMTQLGS HENIVNLLGA CTLSGPIYLI FEYCCYGDLL NYLRSKREKF HRTWTEIFKE
     HNFSFYPTFQ SHPNSSMPGS REVQIHPDSD QISGLHGNSF HSEDEIEYEN QKRLEEEEDL
     NVLTFEDLLC FAYQVAKGME FLEFKSCVHR DLAARNVLVT HGKVVKICDF GLARDIMSDS
     NYVVRGNARL PVKWMAPESL FEGIYTIKSD VWSYGILLWE IFSLGVNPYP GIPVDANFYK
     LIQNGFKMDQ PFYATEEIYI IMQSCWAFDS RKRPSFPNLT SFLGCQLADA EEAMYQNVDG
     RVSECPHTYQ NRRPFSREMD LGLLSPQAQV EDS
//
ID   NMDZ1_HUMAN             Reviewed;         938 AA.
AC   Q05586; A6NLK7; A6NLR1; C9K0X1; P35437; Q12867; Q12868; Q5VSF3;
AC   Q5VSF4; Q5VSF5; Q5VSF6; Q5VSF7; Q5VSF8; Q9UPF8; Q9UPF9;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   17-FEB-2016, entry version 190.
DE   RecName: Full=Glutamate receptor ionotropic, NMDA 1;
DE            Short=GluN1;
DE   AltName: Full=Glutamate [NMDA] receptor subunit zeta-1;
DE   AltName: Full=N-methyl-D-aspartate receptor subunit NR1;
DE            Short=NMD-R1;
DE   Flags: Precursor;
GN   Name=GRIN1; Synonyms=NMDAR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   11-938 (ISOFORM 3), AND NUCLEOTIDE SEQUENCE [MRNA] OF 300-938 (ISOFORM
RP   2).
RC   TISSUE=Brain;
RX   PubMed=8406025; DOI=10.1016/0378-1119(93)90309-Q;
RA   Foldes R.L., Rampersad V., Kamboj R.K.;
RT   "Cloning and sequence analysis of cDNAs encoding human hippocampus N-
RT   methyl-D-aspartate receptor subunits: evidence for alternative RNA
RT   splicing.";
RL   Gene 131:293-298(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=7679115;
RA   Karp S.J., Masu M., Eki T., Ozawa K., Nakanishi S.;
RT   "Molecular cloning and chromosomal localization of the key subunit of
RT   the human N-methyl-D-aspartate receptor.";
RL   J. Biol. Chem. 268:3728-3733(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7685113; DOI=10.1073/pnas.90.11.5057;
RA   Planells-Cases R., Sun W., Ferrer-Montiel A.V., Montal M.;
RT   "Molecular cloning, functional expression, and pharmacological
RT   characterization of an N-methyl-D-aspartate receptor subunit from
RT   human brain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5057-5061(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7622053; DOI=10.1016/0378-1119(95)00044-7;
RA   Zimmer M., Fink T.M., Franke Y., Lichter P., Spiess J.;
RT   "Cloning and structure of the gene encoding the human N-methyl-D-
RT   aspartate receptor (NMDAR1).";
RL   Gene 159:219-223(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6 AND 7), AND VARIANTS MET-540
RP   AND SER-682.
RX   PubMed=9231706;
RA   Nash N.R., Heilman C.J., Rees H.D., Levey A.I.;
RT   "Cloning and localization of exon 5-containing isoforms of the NMDAR1
RT   subunit in human and rat brains.";
RL   J. Neurochem. 69:485-493(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 332-922 (ISOFORM 4), AND NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 86-259 (ISOFORM 5).
RC   TISSUE=Cerebellum, and Hippocampus;
RX   PubMed=7926821; DOI=10.1016/0378-1119(94)90089-2;
RA   Foldes R.L., Rampersad V., Kamboj R.K.;
RT   "Cloning and sequence analysis of additional splice variants encoding
RT   human N-methyl-D-aspartate receptor (hNR1) subunits.";
RL   Gene 147:303-304(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 364-464 (ISOFORMS 1/2/3).
RX   PubMed=7681588; DOI=10.1073/pnas.90.6.2174;
RA   Younkin D.P., Tang C.-M., Hardy M., Reddy U.R., Shi Q.-Y.,
RA   Pleasure S.J., Lee V.M.-Y., Pleasure D.;
RT   "Inducible expression of neuronal glutamate receptor channels in the
RT   NT2 human cell line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2174-2178(1993).
RN   [9]
RP   PHOSPHORYLATION BY PKC.
RX   PubMed=8316301; DOI=10.1038/364070a0;
RA   Tingley W.G., Roche K.W., Thompson A.K., Huganir R.L.;
RT   "Regulation of NMDA receptor phosphorylation by alternative splicing
RT   of the C-terminal domain.";
RL   Nature 364:70-73(1993).
RN   [10]
RP   INTERCHAIN DISULFIDE BOND.
RX   PubMed=14732708; DOI=10.1074/jbc.M313446200;
RA   Papadakis M., Hawkins L.M., Stephenson F.A.;
RT   "Appropriate NR1-NR1 disulfide-linked homodimer formation is requisite
RT   for efficient expression of functional, cell surface N-methyl-D-
RT   aspartate NR1/NR2 receptors.";
RL   J. Biol. Chem. 279:14703-14712(2004).
RN   [11]
RP   INTERACTION WITH MYZAP.
RX   PubMed=18849881; DOI=10.1097/WNR.0b013e328317f05f;
RA   Roginski R.S., Goubaeva F., Mikami M., Fried-Cassorla E., Nair M.R.,
RA   Yang J.;
RT   "GRINL1A colocalizes with N-methyl D-aspartate receptor NR1 subunit
RT   and reduces N-methyl D-aspartate toxicity.";
RL   NeuroReport 19:1721-1726(2008).
RN   [12]
RP   STRUCTURE BY NMR OF 599-621.
RX   PubMed=10201407; DOI=10.1038/7610;
RA   Opella S.J., Marassi F.M., Gesell J.J., Valente A.P., Kim Y.,
RA   Oblatt-Montal M., Montal M.;
RT   "Structures of the M2 channel-lining segments from nicotinic
RT   acetylcholine and NMDA receptors by NMR spectroscopy.";
RL   Nat. Struct. Biol. 6:374-379(1999).
RN   [13]
RP   VARIANTS MRD8 SER-560 INS AND LYS-662, AND CHARACTERIZATION OF
RP   VARIANTS MRD8 SER-560 INS AND LYS-662.
RX   PubMed=21376300; DOI=10.1016/j.ajhg.2011.02.001;
RA   Hamdan F.F., Gauthier J., Araki Y., Lin D.T., Yoshizawa Y.,
RA   Higashi K., Park A.R., Spiegelman D., Dobrzeniecka S., Piton A.,
RA   Tomitori H., Daoud H., Massicotte C., Henrion E., Diallo O.,
RA   Shekarabi M., Marineau C., Shevell M., Maranda B., Mitchell G.,
RA   Nadeau A., D'Anjou G., Vanasse M., Srour M., Lafreniere R.G.,
RA   Drapeau P., Lacaille J.C., Kim E., Lee J.R., Igarashi K.,
RA   Huganir R.L., Rouleau G.A., Michaud J.L.;
RT   "Excess of de novo deleterious mutations in genes associated with
RT   glutamatergic systems in nonsyndromic intellectual disability.";
RL   Am. J. Hum. Genet. 88:306-316(2011).
CC   -!- FUNCTION: NMDA receptor subtype of glutamate-gated ion channels
CC       with high calcium permeability and voltage-dependent sensitivity
CC       to magnesium. Mediated by glycine. This protein plays a key role
CC       in synaptic plasticity, synaptogenesis, excitotoxicity, memory
CC       acquisition and learning. It mediates neuronal functions in
CC       glutamate neurotransmission. Is involved in the cell surface
CC       targeting of NMDA receptors (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Forms heteromeric channel of a zeta subunit (GRIN1), a
CC       epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third
CC       subunit (GRIN3A or GRIN3B); disulfide-linked. Found in a complex
CC       with GRIN2A or GRIN2B, GRIN3A or GRIN3B and PPP2CB. Interacts with
CC       DLG4 and MPDZ. Interacts with SNX27 (via PDZ domain); the
CC       interaction is required for recycling to the plasma membrane when
CC       endocytosed and prevent degradation in lysosomes (By similarity).
CC       Interacts with LRFN1 and LRFN2 (By similarity). Interacts with
CC       MYZAP. {ECO:0000250, ECO:0000269|PubMed:18849881}.
CC   -!- INTERACTION:
CC       Q62936:Dlg3 (xeno); NbExp=3; IntAct=EBI-8286218, EBI-349596;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}. Cell junction, synapse,
CC       postsynaptic cell membrane {ECO:0000250}. Cell junction, synapse,
CC       postsynaptic cell membrane, postsynaptic density {ECO:0000250}.
CC       Note=Enriched in postsynaptic plasma membrane and postsynaptic
CC       densities. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=3; Synonyms=Long, NR1-3;
CC         IsoId=Q05586-1; Sequence=Displayed;
CC       Name=1; Synonyms=Short, NR1-1;
CC         IsoId=Q05586-2; Sequence=VSP_000137, VSP_000138;
CC       Name=2; Synonyms=Medium, NR1-2;
CC         IsoId=Q05586-3; Sequence=VSP_000139;
CC       Name=4;
CC         IsoId=Q05586-4; Sequence=VSP_011778, VSP_011779;
CC       Name=5;
CC         IsoId=Q05586-5; Sequence=VSP_011777;
CC       Name=6;
CC         IsoId=Q05586-6; Sequence=VSP_011777, VSP_011778, VSP_011779;
CC       Name=7;
CC         IsoId=Q05586-7; Sequence=VSP_011777, VSP_045464;
CC   -!- PTM: NMDA is probably regulated by C-terminal phosphorylation of
CC       an isoform of NR1 by PKC. Dephosphorylated on Ser-897 probably by
CC       protein phosphatase 2A (PPP2CB). Its phosphorylated state is
CC       influenced by the formation of the NMDAR-PPP2CB complex and the
CC       NMDAR channel activity. {ECO:0000269|PubMed:8316301}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 8 (MRD8)
CC       [MIM:614254]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. {ECO:0000269|PubMed:21376300}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the glutamate-gated ion channel
CC       (TC 1.A.10.1) family. NR1/GRIN1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=NMDA receptor entry;
CC       URL="https://en.wikipedia.org/wiki/NMDA_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L13266; AAB59360.1; -; mRNA.
DR   EMBL; L13267; AAA36198.1; -; mRNA.
DR   EMBL; L13268; AAB59361.1; -; mRNA.
DR   EMBL; D13515; BAA02732.1; -; mRNA.
DR   EMBL; L05666; AAA21180.1; -; mRNA.
DR   EMBL; AF015730; AAB67723.1; -; mRNA.
DR   EMBL; AF015731; AAB67724.1; -; mRNA.
DR   EMBL; Z32772; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z32773; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z32774; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL929554; CAH72874.2; -; Genomic_DNA.
DR   EMBL; AL929554; CAH72875.2; -; Genomic_DNA.
DR   EMBL; AL929554; CAH72876.2; -; Genomic_DNA.
DR   EMBL; AL929554; CAH72879.2; -; Genomic_DNA.
DR   EMBL; U08106; AAA62111.1; -; mRNA.
DR   EMBL; U08107; AAA62112.1; -; mRNA.
DR   EMBL; S57708; AAB25917.1; -; mRNA.
DR   CCDS; CCDS43910.1; -. [Q05586-2]
DR   CCDS; CCDS55354.1; -. [Q05586-6]
DR   CCDS; CCDS55355.1; -. [Q05586-7]
DR   CCDS; CCDS7031.1; -. [Q05586-1]
DR   CCDS; CCDS7032.1; -. [Q05586-3]
DR   PIR; A46612; A46612.
DR   PIR; A47551; A47551.
DR   RefSeq; NP_000823.4; NM_000832.6. [Q05586-2]
DR   RefSeq; NP_001172019.1; NM_001185090.1. [Q05586-6]
DR   RefSeq; NP_001172020.1; NM_001185091.1. [Q05586-7]
DR   RefSeq; NP_015566.1; NM_007327.3. [Q05586-1]
DR   RefSeq; NP_067544.1; NM_021569.3. [Q05586-3]
DR   RefSeq; XP_005266128.1; XM_005266071.2. [Q05586-4]
DR   RefSeq; XP_005266130.1; XM_005266073.3. [Q05586-5]
DR   UniGene; Hs.558334; -.
DR   PDB; 2HQW; X-ray; 1.90 A; B=875-898.
DR   PDB; 2NR1; NMR; -; A=599-621.
DR   PDB; 3BYA; X-ray; 1.85 A; B=875-898.
DR   PDBsum; 2HQW; -.
DR   PDBsum; 2NR1; -.
DR   PDBsum; 3BYA; -.
DR   ProteinModelPortal; Q05586; -.
DR   SMR; Q05586; 24-833.
DR   BioGrid; 109159; 11.
DR   IntAct; Q05586; 7.
DR   MINT; MINT-1900224; -.
DR   STRING; 9606.ENSP00000360608; -.
DR   BindingDB; Q05586; -.
DR   ChEMBL; CHEMBL3038505; -.
DR   DrugBank; DB00659; Acamprosate.
DR   DrugBank; DB06151; Acetylcysteine.
DR   DrugBank; DB00289; Atomoxetine.
DR   DrugBank; DB00996; Gabapentin.
DR   DrugBank; DB08954; Ifenprodil.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB04896; Milnacipran.
DR   DrugBank; DB01173; Orphenadrine.
DR   DrugBank; DB00312; Pentobarbital.
DR   DrugBank; DB00454; Pethidine.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB00418; Secobarbital.
DR   TCDB; 1.A.10.1.6; the glutamate-gated ion channel (gic) family of neurotransmitter receptors.
DR   iPTMnet; Q05586; -.
DR   PhosphoSite; Q05586; -.
DR   BioMuta; GRIN1; -.
DR   DMDM; 548377; -.
DR   PaxDb; Q05586; -.
DR   PRIDE; Q05586; -.
DR   Ensembl; ENST00000371546; ENSP00000360601; ENSG00000176884. [Q05586-5]
DR   Ensembl; ENST00000371550; ENSP00000360605; ENSG00000176884. [Q05586-3]
DR   Ensembl; ENST00000371553; ENSP00000360608; ENSG00000176884. [Q05586-6]
DR   Ensembl; ENST00000371559; ENSP00000360614; ENSG00000176884. [Q05586-2]
DR   Ensembl; ENST00000371560; ENSP00000360615; ENSG00000176884. [Q05586-7]
DR   Ensembl; ENST00000371561; ENSP00000360616; ENSG00000176884. [Q05586-1]
DR   GeneID; 2902; -.
DR   KEGG; hsa:2902; -.
DR   UCSC; uc004clk.3; human. [Q05586-1]
DR   UCSC; uc004cll.3; human. [Q05586-3]
DR   UCSC; uc004clm.3; human. [Q05586-2]
DR   CTD; 2902; -.
DR   GeneCards; GRIN1; -.
DR   HGNC; HGNC:4584; GRIN1.
DR   HPA; CAB006831; -.
DR   MalaCards; GRIN1; -.
DR   MIM; 138249; gene.
DR   MIM; 614254; phenotype.
DR   neXtProt; NX_Q05586; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA28978; -.
DR   eggNOG; KOG1053; Eukaryota.
DR   eggNOG; ENOG410XNUR; LUCA.
DR   GeneTree; ENSGT00760000119186; -.
DR   HOGENOM; HOG000231491; -.
DR   HOVERGEN; HBG052638; -.
DR   InParanoid; Q05586; -.
DR   KO; K05208; -.
DR   OMA; TMSDGTC; -.
DR   OrthoDB; EOG79GT5V; -.
DR   PhylomeDB; Q05586; -.
DR   TreeFam; TF351405; -.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-438066; Unblocking of NMDA receptor, glutamate binding and activation.
DR   Reactome; R-HSA-442729; CREB phosphorylation through the activation of CaMKII.
DR   Reactome; R-HSA-442982; Ras activation uopn Ca2+ infux through NMDA receptor.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q05586; -.
DR   ChiTaRS; GRIN1; human.
DR   EvolutionaryTrace; Q05586; -.
DR   GeneWiki; GRIN1; -.
DR   GenomeRNAi; 2902; -.
DR   NextBio; 11487; -.
DR   PMAP-CutDB; Q5VSF3; -.
DR   PRO; PR:Q05586; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; Q05586; -.
DR   CleanEx; HS_GRIN1; -.
DR   ExpressionAtlas; Q05586; baseline and differential.
DR   Genevisible; Q05586; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; ISS:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0044307; C:dendritic branch; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; ISS:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0060076; C:excitatory synapse; ISS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IEA:Ensembl.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0045202; C:synapse; ISS:UniProtKB.
DR   GO; GO:0043083; C:synaptic cleft; ISS:BHF-UCL.
DR   GO; GO:0008021; C:synaptic vesicle; ISS:UniProtKB.
DR   GO; GO:0043195; C:terminal bouton; ISS:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; ISS:UniProtKB.
DR   GO; GO:0005234; F:extracellular-glutamate-gated ion channel activity; IEA:InterPro.
DR   GO; GO:0016595; F:glutamate binding; IDA:UniProtKB.
DR   GO; GO:0016594; F:glycine binding; IDA:UniProtKB.
DR   GO; GO:0004970; F:ionotropic glutamate receptor activity; IEA:InterPro.
DR   GO; GO:0042165; F:neurotransmitter binding; ISS:BHF-UCL.
DR   GO; GO:0022843; F:voltage-gated cation channel activity; IEA:Ensembl.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0055074; P:calcium ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:GOC.
DR   GO; GO:0006812; P:cation transport; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0001661; P:conditioned taste aversion; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0060179; P:male mating behavior; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008355; P:olfactory learning; IEA:Ensembl.
DR   GO; GO:0021586; P:pons maturation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0060134; P:prepulse inhibition; IEA:Ensembl.
DR   GO; GO:0018964; P:propylene metabolic process; ISS:BHF-UCL.
DR   GO; GO:0051262; P:protein tetramerization; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:UniProtKB.
DR   GO; GO:0043576; P:regulation of respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0051963; P:regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0007585; P:respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IDA:UniProtKB.
DR   GO; GO:0060992; P:response to fungicide; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0035176; P:social behavior; IEA:Ensembl.
DR   GO; GO:0001967; P:suckling behavior; IEA:Ensembl.
DR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR018882; CaM-bd_C0_NMDA_rcpt_NR1.
DR   InterPro; IPR019594; Glu/Gly-bd.
DR   InterPro; IPR001508; Iono_rcpt_met.
DR   InterPro; IPR001320; Iontro_rcpt.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF10562; CaM_bdg_C0; 1.
DR   Pfam; PF00060; Lig_chan; 1.
DR   Pfam; PF10613; Lig_chan-Glu_bd; 1.
DR   PRINTS; PR00177; NMDARECEPTOR.
DR   SMART; SM00918; Lig_chan-Glu_bd; 1.
DR   SMART; SM00079; PBPe; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell junction;
KW   Cell membrane; Complete proteome; Disease mutation; Disulfide bond;
KW   Glycoprotein; Ion channel; Ion transport; Ligand-gated ion channel;
KW   Magnesium; Membrane; Mental retardation; Phosphoprotein; Polymorphism;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Signal;
KW   Synapse; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    938       Glutamate receptor ionotropic, NMDA 1.
FT                                /FTId=PRO_0000011587.
FT   TOPO_DOM     19    559       Extracellular. {ECO:0000255}.
FT   TRANSMEM    560    580       Helical. {ECO:0000255}.
FT   TOPO_DOM    581    636       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    637    657       Helical. {ECO:0000255}.
FT   TOPO_DOM    658    812       Extracellular. {ECO:0000255}.
FT   TRANSMEM    813    833       Helical. {ECO:0000255}.
FT   TOPO_DOM    834    938       Cytoplasmic. {ECO:0000255}.
FT   REGION      516    518       Glycine binding. {ECO:0000250}.
FT   BINDING     523    523       Glycine. {ECO:0000250}.
FT   BINDING     688    688       Glycine. {ECO:0000250}.
FT   BINDING     732    732       Glycine. {ECO:0000250}.
FT   MOD_RES     889    889       Phosphoserine; by PKC.
FT                                {ECO:0000305|PubMed:8316301}.
FT   MOD_RES     890    890       Phosphoserine; by PKC.
FT                                {ECO:0000305|PubMed:8316301}.
FT   MOD_RES     896    896       Phosphoserine; by PKC.
FT                                {ECO:0000305|PubMed:8316301}.
FT   MOD_RES     897    897       Phosphoserine; by PKC.
FT                                {ECO:0000305|PubMed:8316301}.
FT   CARBOHYD     61     61       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    203    203       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    239    239       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    276    276       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    350    350       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    368    368       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    440    440       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    471    471       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    491    491       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID     79     79       Interchain.
FT   VAR_SEQ     190    190       K -> KSKKRNYENLDQLSYDNKRGPK (in isoform
FT                                5, isoform 6 and isoform 7).
FT                                {ECO:0000303|PubMed:7926821,
FT                                ECO:0000303|PubMed:9231706}.
FT                                /FTId=VSP_011777.
FT   VAR_SEQ     864    938       DRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDTSTGG
FT                                GRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES -> QYH
FT                                PTDITGPLNLSDPSVSTVV (in isoform 7).
FT                                {ECO:0000303|PubMed:9231706}.
FT                                /FTId=VSP_045464.
FT   VAR_SEQ     864    900       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8406025}.
FT                                /FTId=VSP_000139.
FT   VAR_SEQ     864    885       DRKSGRAEPDPKKKATFRAITS -> QYHPTDITGPLNLSD
FT                                PSVSTVV (in isoform 1).
FT                                {ECO:0000303|PubMed:7685113,
FT                                ECO:0000303|PubMed:8406025}.
FT                                /FTId=VSP_000137.
FT   VAR_SEQ     886    938       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:7685113,
FT                                ECO:0000303|PubMed:8406025}.
FT                                /FTId=VSP_000138.
FT   VAR_SEQ     901    922       STGGGRGALQNQKDTVLPRRAI -> QYHPTDITGPLNLSD
FT                                PSVSTVV (in isoform 4 and isoform 6).
FT                                {ECO:0000303|PubMed:7926821,
FT                                ECO:0000303|PubMed:9231706}.
FT                                /FTId=VSP_011778.
FT   VAR_SEQ     923    938       Missing (in isoform 4 and isoform 6).
FT                                {ECO:0000303|PubMed:7926821,
FT                                ECO:0000303|PubMed:9231706}.
FT                                /FTId=VSP_011779.
FT   VARIANT     540    540       I -> M (in dbSNP:rs3181457).
FT                                {ECO:0000269|PubMed:9231706}.
FT                                /FTId=VAR_049187.
FT   VARIANT     560    560       S -> SS (in MRD8; there is near abolition
FT                                of the activity of the NMDA receptor in
FT                                Xenopus oocytes; alters the 3-dimensional
FT                                structure at the receptor's channel pore
FT                                entrance). {ECO:0000269|PubMed:21376300}.
FT                                /FTId=VAR_066597.
FT   VARIANT     662    662       E -> K (in MRD8; this mutation produces a
FT                                significant increase in NMDA receptor-
FT                                induced calcium currents; excessive
FT                                calcium influx through NMDA receptor
FT                                could lead to excitotoxic neuronal cell
FT                                damage). {ECO:0000269|PubMed:21376300}.
FT                                /FTId=VAR_066598.
FT   VARIANT     682    682       A -> S (in dbSNP:rs1126448).
FT                                {ECO:0000269|PubMed:9231706}.
FT                                /FTId=VAR_069057.
FT   CONFLICT    389    389       P -> S (in Ref. 8; AAB25917).
FT                                {ECO:0000305}.
FT   CONFLICT    488    488       E -> K (in Ref. 1; AAB59361).
FT                                {ECO:0000305}.
FT   HELIX       600    620       {ECO:0000244|PDB:2NR1}.
FT   HELIX       877    892       {ECO:0000244|PDB:3BYA}.
SQ   SEQUENCE   938 AA;  105373 MW;  CDF5402769E530AB CRC64;
     MSTMRLLTLA LLFSCSVARA ACDPKIVNIG AVLSTRKHEQ MFREAVNQAN KRHGSWKIQL
     NATSVTHKPN AIQMALSVCE DLISSQVYAI LVSHPPTPND HFTPTPVSYT AGFYRIPVLG
     LTTRMSIYSD KSIHLSFLRT VPPYSHQSSV WFEMMRVYSW NHIILLVSDD HEGRAAQKRL
     ETLLEERESK AEKVLQFDPG TKNVTALLME AKELEARVII LSASEDDAAT VYRAAAMLNM
     TGSGYVWLVG EREISGNALR YAPDGILGLQ LINGKNESAH ISDAVGVVAQ AVHELLEKEN
     ITDPPRGCVG NTNIWKTGPL FKRVLMSSKY ADGVTGRVEF NEDGDRKFAN YSIMNLQNRK
     LVQVGIYNGT HVIPNDRKII WPGGETEKPR GYQMSTRLKI VTIHQEPFVY VKPTLSDGTC
     KEEFTVNGDP VKKVICTGPN DTSPGSPRHT VPQCCYGFCI DLLIKLARTM NFTYEVHLVA
     DGKFGTQERV NNSNKKEWNG MMGELLSGQA DMIVAPLTIN NERAQYIEFS KPFKYQGLTI
     LVKKEIPRST LDSFMQPFQS TLWLLVGLSV HVVAVMLYLL DRFSPFGRFK VNSEEEEEDA
     LTLSSAMWFS WGVLLNSGIG EGAPRSFSAR ILGMVWAGFA MIIVASYTAN LAAFLVLDRP
     EERITGINDP RLRNPSDKFI YATVKQSSVD IYFRRQVELS TMYRHMEKHN YESAAEAIQA
     VRDNKLHAFI WDSAVLEFEA SQKCDLVTTG ELFFRSGFGI GMRKDSPWKQ NVSLSILKSH
     ENGFMEDLDK TWVRYQECDS RSNAPATLTF ENMAGVFMLV AGGIVAGIFL IFIEIAYKRH
     KDARRKQMQL AFAAVNVWRK NLQDRKSGRA EPDPKKKATF RAITSTLASS FKRRRSSKDT
     STGGGRGALQ NQKDTVLPRR AIEREEGQLQ LCSRHRES
//
ID   TPP1_HUMAN              Reviewed;         563 AA.
AC   O14773; Q53HT1; Q5JAK6; Q6UX56; Q71JP6; Q96C37;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   20-JAN-2016, entry version 170.
DE   RecName: Full=Tripeptidyl-peptidase 1;
DE            Short=TPP-1;
DE            EC=3.4.14.9;
DE   AltName: Full=Cell growth-inhibiting gene 1 protein;
DE   AltName: Full=Lysosomal pepstatin-insensitive protease;
DE            Short=LPIC;
DE   AltName: Full=Tripeptidyl aminopeptidase;
DE   AltName: Full=Tripeptidyl-peptidase I;
DE            Short=TPP-I;
DE   Flags: Precursor;
GN   Name=TPP1; Synonyms=CLN2; ORFNames=GIG1, UNQ267/PRO304;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   VARIANTS CLN2 ARG-365 AND TYR-365, AND VARIANT HIS-175.
RC   TISSUE=Placenta;
RX   PubMed=9295267; DOI=10.1126/science.277.5333.1802;
RA   Sleat D.E., Donnelly R.J., Lackland H., Liu C.-G., Sohar I.,
RA   Pullarkat R.K., Lobel P.;
RT   "Association of mutations in a lysosomal protein with classical late-
RT   infantile neuronal ceroid lipofuscinosis.";
RL   Science 277:1802-1805(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9653647; DOI=10.1006/geno.1998.5328;
RA   Liu C.-G., Sleat D.E., Donnelly R.J., Lobel P.;
RT   "Structural organization and sequence of CLN2, the defective gene in
RT   classical late infantile neuronal ceroid lipofuscinosis.";
RL   Genomics 50:206-212(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain cortex;
RA   Junaid M.A., Barua M., Pullarkat R.K.;
RT   "Bovine brain homolog of the tripeptidyl peptidase I which is
RT   deficient in the human classic late-infantile neuronal ceroid
RT   lipofuscinosis.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kim J.W.;
RT   "Identification of a human growth inhibition gene 1 (GIG1).";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 20-24; 196-200 AND 466-492, MUTAGENESIS, AND
RP   CHARACTERIZATION.
RX   PubMed=11054422; DOI=10.1074/jbc.M008562200;
RA   Lin L., Sohar I., Lackland H., Lobel P.;
RT   "The human CLN2 protein/tripeptidyl-peptidase I is a serine protease
RT   that autoactivates at acidic pH.";
RL   J. Biol. Chem. 276:2249-2255(2001).
RN   [9]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [10]
RP   GLYCOSYLATION AT ASN-443.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [11]
RP   REVIEW ON VARIANTS.
RX   PubMed=10477428;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<199::AID-HUMU3>3.0.CO;2-A;
RA   Mole S.E., Mitchison H.M., Munroe P.B.;
RT   "Molecular basis of the neuronal ceroid lipofuscinoses: mutations in
RT   CLN1, CLN2, CLN3, and CLN5.";
RL   Hum. Mutat. 14:199-215(1999).
RN   [12]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-210; ASN-222; ASN-313 AND
RP   ASN-443.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   CLEAVAGE OF PROPEPTIDE [LARGE SCALE ANALYSIS] AFTER GLY-195, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS), ACTIVE SITE, CALCIUM-BINDING
RP   SITES, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-210; ASN-286; ASN-313
RP   AND ASN-443.
RX   PubMed=19038966; DOI=10.1074/jbc.M806947200;
RA   Pal A., Kraetzner R., Gruene T., Grapp M., Schreiber K., Gronborg M.,
RA   Urlaub H., Becker S., Asif A.R., Gartner J., Sheldrick G.M.,
RA   Steinfeld R.;
RT   "Structure of tripeptidyl-peptidase I provides insight into the
RT   molecular basis of late infantile neuronal ceroid lipofuscinosis.";
RL   J. Biol. Chem. 284:3976-3984(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 20-563, ACTIVE SITE,
RP   DISULFIDE BONDS, CALCIUM-BINDING SITES, SUBUNIT, AUTOPROTEOLYTIC
RP   CLEAVAGE, AND GLYCOSYLATION AT ASN-210; ASN-286; ASN-313 AND ASN-443.
RX   PubMed=19038967; DOI=10.1074/jbc.M806943200;
RA   Guhaniyogi J., Sohar I., Das K., Stock A.M., Lobel P.;
RT   "Crystal structure and autoactivation pathway of the precursor form of
RT   human tripeptidyl-peptidase 1, the enzyme deficient in late infantile
RT   ceroid lipofuscinosis.";
RL   J. Biol. Chem. 284:3985-3997(2009).
RN   [19]
RP   VARIANTS CLN2 ARG-77; ASN-287; LYS-343; ARG-365; TYR-365; ASP-385;
RP   GLU-389; HIS-422; HIS-447; GLU-454 AND LEU-475, AND VARIANT ARG-100.
RX   PubMed=10330339; DOI=10.1086/302427;
RA   Sleat D.E., Gin R.M., Sohar I., Wisniewski K., Sklower-Brooks S.,
RA   Pullarkat R.K., Palmer D.N., Lerner T.J., Boustany R.-M.N., Uldall P.,
RA   Siakotos A.N., Donnelly R.J., Lobel P.;
RT   "Mutational analysis of the defective protease in classic late-
RT   infantile neuronal ceroid lipofuscinosis, a neurodegenerative
RT   lysosomal storage disorder.";
RL   Am. J. Hum. Genet. 64:1511-1523(1999).
RN   [20]
RP   VARIANT CLN2 CYS-206.
RX   PubMed=10665500;
RX   DOI=10.1002/1531-8249(200002)47:2<254::AID-ANA19>3.3.CO;2-Z;
RA   Berry-Kravis E., Sleat D.E., Sohar I., Meyer P., Donnelly R.,
RA   Lobel P.;
RT   "Prenatal testing for late infantile neuronal ceroid lipofuscinosis.";
RL   Ann. Neurol. 47:254-257(2000).
RN   [21]
RP   VARIANTS CLN2 GLN-127; VAL-284; ASN-428 AND ARG-473.
RX   PubMed=11339651; DOI=10.1097/00125817-200011000-00002;
RA   Zhong N., Moroziewicz D.N., Ju W., Jurkiewicz A., Johnston L.,
RA   Wisniewski K.E., Brown W.T.;
RT   "Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.";
RL   Genet. Med. 2:312-318(2000).
RN   [22]
RP   VARIANT CLN2 ARG-473.
RX   PubMed=11241479;
RX   DOI=10.1002/1096-8628(2001)9999:9999<::AID-AJMG1145>3.0.CO;2-Z;
RA   Lam C.W., Poon P.M., Tong S.F., Ko C.H.;
RT   "Two novel CLN2 gene mutations in a Chinese patient with classical
RT   late-infantile neuronal ceroid lipofuscinosis.";
RL   Am. J. Med. Genet. 99:161-163(2001).
RN   [23]
RP   VARIANT CLN2 LEU-202.
RX   PubMed=11589012; DOI=10.1053/ejpn.2000.0427;
RA   Mole S.E., Zhong N.A., Sarpong A., Logan W.P., Hofmann S., Yi W.,
RA   Franken P.F., van Diggelen O.P., Breuning M.H., Moroziewicz D., Ju W.,
RA   Salonen T., Holmberg V., Jaervelae I., Taschner P.E.M.;
RT   "New mutations in the neuronal ceroid lipofuscinosis genes.";
RL   Eur. J. Paediatr. Neurol. 5:7-10(2001).
RN   [24]
RP   CHARACTERIZATION OF VARIANTS ARG-100; GLU-389 AND HIS-447.
RX   PubMed=11462245; DOI=10.1002/humu.1170;
RA   Lin L., Lobel P.;
RT   "Expression and analysis of CLN2 variants in CHO cells: Q100R
RT   represents a polymorphism, and G389E and R447H represent loss-of-
RT   function mutations.";
RL   Hum. Mutat. 18:165-165(2001).
RN   [25]
RP   VARIANTS CLN2 GLN-127; SER-286 AND PRO-353.
RX   PubMed=12376936; DOI=10.1002/ajmg.10660;
RA   Steinfeld R., Heim P., von Gregory H., Meyer K., Ullrich K.,
RA   Goebel H.H., Kohlschutter A.;
RT   "Late infantile neuronal ceroid lipofuscinosis: quantitative
RT   description of the clinical course in patients with CLN2 mutations.";
RL   Am. J. Med. Genet. 112:347-354(2002).
RN   [26]
RP   VARIANTS CLN2 MET-277; PRO-278; VAL-284 AND CYS-481.
RX   PubMed=12414822; DOI=10.1136/jmg.39.11.822;
RA   Ju W., Zhong R., Moore S., Moroziewicz D., Currie J.R., Parfrey P.,
RA   Brown W.T., Zhong N.;
RT   "Identification of novel CLN2 mutations shows Canadian specific NCL2
RT   alleles.";
RL   J. Med. Genet. 39:822-825(2002).
RN   [27]
RP   VARIANT CLN2 HIS-206.
RX   PubMed=12698559;
RA   Bukina A.M., Tsvetkova I.V., Semiachkina A.N., Il'ina E.S.;
RT   "Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis.
RT   A novel mutation.";
RL   Vopr. Med. Khim. 48:594-598(2002).
RN   [28]
RP   CHARACTERIZATION OF VARIANT CLN2 SER-286.
RX   PubMed=14736728; DOI=10.1093/glycob/cwh054;
RA   Tsiakas K., Steinfeld R., Storch S., Ezaki J., Lukacs Z., Kominami E.,
RA   Kohlschuetter A., Ullrich K., Braulke T.;
RT   "Mutation of the glycosylated asparagine residue 286 in human CLN2
RT   protein results in loss of enzymatic activity.";
RL   Glycobiology 14:1C-5C(2004).
RN   [29]
RP   VARIANT CLN2 ARG-482.
RX   PubMed=19201763; DOI=10.1093/brain/awn366;
RA   Kousi M., Siintola E., Dvorakova L., Vlaskova H., Turnbull J.,
RA   Topcu M., Yuksel D., Gokben S., Minassian B.A., Elleder M., Mole S.E.,
RA   Lehesjoki A.-E.;
RT   "Mutations in CLN7/MFSD8 are a common cause of variant late-infantile
RT   neuronal ceroid lipofuscinosis.";
RL   Brain 132:810-819(2009).
RN   [30]
RP   VARIANT CLN2 SER-544, AND CHARACTERIZATION OF VARIANTS CLN2 ARG-77;
RP   GLN-127; LEU-202; CYS-206; MET-277; VAL-284; SER-286; ASN-287;
RP   LYS-343; ARG-365; HIS-422; HIS-447; LEU-475 AND SER-544.
RX   PubMed=20340139; DOI=10.1002/humu.21251;
RA   Walus M., Kida E., Golabek A.A.;
RT   "Functional consequences and rescue potential of pathogenic missense
RT   mutations in tripeptidyl peptidase I.";
RL   Hum. Mutat. 31:710-721(2010).
RN   [31]
RP   VARIANTS CLN2 ARG-278 AND HIS-422.
RX   PubMed=22612257; DOI=10.1111/j.1528-1167.2012.03516.x;
RA   Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C.,
RA   Steiner I., Hansen J., Courage C., Gallati S., Buerki S., Strozzi S.,
RA   Simonetti B.G., Grunt S., Steinlin M., Alber M., Wolff M.,
RA   Klopstock T., Prott E.C., Lorenz R., Spaich C., Rona S.,
RA   Lakshminarasimhan M., Kroell J., Dorn T., Kraemer G., Synofzik M.,
RA   Becker F., Weber Y.G., Lerche H., Boehm D., Biskup S.;
RT   "Targeted next generation sequencing as a diagnostic tool in epileptic
RT   disorders.";
RL   Epilepsia 53:1387-1398(2012).
RN   [32]
RP   VARIANTS CLN2 THR-62; HIS-209; GLN-266; GLN-339; ARG-382; VAL-448;
RP   CYS-501; TYR-504 AND ARG-548.
RX   PubMed=21990111; DOI=10.1002/humu.21624;
RA   Kousi M., Lehesjoki A.E., Mole S.E.;
RT   "Update of the mutation spectrum and clinical correlations of over 360
RT   mutations in eight genes that underlie the neuronal ceroid
RT   lipofuscinoses.";
RL   Hum. Mutat. 33:42-63(2012).
RN   [33]
RP   VARIANT SCAR7 GLY-466.
RX   PubMed=23418007; DOI=10.1002/humu.22292;
RA   Sun Y., Almomani R., Breedveld G.J., Santen G.W., Aten E.,
RA   Lefeber D.J., Hoff J.I., Brusse E., Verheijen F.W., Verdijk R.M.,
RA   Kriek M., Oostra B., Breuning M.H., Losekoot M., den Dunnen J.T.,
RA   van de Warrenburg B.P., Maat-Kievit A.J.;
RT   "Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by
RT   variants in TPP1, the gene involved in classic late-infantile neuronal
RT   ceroid lipofuscinosis 2 disease (CLN2 disease).";
RL   Hum. Mutat. 34:706-713(2013).
CC   -!- FUNCTION: Lysosomal serine protease with tripeptidyl-peptidase I
CC       activity. May act as a non-specific lysosomal peptidase which
CC       generates tripeptides from the breakdown products produced by
CC       lysosomal proteinases. Requires substrates with an unsubstituted
CC       N-terminus (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Release of an N-terminal tripeptide from a
CC       polypeptide, but also has endopeptidase activity.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:19038967}.
CC   -!- SUBCELLULAR LOCATION: Lysosome. Melanosome. Note=Identified by
CC       mass spectrometry in melanosome fractions from stage I to stage
CC       IV.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14773-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14773-2; Sequence=VSP_013118;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in all tissues examined with highest
CC       levels in heart and placenta and relatively similar levels in
CC       other tissues.
CC   -!- PTM: Activated by autocatalytic proteolytical processing upon
CC       acidification. N-glycosylation is required for processing and
CC       activity. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:19038966, ECO:0000269|PubMed:19038967,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: Ceroid lipofuscinosis, neuronal, 2 (CLN2) [MIM:204500]: A
CC       form of neuronal ceroid lipofuscinosis. Neuronal ceroid
CC       lipofuscinoses are progressive neurodegenerative, lysosomal
CC       storage diseases characterized by intracellular accumulation of
CC       autofluorescent liposomal material, and clinically by seizures,
CC       dementia, visual loss, and/or cerebral atrophy. The lipopigment
CC       pattern seen most often in CLN2 consists of curvilinear profiles.
CC       {ECO:0000269|PubMed:10330339, ECO:0000269|PubMed:10665500,
CC       ECO:0000269|PubMed:11241479, ECO:0000269|PubMed:11339651,
CC       ECO:0000269|PubMed:11589012, ECO:0000269|PubMed:12376936,
CC       ECO:0000269|PubMed:12414822, ECO:0000269|PubMed:12698559,
CC       ECO:0000269|PubMed:19201763, ECO:0000269|PubMed:20340139,
CC       ECO:0000269|PubMed:21990111, ECO:0000269|PubMed:22612257,
CC       ECO:0000269|PubMed:9295267}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 7 (SCAR7)
CC       [MIM:609270]: Spinocerebellar ataxia defines a clinically and
CC       genetically heterogeneous group of cerebellar disorders. Patients
CC       show progressive incoordination of gait and often poor
CC       coordination of hands, speech and eye movements, due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR7 patients show difficulty walking
CC       and writing, dysarthria, limb ataxia, and cerebellar atrophy.
CC       {ECO:0000269|PubMed:23418007}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Contains 1 peptidase S53 domain. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM08412.1; Type=Miscellaneous discrepancy; Note=Incorrectly indicated as originating from bovine.; Evidence={ECO:0000305};
CC       Sequence=AAQ88866.1; Type=Frameshift; Positions=551; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NCL CLN2; Note=Neural Ceroid Lipofuscinoses
CC       mutation db;
CC       URL="http://www.ucl.ac.uk/ncl/cln2.shtml";
CC   -!- WEB RESOURCE: Name=Mendelian genes trieptidyl peptidase I (TPP1);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/TPP1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF017456; AAB80725.1; -; mRNA.
DR   EMBL; AF039704; AAC98480.1; -; Genomic_DNA.
DR   EMBL; AF491290; AAM08412.1; ALT_SEQ; mRNA.
DR   EMBL; AY268890; AAQ72732.1; -; mRNA.
DR   EMBL; AY358502; AAQ88866.1; ALT_FRAME; mRNA.
DR   EMBL; AK222499; BAD96219.1; -; mRNA.
DR   EMBL; BC014863; AAH14863.1; -; mRNA.
DR   CCDS; CCDS7770.1; -. [O14773-1]
DR   RefSeq; NP_000382.3; NM_000391.3. [O14773-1]
DR   UniGene; Hs.523454; -.
DR   PDB; 1R60; Model; -; A=196-563.
DR   PDB; 3EDY; X-ray; 1.85 A; A=20-563.
DR   PDB; 3EE6; X-ray; 2.35 A; A/B=1-563.
DR   PDBsum; 1R60; -.
DR   PDBsum; 3EDY; -.
DR   PDBsum; 3EE6; -.
DR   ProteinModelPortal; O14773; -.
DR   SMR; O14773; 20-563.
DR   BioGrid; 107611; 16.
DR   DIP; DIP-47434N; -.
DR   IntAct; O14773; 21.
DR   MINT; MINT-5002180; -.
DR   STRING; 9606.ENSP00000299427; -.
DR   MEROPS; S53.003; -.
DR   iPTMnet; O14773; -.
DR   PhosphoSite; O14773; -.
DR   BioMuta; TPP1; -.
DR   MaxQB; O14773; -.
DR   PaxDb; O14773; -.
DR   PRIDE; O14773; -.
DR   DNASU; 1200; -.
DR   Ensembl; ENST00000299427; ENSP00000299427; ENSG00000166340. [O14773-1]
DR   Ensembl; ENST00000533371; ENSP00000437066; ENSG00000166340. [O14773-2]
DR   GeneID; 1200; -.
DR   KEGG; hsa:1200; -.
DR   UCSC; uc001mek.1; human. [O14773-1]
DR   CTD; 1200; -.
DR   GeneCards; TPP1; -.
DR   GeneReviews; TPP1; -.
DR   H-InvDB; HIX0009410; -.
DR   HGNC; HGNC:2073; TPP1.
DR   HPA; HPA037709; -.
DR   MalaCards; TPP1; -.
DR   MIM; 204500; phenotype.
DR   MIM; 607998; gene.
DR   MIM; 609270; phenotype.
DR   neXtProt; NX_O14773; -.
DR   Orphanet; 284324; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia.
DR   Orphanet; 228349; CLN2 disease.
DR   PharmGKB; PA26600; -.
DR   eggNOG; ENOG410IICY; Eukaryota.
DR   eggNOG; COG4934; LUCA.
DR   GeneTree; ENSGT00390000008684; -.
DR   HOGENOM; HOG000171253; -.
DR   HOVERGEN; HBG004449; -.
DR   InParanoid; O14773; -.
DR   KO; K01279; -.
DR   OMA; GNFAHQA; -.
DR   OrthoDB; EOG7RNJZW; -.
DR   PhylomeDB; O14773; -.
DR   TreeFam; TF333497; -.
DR   BRENDA; 3.4.14.9; 2681.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   SABIO-RK; O14773; -.
DR   SignaLink; O14773; -.
DR   ChiTaRS; TPP1; human.
DR   EvolutionaryTrace; O14773; -.
DR   GeneWiki; Tripeptidyl_peptidase_I; -.
DR   GenomeRNAi; 1200; -.
DR   NextBio; 4955; -.
DR   PMAP-CutDB; O14773; -.
DR   PRO; PR:O14773; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; O14773; -.
DR   CleanEx; HS_TPP1; -.
DR   ExpressionAtlas; O14773; baseline and differential.
DR   Genevisible; O14773; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; IMP:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; ISS:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0008236; F:serine-type peptidase activity; IMP:UniProtKB.
DR   GO; GO:0008240; F:tripeptidyl-peptidase activity; IDA:UniProtKB.
DR   GO; GO:0045453; P:bone resorption; IMP:UniProtKB.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:Reactome.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISS:UniProtKB.
DR   GO; GO:0043171; P:peptide catabolic process; IMP:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IMP:UniProtKB.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR015366; Peptidase_S53_propep.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR009020; Prot_inh_propept.
DR   InterPro; IPR030400; Sedolisin_dom.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   Pfam; PF09286; Pro-kuma_activ; 1.
DR   SMART; SM00944; Pro-kuma_activ; 1.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF54897; SSF54897; 1.
DR   PROSITE; PS51695; SEDOLISIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage; Calcium;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Epilepsy; Glycoprotein; Hydrolase; Lysosome;
KW   Metal-binding; Neurodegeneration; Neuronal ceroid lipofuscinosis;
KW   Polymorphism; Protease; Reference proteome; Serine protease; Signal;
KW   Spinocerebellar ataxia; Zymogen.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:11054422}.
FT   PROPEP       20    195       Removed in mature form.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|PubMed:11054422}.
FT                                /FTId=PRO_0000027374.
FT   CHAIN       196    563       Tripeptidyl-peptidase 1.
FT                                /FTId=PRO_0000027375.
FT   DOMAIN      199    563       Peptidase S53.
FT   ACT_SITE    272    272       Charge relay system.
FT   ACT_SITE    276    276       Charge relay system.
FT   ACT_SITE    475    475       Charge relay system.
FT   METAL       517    517       Calcium.
FT   METAL       518    518       Calcium; via carbonyl oxygen.
FT   METAL       539    539       Calcium; via carbonyl oxygen.
FT   METAL       541    541       Calcium; via carbonyl oxygen.
FT   METAL       543    543       Calcium.
FT   CARBOHYD    210    210       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    286    286       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   CARBOHYD    313    313       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    443    443       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID    111    122
FT   DISULFID    365    526
FT   DISULFID    522    537
FT   VAR_SEQ       1    243       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_013118.
FT   VARIANT      62     62       S -> L (in dbSNP:rs2734715).
FT                                /FTId=VAR_037572.
FT   VARIANT      62     62       S -> T (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066883.
FT   VARIANT      77     77       G -> R (in CLN2; displays very low
FT                                residual enzyme activity; altered
FT                                intracellular trafficking;
FT                                dbSNP:rs121908195).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009603.
FT   VARIANT     100    100       Q -> R (in dbSNP:rs1800746).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245}.
FT                                /FTId=VAR_009604.
FT   VARIANT     127    127       R -> Q (in CLN2; displays residual enzyme
FT                                activity; effectively transported to the
FT                                lysosome; dbSNP:rs121908204).
FT                                {ECO:0000269|PubMed:11339651,
FT                                ECO:0000269|PubMed:12376936,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016790.
FT   VARIANT     153    153       S -> P (in CLN2).
FT                                /FTId=VAR_016791.
FT   VARIANT     175    175       R -> H. {ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005642.
FT   VARIANT     185    185       R -> C (in dbSNP:rs34758634).
FT                                /FTId=VAR_037573.
FT   VARIANT     202    202       P -> L (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908205).
FT                                {ECO:0000269|PubMed:11589012,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_063640.
FT   VARIANT     206    206       R -> C (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs28940573).
FT                                {ECO:0000269|PubMed:10665500,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009605.
FT   VARIANT     206    206       R -> H (in CLN2; dbSNP:rs121908209).
FT                                {ECO:0000269|PubMed:12698559}.
FT                                /FTId=VAR_016792.
FT   VARIANT     209    209       Y -> H (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066884.
FT   VARIANT     266    266       R -> Q (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066885.
FT   VARIANT     277    277       V -> M (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; demonstrates enhanced
FT                                processing in response to folding
FT                                improvement treatment;
FT                                dbSNP:rs121908207).
FT                                {ECO:0000269|PubMed:12414822,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016793.
FT   VARIANT     278    278       Q -> P (in CLN2).
FT                                {ECO:0000269|PubMed:12414822}.
FT                                /FTId=VAR_016794.
FT   VARIANT     278    278       Q -> R (in CLN2).
FT                                {ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_072749.
FT   VARIANT     284    284       G -> V (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs119455957).
FT                                {ECO:0000269|PubMed:11339651,
FT                                ECO:0000269|PubMed:12414822,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016795.
FT   VARIANT     286    286       N -> S (in CLN2; enzymatically inactive;
FT                                lacks one oligosaccharide chain resulting
FT                                in enzymatic inactivation and possibly
FT                                prelysosomal protein degradation; altered
FT                                intracellular trafficking;
FT                                dbSNP:rs119455958).
FT                                {ECO:0000269|PubMed:12376936,
FT                                ECO:0000269|PubMed:14736728,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016796.
FT   VARIANT     287    287       I -> N (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908196).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009606.
FT   VARIANT     339    339       R -> Q (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066886.
FT   VARIANT     343    343       E -> K (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908197).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009607.
FT   VARIANT     353    353       T -> P (in CLN2; dbSNP:rs121908206).
FT                                {ECO:0000269|PubMed:12376936}.
FT                                /FTId=VAR_016797.
FT   VARIANT     365    365       C -> R (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs119455953).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139,
FT                                ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005643.
FT   VARIANT     365    365       C -> Y (in CLN2; dbSNP:rs119455954).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005644.
FT   VARIANT     382    382       S -> R (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066887.
FT   VARIANT     385    385       V -> D (in CLN2; dbSNP:rs121908198).
FT                                {ECO:0000269|PubMed:10330339}.
FT                                /FTId=VAR_009608.
FT   VARIANT     389    389       G -> E (in CLN2; dbSNP:rs121908199).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245}.
FT                                /FTId=VAR_009609.
FT   VARIANT     422    422       Q -> H (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking;; dbSNP:rs121908200).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139,
FT                                ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_009610.
FT   VARIANT     428    428       K -> N (in CLN2).
FT                                {ECO:0000269|PubMed:11339651}.
FT                                /FTId=VAR_016798.
FT   VARIANT     447    447       R -> H (in CLN2; displays very low
FT                                residual enzyme activity; altered
FT                                intracellular trafficking; demonstrates
FT                                enhanced processing in response to
FT                                folding improvement treatment; shows a
FT                                five fold increase under permissive
FT                                temperature conditions;
FT                                dbSNP:rs119455956).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_005645.
FT   VARIANT     448    448       A -> V (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066888.
FT   VARIANT     454    454       A -> E (in CLN2; dbSNP:rs121908201).
FT                                {ECO:0000269|PubMed:10330339}.
FT                                /FTId=VAR_009611.
FT   VARIANT     466    466       V -> G (in SCAR7).
FT                                {ECO:0000269|PubMed:23418007}.
FT                                /FTId=VAR_070917.
FT   VARIANT     473    473       G -> R (in CLN2; dbSNP:rs121908203).
FT                                {ECO:0000269|PubMed:11241479,
FT                                ECO:0000269|PubMed:11339651}.
FT                                /FTId=VAR_016799.
FT   VARIANT     475    475       S -> L (in CLN2; displays no residual
FT                                enzyme activity; effectively transported
FT                                to the lysosome; dbSNP:rs121908202).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009612.
FT   VARIANT     481    481       F -> C (in CLN2).
FT                                {ECO:0000269|PubMed:12414822}.
FT                                /FTId=VAR_016800.
FT   VARIANT     482    482       G -> R (in CLN2; dbSNP:rs121908208).
FT                                {ECO:0000269|PubMed:19201763}.
FT                                /FTId=VAR_058435.
FT   VARIANT     501    501       G -> C (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066889.
FT   VARIANT     504    504       N -> Y (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066890.
FT   VARIANT     544    544       P -> S (in CLN2; displays residual enzyme
FT                                activity; effectively transported to the
FT                                lysosome; dbSNP:rs121908210).
FT                                {ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_063641.
FT   VARIANT     548    548       W -> R (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066891.
FT   MUTAGEN     236    236       H->A: No effect.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     360    360       D->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     475    475       S->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     517    517       D->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   CONFLICT    115    115       I -> N (in Ref. 6; BAD96219).
FT                                {ECO:0000305}.
FT   CONFLICT    373    373       Q -> E (in Ref. 7; AAH14863).
FT                                {ECO:0000305}.
FT   STRAND       35     40       {ECO:0000244|PDB:3EDY}.
FT   STRAND       46     53       {ECO:0000244|PDB:3EDY}.
FT   HELIX        58     69       {ECO:0000244|PDB:3EDY}.
FT   TURN         74     77       {ECO:0000244|PDB:3EDY}.
FT   HELIX        82     89       {ECO:0000244|PDB:3EDY}.
FT   HELIX        93    106       {ECO:0000244|PDB:3EDY}.
FT   STRAND      109    113       {ECO:0000244|PDB:3EDY}.
FT   STRAND      119    125       {ECO:0000244|PDB:3EDY}.
FT   HELIX       126    132       {ECO:0000244|PDB:3EDY}.
FT   STRAND      139    143       {ECO:0000244|PDB:3EDY}.
FT   TURN        144    147       {ECO:0000244|PDB:3EDY}.
FT   STRAND      148    152       {ECO:0000244|PDB:3EDY}.
FT   HELIX       161    163       {ECO:0000244|PDB:3EDY}.
FT   TURN        164    166       {ECO:0000244|PDB:3EDY}.
FT   STRAND      167    170       {ECO:0000244|PDB:3EDY}.
FT   HELIX       202    208       {ECO:0000244|PDB:3EDY}.
FT   STRAND      219    221       {ECO:0000244|PDB:3EDY}.
FT   STRAND      224    229       {ECO:0000244|PDB:3EDY}.
FT   HELIX       237    247       {ECO:0000244|PDB:3EDY}.
FT   STRAND      258    262       {ECO:0000244|PDB:3EDY}.
FT   HELIX       271    283       {ECO:0000244|PDB:3EDY}.
FT   TURN        284    286       {ECO:0000244|PDB:3EE6}.
FT   STRAND      287    292       {ECO:0000244|PDB:3EDY}.
FT   TURN        295    300       {ECO:0000244|PDB:3EE6}.
FT   HELIX       303    311       {ECO:0000244|PDB:3EDY}.
FT   STRAND      319    324       {ECO:0000244|PDB:3EDY}.
FT   HELIX       329    331       {ECO:0000244|PDB:3EDY}.
FT   HELIX       334    349       {ECO:0000244|PDB:3EDY}.
FT   STRAND      353    357       {ECO:0000244|PDB:3EDY}.
FT   STRAND      366    368       {ECO:0000244|PDB:3EDY}.
FT   STRAND      371    373       {ECO:0000244|PDB:3EDY}.
FT   TURN        379    381       {ECO:0000244|PDB:3EDY}.
FT   STRAND      385    397       {ECO:0000244|PDB:3EDY}.
FT   STRAND      402    404       {ECO:0000244|PDB:3EDY}.
FT   STRAND      411    417       {ECO:0000244|PDB:3EDY}.
FT   HELIX       420    422       {ECO:0000244|PDB:3EDY}.
FT   HELIX       423    432       {ECO:0000244|PDB:3EDY}.
FT   HELIX       439    441       {ECO:0000244|PDB:3EDY}.
FT   STRAND      446    449       {ECO:0000244|PDB:3EDY}.
FT   STRAND      451    455       {ECO:0000244|PDB:3EDY}.
FT   STRAND      457    463       {ECO:0000244|PDB:3EDY}.
FT   STRAND      466    471       {ECO:0000244|PDB:3EDY}.
FT   HELIX       474    494       {ECO:0000244|PDB:3EDY}.
FT   HELIX       504    509       {ECO:0000244|PDB:3EDY}.
FT   TURN        510    514       {ECO:0000244|PDB:3EDY}.
FT   STRAND      522    525       {ECO:0000244|PDB:3EDY}.
FT   TURN        529    533       {ECO:0000244|PDB:3EDY}.
FT   STRAND      534    537       {ECO:0000244|PDB:3EDY}.
FT   TURN        544    546       {ECO:0000244|PDB:3EDY}.
FT   HELIX       553    558       {ECO:0000244|PDB:3EDY}.
SQ   SEQUENCE   563 AA;  61248 MW;  7299D902F6AE8555 CRC64;
     MGLQACLLGL FALILSGKCS YSPEPDQRRT LPPGWVSLGR ADPEEELSLT FALRQQNVER
     LSELVQAVSD PSSPQYGKYL TLENVADLVR PSPLTLHTVQ KWLLAAGAQK CHSVITQDFL
     TCWLSIRQAE LLLPGAEFHH YVGGPTETHV VRSPHPYQLP QALAPHVDFV GGLHRFPPTS
     SLRQRPEPQV TGTVGLHLGV TPSVIRKRYN LTSQDVGSGT SNNSQACAQF LEQYFHDSDL
     AQFMRLFGGN FAHQASVARV VGQQGRGRAG IEASLDVQYL MSAGANISTW VYSSPGRHEG
     QEPFLQWLML LSNESALPHV HTVSYGDDED SLSSAYIQRV NTELMKAAAR GLTLLFASGD
     SGAGCWSVSG RHQFRPTFPA SSPYVTTVGG TSFQEPFLIT NEIVDYISGG GFSNVFPRPS
     YQEEAVTKFL SSSPHLPPSS YFNASGRAYP DVAALSDGYW VVSNRVPIPW VSGTSASTPV
     FGGILSLINE HRILSGRPPL GFLNPRLYQQ HGAGLFDVTR GCHESCLDEE VEGQGFCSGP
     GWDPVTGWGT PNFPALLKTL LNP
//
ID   005L_IIV3               Reviewed;         217 AA.
AC   Q197F5;
DT   16-JUN-2009, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2006, sequence version 1.
DT   01-APR-2015, entry version 22.
DE   RecName: Full=Uncharacterized protein 005L;
DE   Flags: Precursor;
GN   ORFNames=IIV3-005L;
OS   Invertebrate iridescent virus 3 (IIV-3) (Mosquito iridescent virus).
OC   Viruses; dsDNA viruses, no RNA stage; Iridoviridae; Chloriridovirus.
OX   NCBI_TaxID=345201;
OH   NCBI_TaxID=7163; Aedes vexans (Inland floodwater mosquito) (Culex vexans).
OH   NCBI_TaxID=42431; Culex territans.
OH   NCBI_TaxID=332058; Culiseta annulata.
OH   NCBI_TaxID=310513; Ochlerotatus sollicitans (eastern saltmarsh mosquito).
OH   NCBI_TaxID=329105; Ochlerotatus taeniorhynchus (Black salt marsh mosquito) (Aedes taeniorhynchus).
OH   NCBI_TaxID=7183; Psorophora ferox.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16912294; DOI=10.1128/JVI.00464-06;
RA   Delhon G., Tulman E.R., Afonso C.L., Lu Z., Becnel J.J., Moser B.A.,
RA   Kutish G.F., Rock D.L.;
RT   "Genome of invertebrate iridescent virus type 3 (mosquito iridescent
RT   virus).";
RL   J. Virol. 80:8439-8449(2006).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ643392; ABF82035.1; -; Genomic_DNA.
DR   RefSeq; YP_654577.1; NC_008187.1.
DR   ProteinModelPortal; Q197F5; -.
DR   GeneID; 4156254; -.
DR   KEGG; vg:4156254; -.
DR   Proteomes; UP000001358; Genome.
PE   3: Inferred from homology;
KW   Complete proteome; Reference proteome; Signal.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25    217       Uncharacterized protein 005L.
FT                                /FTId=PRO_0000377940.
SQ   SEQUENCE   217 AA;  23854 MW;  6DBE65967D7EEBD5 CRC64;
     MRYTVLIALQ GALLLLLLID DGQGQSPYPY PGMPCNSSRQ CGLGTCVHSR CAHCSSDGTL
     CSPEDPTMVW PCCPESSCQL VVGLPSLVNH YNCLPNQCTD SSQCPGGFGC MTRRSKCELC
     KADGEACNSP YLDWRKDKEC CSGYCHTEAR GLEGVCIDPK KIFCTPKNPW QLAPYPPSYH
     QPTTLRPPTS LYDSWLMSGF LVKSTTAPST QEEEDDY
//
ID   095L_IIV3               Reviewed;         363 AA.
AC   Q196W5;
DT   16-JUN-2009, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2006, sequence version 1.
DT   17-FEB-2016, entry version 53.
DE   RecName: Full=Probable matrix metalloproteinase 095L;
DE            EC=3.4.24.-;
DE   Flags: Precursor;
GN   ORFNames=IIV3-095L;
OS   Invertebrate iridescent virus 3 (IIV-3) (Mosquito iridescent virus).
OC   Viruses; dsDNA viruses, no RNA stage; Iridoviridae; Chloriridovirus.
OX   NCBI_TaxID=345201;
OH   NCBI_TaxID=7163; Aedes vexans (Inland floodwater mosquito) (Culex vexans).
OH   NCBI_TaxID=42431; Culex territans.
OH   NCBI_TaxID=332058; Culiseta annulata.
OH   NCBI_TaxID=310513; Ochlerotatus sollicitans (eastern saltmarsh mosquito).
OH   NCBI_TaxID=329105; Ochlerotatus taeniorhynchus (Black salt marsh mosquito) (Aedes taeniorhynchus).
OH   NCBI_TaxID=7183; Psorophora ferox.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16912294; DOI=10.1128/JVI.00464-06;
RA   Delhon G., Tulman E.R., Afonso C.L., Lu Z., Becnel J.J., Moser B.A.,
RA   Kutish G.F., Rock D.L.;
RT   "Genome of invertebrate iridescent virus type 3 (mosquito iridescent
RT   virus).";
RL   J. Virol. 80:8439-8449(2006).
CC   -!- FUNCTION: Probable endopeptidase.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305}.
CC   -!- DOMAIN: The conserved cysteine present in the cysteine-switch
CC       motif binds the catalytic zinc ion, thus inhibiting the enzyme.
CC       The dissociation of the cysteine from the zinc ion upon the
CC       activation-peptide release activates the enzyme.
CC   -!- SIMILARITY: Belongs to the peptidase M10A family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ643392; ABF82125.1; -; Genomic_DNA.
DR   RefSeq; YP_654667.1; NC_008187.1.
DR   ProteinModelPortal; Q196W5; -.
DR   SwissPalm; Q196W5; -.
DR   GeneID; 4156239; -.
DR   KEGG; vg:4156239; -.
DR   Proteomes; UP000001358; Genome.
DR   GO; GO:0031012; C:extracellular matrix; IEA:InterPro.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   Gene3D; 3.40.390.10; -; 1.
DR   InterPro; IPR024079; MetalloPept_cat_dom.
DR   InterPro; IPR001818; Pept_M10_metallopeptidase.
DR   InterPro; IPR021190; Pept_M10A.
DR   InterPro; IPR021158; Pept_M10A_Zn_BS.
DR   InterPro; IPR006026; Peptidase_Metallo.
DR   InterPro; IPR002477; Peptidoglycan-bd-like.
DR   Pfam; PF00413; Peptidase_M10; 1.
DR   PRINTS; PR00138; MATRIXIN.
DR   SMART; SM00235; ZnMc; 1.
DR   SUPFAM; SSF47090; SSF47090; 1.
DR   PROSITE; PS00546; CYSTEINE_SWITCH; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Hydrolase; Metal-binding; Metalloprotease;
KW   Protease; Reference proteome; Secreted; Signal; Zinc; Zymogen.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   PROPEP       26    126       Activation peptide. {ECO:0000250}.
FT                                /FTId=PRO_0000377512.
FT   CHAIN       127    363       Probable matrix metalloproteinase 095L.
FT                                /FTId=PRO_0000377513.
FT   MOTIF       117    124       Cysteine switch. {ECO:0000250}.
FT   COMPBIAS    133    139       Poly-Arg.
FT   ACT_SITE    276    276       {ECO:0000255|PROSITE-ProRule:PRU10095}.
FT   METAL       119    119       Zinc; in inhibited form. {ECO:0000250}.
FT   METAL       275    275       Zinc; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10095}.
FT   METAL       279    279       Zinc; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10095}.
FT   METAL       285    285       Zinc; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10095}.
SQ   SEQUENCE   363 AA;  40667 MW;  BFE243A6AF604F1A CRC64;
     MSVDSFTSRL AVVMTAVVLV WWAQALPVPS PRRGESDCDA ACRKFLLQYG YLDLGEENCT
     EVDSNRKLCS VDDELVGVPR PLARVDLAAG VSHLQTMAGL EPTGRIDAST ARLFTSPRCG
     VPDVSKYIVA AGRRRRTRRE SVIVCTTRWT TTKSNSNETL VKWWLDQSSM QWLNSTLNWV
     SLTNVLHHSF WKWSKESMLA FQQVSLERDA QIVVRFENGS HGDGWDFDGP GNVLAHAFQP
     GQSLGGDIHL DAAEPWTIYD IDGHDGNSIL HVVLHEIGHA LGLEHSRDPT SIMYAWYTPF
     KYDLGPEDVS AVAGLYGAKP ASSVAAWNPK IQKFYWDRHV RNDLLPLLER DLDAEEEDSD
     EVR
//
ID   105R_ADES1              Reviewed;         178 AA.
AC   A9CBA2;
DT   19-MAR-2014, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 1.
DT   01-APR-2015, entry version 21.
DE   RecName: Full=Protein 105R;
DE   Flags: Precursor;
OS   Snake adenovirus serotype 1 (SnAdV-1).
OC   Viruses; dsDNA viruses, no RNA stage; Adenoviridae; Atadenovirus.
OX   NCBI_TaxID=189830;
OH   NCBI_TaxID=94885; Pantherophis guttatus (Corn snake).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12237421;
RA   Farkas S.L., Benko M., Elo P.T., Ursu K., Dan A., Ahne W., Harrach B.;
RT   "Genetic analysis of an adenovirus isolated from corn snake (Elaphe
RT   guttata) implies common origin with the members of the proposed new
RT   genus Atadenovirus.";
RL   J. Gen. Virol. 83:2403-2410(2002).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ106414; ABA47252.1; -; Genomic_DNA.
DR   RefSeq; YP_001552269.1; NC_009989.1.
DR   GeneID; 10973883; -.
DR   KEGG; vg:10973883; -.
PE   3: Inferred from homology;
KW   Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    178       Protein 105R.
FT                                /FTId=PRO_0000425915.
SQ   SEQUENCE   178 AA;  19843 MW;  CBDC9A53E366E045 CRC64;
     MYFLFFFLLF LFPVGVKGVE EELRALEGED VSFYGEERAL AFFLLIGRED GKFQELCSGG
     NCSSCSAFAG RVRFKERQFT LSKVQVRETG TRFKVRSRHA KGNSTLLCYK LTVAKFRPVL
     VPVVLSGFSI GLSCVDHSNP WGFSAVFIWD MNHRGTTDGR GGITGGKKWV SALARAAF
//
ID   1102L_ASFB7             Reviewed;         104 AA.
AC   P18559;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   01-APR-2015, entry version 58.
DE   RecName: Full=Protein MGF 110-2L;
DE   Flags: Precursor;
GN   OrderedLocusNames=BA71V-009, BA71V-010; ORFNames=U104L;
OS   African swine fever virus (strain Badajoz 1971 Vero-adapted) (Ba71V)
OS   (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=10498;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2325202;
RA   Almendral J.M., Almazan F., Blasco R., Vinuela E.;
RT   "Multigene families in African swine fever virus: family 110.";
RL   J. Virol. 64:2064-2072(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11831707; DOI=10.1006/viro.1995.1149;
RA   Yanez R.J., Rodriguez J.M., Nogal M.L., Yuste L., Enriquez C.,
RA   Rodriguez J.F., Vinuela E.;
RT   "Analysis of the complete nucleotide sequence of African swine fever
RT   virus.";
RL   Virology 208:249-278(1995).
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M36467; AAA42687.1; -; Genomic_DNA.
DR   EMBL; U18466; AAA65244.1; -; Genomic_DNA.
DR   PIR; D43702; D43702.
DR   RefSeq; NP_042708.1; NC_001659.2.
DR   GeneID; 22220398; -.
DR   KEGG; vg:22220398; -.
DR   Proteomes; UP000000624; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Reference proteome; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    104       Protein MGF 110-2L.
FT                                /FTId=PRO_0000036739.
FT   COMPBIAS     34     91       Cys-rich.
SQ   SEQUENCE   104 AA;  12213 MW;  07A0312CD248BA21 CRC64;
     MRFFSYLGLL LAGLTSLQGF STDNLLEEEL RYWCQYVKNC RFCWTCQDGL CKNKVLKDMS
     SVQEHSYPME HCMIHRQCKY IRDGPIFQVE CTMQTSDATH LINA
//
ID   1102L_ASFP4             Reviewed;         104 AA.
AC   P0C9G8;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 5.
DE   RecName: Full=Protein MGF 110-2L;
DE   Flags: Precursor;
GN   OrderedLocusNames=Pret-009;
OS   African swine fever virus (isolate Tick/South Africa/Pretoriuskop
OS   Pr4/1996) (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561443;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261363; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000859; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    104       Protein MGF 110-2L.
FT                                /FTId=PRO_0000373190.
SQ   SEQUENCE   104 AA;  12100 MW;  1613E6E66C635B2E CRC64;
     MRFFSYLGLL LAGLASLQGF STDNPLEEEL RCWCLYVKNC RFCWACQDGL CKNKVLKDMP
     PVQEHSYPME YCMLHRQCKY ITDGPIFQVE CTMQTCDAIR LLNA
//
ID   1104L_ASFB7             Reviewed;         124 AA.
AC   P18558;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   01-APR-2015, entry version 60.
DE   RecName: Full=Protein MGF 110-4L;
DE   Flags: Precursor;
GN   OrderedLocusNames=BA71V-011, BA71V-012; ORFNames=XP124L;
OS   African swine fever virus (strain Badajoz 1971 Vero-adapted) (Ba71V)
OS   (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=10498;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2325202;
RA   Almendral J.M., Almazan F., Blasco R., Vinuela E.;
RT   "Multigene families in African swine fever virus: family 110.";
RL   J. Virol. 64:2064-2072(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11831707; DOI=10.1006/viro.1995.1149;
RA   Yanez R.J., Rodriguez J.M., Nogal M.L., Yuste L., Enriquez C.,
RA   Rodriguez J.F., Vinuela E.;
RT   "Analysis of the complete nucleotide sequence of African swine fever
RT   virus.";
RL   Virology 208:249-278(1995).
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M36467; AAA42686.1; -; Genomic_DNA.
DR   EMBL; U18466; AAA65245.1; -; Genomic_DNA.
DR   PIR; C43702; C43702.
DR   RefSeq; NP_042709.1; NC_001659.2.
DR   GeneID; 22220399; -.
DR   KEGG; vg:22220399; -.
DR   Proteomes; UP000000624; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Glycoprotein; Reference proteome;
KW   Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    124       Protein MGF 110-4L.
FT                                /FTId=PRO_0000036736.
FT   COMPBIAS     42    102       Cys-rich.
FT   CARBOHYD     64     64       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   124 AA;  14194 MW;  DD62EB6C7067D74B CRC64;
     MLVIFLGILG LLANQVLGLP TQAGGHLRST DNPPQEELGY WCTYMESCKF CWECAHGICK
     NKVNESMPLI IENSYLTSCE VSRWYNQCTY SEGNGHYHVM DCSNPVPHNR PHRLGRKIYE
     KEDL
//
ID   1104L_ASFP4             Reviewed;         124 AA.
AC   P0C9H3;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 5.
DE   RecName: Full=Protein MGF 110-4L;
DE   Flags: Precursor;
GN   OrderedLocusNames=Pret-011;
OS   African swine fever virus (isolate Tick/South Africa/Pretoriuskop
OS   Pr4/1996) (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561443;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261363; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000859; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Glycoprotein; Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    124       Protein MGF 110-4L.
FT                                /FTId=PRO_0000373195.
FT   CARBOHYD     64     64       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   124 AA;  14195 MW;  DD6B0C7EA30AA65A CRC64;
     MLVIFLGILG LLANQVLGLP TQAGGHLRST DNPPQEELGY WCTYMESCKF CWECAHGICK
     NKVNTSMPLI IENSYLTSCE VSRWYNQCTY SEGNGHYHVM DCSDPVPHNR PHQLLRKIYE
     KEDL
//
ID   1105L_ASFB7             Reviewed;          82 AA.
AC   P18557;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   16-SEP-2015, entry version 57.
DE   RecName: Full=Protein MGF 110-5L;
DE   Flags: Precursor;
GN   OrderedLocusNames=BA71V-013, BA71V-014; ORFNames=V82L, X'82;
OS   African swine fever virus (strain Badajoz 1971 Vero-adapted) (Ba71V)
OS   (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=10498;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2325202;
RA   Almendral J.M., Almazan F., Blasco R., Vinuela E.;
RT   "Multigene families in African swine fever virus: family 110.";
RL   J. Virol. 64:2064-2072(1990).
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M36467; AAA42685.1; -; Genomic_DNA.
DR   EMBL; U18466; AAA65246.1; -; Genomic_DNA.
DR   PIR; B43702; B43702.
DR   RefSeq; NP_042710.1; NC_001659.2.
DR   GeneID; 22220400; -.
DR   KEGG; vg:22220400; -.
DR   Proteomes; UP000000624; Genome.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Glycoprotein; Reference proteome;
KW   Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19     82       Protein MGF 110-5L.
FT                                /FTId=PRO_0000036735.
FT   COMPBIAS     39     74       Cys-rich.
FT   CARBOHYD     62     62       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   82 AA;  9410 MW;  FC26AC604C83F2AA CRC64;
     MLVIFLGILG LLANQVSSQL VGQLHPTENP SENELEYWCT YMECCQFCWD CQNGLCVNKL
     GNTTILENEY VHPCIVSRWL NK
//
ID   1105L_ASFWA             Reviewed;         121 AA.
AC   P0C9H4;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 5.
DE   RecName: Full=Protein MGF 110-5L;
DE   Flags: Precursor;
GN   OrderedLocusNames=War-011;
OS   African swine fever virus (isolate Warthog/Namibia/Wart80/1980)
OS   (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561444;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261366; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000858; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Glycoprotein; Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    121       Protein MGF 110-5L.
FT                                /FTId=PRO_0000373196.
FT   CARBOHYD     62     62       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    116    116       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   121 AA;  14109 MW;  FF3B05F6F2F3010D CRC64;
     MLVIFLGILG LLANQVSSQL VGQLHPTENP SENELEYWCT YMECCQFCWD CQNGLCVNKL
     GNTTILENEY VHPCIVSRWL NKCMYDLGQG IDHVMVCSQP KYWNPYKILK KEWKENNSQN
     K
//
ID   1106L_ASFK5             Reviewed;         122 AA.
AC   P0C9H8;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 7.
DE   RecName: Full=Protein MGF 110-6L;
DE   Flags: Precursor;
GN   OrderedLocusNames=Ken-013;
OS   African swine fever virus (isolate Pig/Kenya/KEN-50/1950) (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561445;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261360; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000861; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
DR   PROSITE; PS00014; ER_TARGET; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Early protein; Glycoprotein; Signal.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19    122       Protein MGF 110-6L.
FT                                /FTId=PRO_0000373200.
FT   MOTIF       119    122       Prevents secretion from ER.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10138}.
FT   CARBOHYD    100    100       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   122 AA;  14367 MW;  49B38E9742B3E3E7 CRC64;
     MLVIFLGILG LMASQVLGLP SNQPTGQLRP TEDPPEEELE YWCAYMESCQ FCWDCQDGNC
     INKIDGSVIY KNEFVRPCSV SRWMDKCMYD LNKGIYHTMN CSQPQSWNPY KYFRKEWKKD
     EL
//
ID   1107L_ASFK5             Reviewed;         137 AA.
AC   P0C9I2;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 5.
DE   RecName: Full=Protein MGF 110-7L;
DE   Flags: Precursor;
GN   OrderedLocusNames=Ken-016;
OS   African swine fever virus (isolate Pig/Kenya/KEN-50/1950) (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561445;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261360; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000861; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Glycoprotein; Signal.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    137       Protein MGF 110-7L.
FT                                /FTId=PRO_0000373204.
FT   CARBOHYD     69     69       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
FT   CARBOHYD    105    105       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   137 AA;  15994 MW;  53D9E7E525DB5A33 CRC64;
     MLVIILGVIG LLASSNLVSS STSTRVGGHL PLTFDPPENE LGYWCTYVES CRFCWDCEDG
     VCTSRIWGNN STSIVENSYI KYCEVSRWGD QCRYDVEEHI YYTMNCSDPK PWNPYKIARK
     EWKKNEHFRK DLKKDEF
//
ID   1108L_ASFWA             Reviewed;         124 AA.
AC   P0C9I5;
DT   05-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 1.
DT   07-JAN-2015, entry version 5.
DE   RecName: Full=Protein MGF 110-8L;
DE   Flags: Precursor;
GN   OrderedLocusNames=War-017;
OS   African swine fever virus (isolate Warthog/Namibia/Wart80/1980)
OS   (ASFV).
OC   Viruses; dsDNA viruses, no RNA stage; Asfarviridae; Asfivirus.
OX   NCBI_TaxID=561444;
OH   NCBI_TaxID=6937; Ornithodoros (relapsing fever ticks).
OH   NCBI_TaxID=85517; Phacochoerus aethiopicus (Warthog).
OH   NCBI_TaxID=41426; Phacochoerus africanus (Warthog).
OH   NCBI_TaxID=273792; Potamochoerus larvatus (Bushpig).
OH   NCBI_TaxID=9823; Sus scrofa (Pig).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Kutish G.F., Rock D.L.;
RT   "African swine fever virus genomes.";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Plays a role in virus cell tropism, and may be required
CC       for efficient virus replication in macrophages. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the asfivirus MGF 110 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY261366; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   Proteomes; UP000000858; Genome.
DR   InterPro; IPR004848; V110_vir.
DR   Pfam; PF01639; v110; 1.
PE   3: Inferred from homology;
KW   Complete proteome; Glycoprotein; Signal.
FT   SIGNAL        1     16       {ECO:0000255}.
FT   CHAIN        17    124       Protein MGF 110-8L.
FT                                /FTId=PRO_0000373207.
FT   CARBOHYD     76     76       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   124 AA;  14778 MW;  99268871299C95F7 CRC64;
     MKVLILVLLG VVILQAAPIR KVENLLPTRN PPQNELVYWC TYANQCDFCW ECIHGICRNR
     IQADWPVIHQ NDWIINCTVS RWNGQCHYYE GSQQYLHHEM DCINPTSHTY PHTEYMKIYE
     RDDL
//
ID   11S3_HELAN              Reviewed;         493 AA.
AC   P19084;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   01-OCT-2014, entry version 72.
DE   RecName: Full=11S globulin seed storage protein G3;
DE   AltName: Full=Helianthinin-G3;
DE   Contains:
DE     RecName: Full=11S globulin seed storage protein G3 acidic chain;
DE   Contains:
DE     RecName: Full=11S globulin seed storage protein G3 basic chain;
DE   Flags: Precursor;
GN   Name=HAG3;
OS   Helianthus annuus (Common sunflower).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Gunneridae;
OC   Pentapetalae; asterids; campanulids; Asterales; Asteraceae;
OC   Asteroideae; Heliantheae alliance; Heliantheae; Helianthus.
OX   NCBI_TaxID=4232;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2469623; DOI=10.1016/0378-1119(88)90176-X;
RA   Vonder Haar R.A., Allen R.D., Cohen E.A., Nessler C.L., Thomas T.L.;
RT   "Organization of the sunflower 11S storage protein gene family.";
RL   Gene 74:433-443(1988).
CC   -!- FUNCTION: This is a seed storage protein.
CC   -!- SUBUNIT: Hexamer; each subunit is composed of an acidic and a
CC       basic chain derived from a single precursor and linked by a
CC       disulfide bond.
CC   -!- SIMILARITY: Belongs to the 11S seed storage protein (globulins)
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28832; AAA33374.1; -; Genomic_DNA.
DR   PIR; JA0089; JA0089.
DR   ProteinModelPortal; P19084; -.
DR   GO; GO:0045735; F:nutrient reservoir activity; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.120.10; -; 3.
DR   InterPro; IPR022379; 11S_seedstore_CS.
DR   InterPro; IPR006044; 11S_seedstore_pln.
DR   InterPro; IPR006045; Cupin_1.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin.
DR   Pfam; PF00190; Cupin_1; 2.
DR   PRINTS; PR00439; 11SGLOBULIN.
DR   SMART; SM00835; Cupin_1; 2.
DR   SUPFAM; SSF51182; SSF51182; 3.
DR   PROSITE; PS00305; 11S_SEED_STORAGE; 1.
PE   3: Inferred from homology;
KW   Disulfide bond; Seed storage protein; Signal; Storage protein.
FT   SIGNAL        1     20
FT   CHAIN        21    305       11S globulin seed storage protein G3
FT                                acidic chain.
FT                                /FTId=PRO_0000032025.
FT   CHAIN       306    493       11S globulin seed storage protein G3
FT                                basic chain.
FT                                /FTId=PRO_0000032026.
FT   COMPBIAS     23     35       Gln-rich.
FT   COMPBIAS    111    127       Gln/Gly-rich.
FT   COMPBIAS    191    297       Gln-rich.
FT   DISULFID     32     65       {ECO:0000250}.
FT   DISULFID    103    312       Interchain (between acidic and basic
FT                                chains). {ECO:0000255}.
SQ   SEQUENCE   493 AA;  55687 MW;  A007B6F99D189AB5 CRC64;
     MASKATLLLA FTLLFATCIA RHQQRQQQQN QCQLQNIEAL EPIEVIQAEA GVTEIWDAYD
     QQFQCAWSIL FDTGFNLVAF SCLPTSTPLF WPSSREGVIL PGCRRTYEYS QEQQFSGEGG
     RRGGGEGTFR TVIRKLENLK EGDVVAIPTG TAHWLHNDGN TELVVVFLDT QNHENQLDEN
     QRRFFLAGNP QAQAQSQQQQ QRQPRQQSPQ RQRQRQRQGQ GQNAGNIFNG FTPELIAQSF
     NVDQETAQKL QGQNDQRGHI VNVGQDLQIV RPPQDRRSPR QQQEQATSPR QQQEQQQGRR
     GGWSNGVEET ICSMKFKVNI DNPSQADFVN PQAGSIANLN SFKFPILEHL RLSVERGELR
     PNAIQSPHWT INAHNLLYVT EGALRVQIVD NQGNSVFDNE LREGQVVVIP QNFAVIKRAN
     EQGSRWVSFK TNDNAMIANL AGRVSASAAS PLTLWANRYQ LSREEAQQLK FSQRETVLFA
     PSFSRGQGIR ASR
//
ID   11SB_CUCMA              Reviewed;         480 AA.
AC   P13744;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1990, sequence version 1.
DT   14-OCT-2015, entry version 89.
DE   RecName: Full=11S globulin subunit beta;
DE   Contains:
DE     RecName: Full=11S globulin gamma chain;
DE     AltName: Full=11S globulin acidic chain;
DE   Contains:
DE     RecName: Full=11S globulin delta chain;
DE     AltName: Full=11S globulin basic chain;
DE   Flags: Precursor;
OS   Cucurbita maxima (Pumpkin) (Winter squash).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Gunneridae;
OC   Pentapetalae; rosids; fabids; Cucurbitales; Cucurbitaceae;
OC   Cucurbiteae; Cucurbita.
OX   NCBI_TaxID=3661;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=cv. Kurokawa Amakuri Nankin;
RX   PubMed=2450746; DOI=10.1111/j.1432-1033.1988.tb13935.x;
RA   Hayashi M., Mori H., Nishimura M., Akazawa T., Hara-Nishimura I.;
RT   "Nucleotide sequence of cloned cDNA coding for pumpkin 11-S globulin
RT   beta subunit.";
RL   Eur. J. Biochem. 172:627-632(1988).
RN   [2]
RP   PROTEIN SEQUENCE OF 22-30 AND 297-302.
RA   Ohmiya M., Hara I., Mastubara H.;
RT   "Pumpkin (Cucurbita sp.) seed globulin IV. Terminal sequences of the
RT   acidic and basic peptide chains and identification of a pyroglutamyl
RT   peptide chain.";
RL   Plant Cell Physiol. 21:157-167(1980).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 22-480, AND DISULFIDE BONDS.
RA   Itoh T., Fukuda T., Mikami B., Utsumi S.;
RT   "Crystal structure of pumpkin seed globulin.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: This is a seed storage protein.
CC   -!- SUBUNIT: Hexamer; each subunit is composed of an acidic and a
CC       basic chain derived from a single precursor and linked by a
CC       disulfide bond.
CC   -!- SIMILARITY: Belongs to the 11S seed storage protein (globulins)
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M36407; AAA33110.1; -; mRNA.
DR   PDB; 2E9Q; X-ray; 2.20 A; A=22-480.
DR   PDB; 2EVX; X-ray; 2.60 A; A=22-480.
DR   PDBsum; 2E9Q; -.
DR   PDBsum; 2EVX; -.
DR   ProteinModelPortal; P13744; -.
DR   SMR; P13744; 47-474.
DR   PRIDE; P13744; -.
DR   EvolutionaryTrace; P13744; -.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0045735; F:nutrient reservoir activity; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR022379; 11S_seedstore_CS.
DR   InterPro; IPR006044; 11S_seedstore_pln.
DR   InterPro; IPR006045; Cupin_1.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin.
DR   Pfam; PF00190; Cupin_1; 2.
DR   PRINTS; PR00439; 11SGLOBULIN.
DR   SMART; SM00835; Cupin_1; 2.
DR   SUPFAM; SSF51182; SSF51182; 2.
DR   PROSITE; PS00305; 11S_SEED_STORAGE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Disulfide bond; Magnesium;
KW   Metal-binding; Pyrrolidone carboxylic acid; Seed storage protein;
KW   Signal; Storage protein.
FT   SIGNAL        1     21       {ECO:0000269|Ref.2}.
FT   CHAIN        22    480       11S globulin subunit beta.
FT                                /FTId=PRO_0000032027.
FT   CHAIN        22    296       11S globulin gamma chain.
FT                                /FTId=PRO_0000032028.
FT   CHAIN       297    480       11S globulin delta chain.
FT                                /FTId=PRO_0000032029.
FT   METAL       408    408       Magnesium.
FT   METAL       468    468       Magnesium.
FT   MOD_RES      22     22       Pyrrolidone carboxylic acid.
FT   DISULFID     48     81       {ECO:0000269|Ref.3}.
FT   DISULFID    124    303       Interchain (between gamma and delta
FT                                chains). {ECO:0000269|Ref.3}.
FT   CONFLICT     27     27       S -> E (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     30     30       E -> S (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       60     64       {ECO:0000244|PDB:2E9Q}.
FT   STRAND       67     71       {ECO:0000244|PDB:2E9Q}.
FT   HELIX        77     82       {ECO:0000244|PDB:2E9Q}.
FT   STRAND       84     91       {ECO:0000244|PDB:2E9Q}.
FT   STRAND       95    104       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      106    112       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      114    119       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      128    130       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      144    146       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      150    153       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      156    160       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      166    170       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      172    174       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      176    186       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      197    202       {ECO:0000244|PDB:2E9Q}.
FT   TURN        230    233       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       236    243       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       247    254       {ECO:0000244|PDB:2E9Q}.
FT   TURN        255    257       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      263    265       {ECO:0000244|PDB:2E9Q}.
FT   TURN        272    275       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       302    304       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      308    310       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      318    321       {ECO:0000244|PDB:2E9Q}.
FT   TURN        322    324       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      325    330       {ECO:0000244|PDB:2E9Q}.
FT   TURN        332    334       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       338    341       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      344    350       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      355    363       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      366    380       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      386    393       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      397    400       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      405    425       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      428    436       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       437    440       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       443    450       {ECO:0000244|PDB:2E9Q}.
FT   HELIX       454    462       {ECO:0000244|PDB:2E9Q}.
FT   STRAND      468    470       {ECO:0000244|PDB:2E9Q}.
SQ   SEQUENCE   480 AA;  54626 MW;  BCD8A83DD1AED93C CRC64;
     MARSSLFTFL CLAVFINGCL SQIEQQSPWE FQGSEVWQQH RYQSPRACRL ENLRAQDPVR
     RAEAEAIFTE VWDQDNDEFQ CAGVNMIRHT IRPKGLLLPG FSNAPKLIFV AQGFGIRGIA
     IPGCAETYQT DLRRSQSAGS AFKDQHQKIR PFREGDLLVV PAGVSHWMYN RGQSDLVLIV
     FADTRNVANQ IDPYLRKFYL AGRPEQVERG VEEWERSSRK GSSGEKSGNI FSGFADEFLE
     EAFQIDGGLV RKLKGEDDER DRIVQVDEDF EVLLPEKDEE ERSRGRYIES ESESENGLEE
     TICTLRLKQN IGRSVRADVF NPRGGRISTA NYHTLPILRQ VRLSAERGVL YSNAMVAPHY
     TVNSHSVMYA TRGNARVQVV DNFGQSVFDG EVREGQVLMI PQNFVVIKRA SDRGFEWIAF
     KTNDNAITNL LAGRVSQMRM LPLGVLSNMY RISREEAQRL KYGQQEMRVL SPGRSQGRRE
//
ID   122R_IIV3               Reviewed;          67 AA.
AC   Q196T8;
DT   16-JUN-2009, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2006, sequence version 1.
DT   01-APR-2015, entry version 17.
DE   RecName: Full=Uncharacterized protein 122R;
DE   Flags: Precursor;
GN   ORFNames=IIV3-122R;
OS   Invertebrate iridescent virus 3 (IIV-3) (Mosquito iridescent virus).
OC   Viruses; dsDNA viruses, no RNA stage; Iridoviridae; Chloriridovirus.
OX   NCBI_TaxID=345201;
OH   NCBI_TaxID=7163; Aedes vexans (Inland floodwater mosquito) (Culex vexans).
OH   NCBI_TaxID=42431; Culex territans.
OH   NCBI_TaxID=332058; Culiseta annulata.
OH   NCBI_TaxID=310513; Ochlerotatus sollicitans (eastern saltmarsh mosquito).
OH   NCBI_TaxID=329105; Ochlerotatus taeniorhynchus (Black salt marsh mosquito) (Aedes taeniorhynchus).
OH   NCBI_TaxID=7183; Psorophora ferox.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16912294; DOI=10.1128/JVI.00464-06;
RA   Delhon G., Tulman E.R., Afonso C.L., Lu Z., Becnel J.J., Moser B.A.,
RA   Kutish G.F., Rock D.L.;
RT   "Genome of invertebrate iridescent virus type 3 (mosquito iridescent
RT   virus).";
RL   J. Virol. 80:8439-8449(2006).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ643392; ABF82152.1; -; Genomic_DNA.
DR   RefSeq; YP_654694.1; NC_008187.1.
DR   GeneID; 4156333; -.
DR   KEGG; vg:4156333; -.
DR   Proteomes; UP000001358; Genome.
PE   3: Inferred from homology;
KW   Complete proteome; Glycoprotein; Reference proteome; Signal.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   CHAIN        29     67       Uncharacterized protein 122R.
FT                                /FTId=PRO_0000377819.
FT   CARBOHYD     39     39       N-linked (GlcNAc...); by host.
FT                                {ECO:0000255}.
SQ   SEQUENCE   67 AA;  7339 MW;  AEABE39819E26CEA CRC64;
     MSHVSVIAAR LLVWVGILLC LGVPQLWANP IYLYEPSANK STRAPQVLGV PPEVYAFTVS
     CKACWLP
//
ID   130R_IIV6               Reviewed;         201 AA.
AC   O55740;
DT   16-JUN-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   11-NOV-2015, entry version 37.
DE   RecName: Full=Uncharacterized protein 130R;
DE   Flags: Precursor;
GN   ORFNames=IIV6-130R;
OS   Invertebrate iridescent virus 6 (IIV-6) (Chilo iridescent virus).
OC   Viruses; dsDNA viruses, no RNA stage; Iridoviridae; Iridovirus.
OX   NCBI_TaxID=176652;
OH   NCBI_TaxID=6997; Acheta domesticus (House cricket).
OH   NCBI_TaxID=168631; Chilo suppressalis (Asiatic rice borer moth).
OH   NCBI_TaxID=6999; Gryllus bimaculatus (Two-spotted cricket).
OH   NCBI_TaxID=58607; Gryllus campestris.
OH   NCBI_TaxID=7108; Spodoptera frugiperda (Fall armyworm).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11448171; DOI=10.1006/viro.2001.0963;
RA   Jakob N.J., Mueller K., Bahr U., Darai G.;
RT   "Analysis of the first complete DNA sequence of an invertebrate
RT   iridovirus: coding strategy of the genome of Chilo iridescent virus.";
RL   Virology 286:182-196(2001).
RN   [2]
RP   GENOME REANNOTATION.
RX   PubMed=17239238; DOI=10.1186/1743-422X-4-11;
RA   Eaton H.E., Metcalf J., Penny E., Tcherepanov V., Upton C.,
RA   Brunetti C.R.;
RT   "Comparative genomic analysis of the family Iridoviridae: re-
RT   annotating and defining the core set of iridovirus genes.";
RL   Virol. J. 4:11-11(2007).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF303741; AAB94451.1; -; Genomic_DNA.
DR   PIR; T03077; T03077.
DR   RefSeq; NP_149593.1; NC_003038.1.
DR   GeneID; 1733000; -.
DR   KEGG; vg:1733000; -.
DR   Proteomes; UP000001359; Genome.
PE   3: Inferred from homology;
KW   Complete proteome; Reference proteome; Signal.
FT   SIGNAL        1     19       {ECO:0000255}.
FT   CHAIN        20    201       Uncharacterized protein 130R.
FT                                /FTId=PRO_0000378002.
SQ   SEQUENCE   201 AA;  23196 MW;  DEF298C202975609 CRC64;
     MKLIVSVFLI GCQFLNILGE RQCITMIPKL CFNNNYSGNT TLDKWRTVMQ FTYGDVEPNI
     IIPNGFVEGS NRCMNVEATT VCFSEPPLSN PELLSETWTM TDLYFKMPRS WWIFEIGKPR
     VCANVENMVC FAVSDDEGTH QWSFKVNMLY GNVVPKLGPP NKRVRNYCMK VDESKICFSE
     QPLLDDFSNK SWKLNKILFN V
//
ID   137R_IIV6               Reviewed;          57 AA.
AC   O55743;
DT   16-JUN-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   11-NOV-2015, entry version 37.
DE   RecName: Full=Uncharacterized protein 137R;
DE   Flags: Precursor;
GN   ORFNames=IIV6-137R;
OS   Invertebrate iridescent virus 6 (IIV-6) (Chilo iridescent virus).
OC   Viruses; dsDNA viruses, no RNA stage; Iridoviridae; Iridovirus.
OX   NCBI_TaxID=176652;
OH   NCBI_TaxID=6997; Acheta domesticus (House cricket).
OH   NCBI_TaxID=168631; Chilo suppressalis (Asiatic rice borer moth).
OH   NCBI_TaxID=6999; Gryllus bimaculatus (Two-spotted cricket).
OH   NCBI_TaxID=58607; Gryllus campestris.
OH   NCBI_TaxID=7108; Spodoptera frugiperda (Fall armyworm).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11448171; DOI=10.1006/viro.2001.0963;
RA   Jakob N.J., Mueller K., Bahr U., Darai G.;
RT   "Analysis of the first complete DNA sequence of an invertebrate
RT   iridovirus: coding strategy of the genome of Chilo iridescent virus.";
RL   Virology 286:182-196(2001).
RN   [2]
RP   GENOME REANNOTATION.
RX   PubMed=17239238; DOI=10.1186/1743-422X-4-11;
RA   Eaton H.E., Metcalf J., Penny E., Tcherepanov V., Upton C.,
RA   Brunetti C.R.;
RT   "Comparative genomic analysis of the family Iridoviridae: re-
RT   annotating and defining the core set of iridovirus genes.";
RL   Virol. J. 4:11-11(2007).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF303741; AAB94454.1; -; Genomic_DNA.
DR   PIR; T03080; T03080.
DR   RefSeq; NP_149600.1; NC_003038.1.
DR   GeneID; 1733001; -.
DR   KEGG; vg:1733001; -.
DR   Proteomes; UP000001359; Genome.
PE   3: Inferred from homology;
KW   Coiled coil; Complete proteome; Reference proteome; Signal.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23     57       Uncharacterized protein 137R.
FT                                /FTId=PRO_0000378006.
FT   COILED       26     57       {ECO:0000255}.
SQ   SEQUENCE   57 AA;  6754 MW;  BC4CCF292D2ACEED CRC64;
     MNEIIITIIV LILLLFITLS RNDRNNNQSN NGKKEKLIKC KKEVQQLRQK LDQLTFQ
//
ID   13S2_FAGES              Reviewed;         504 AA.
AC   O23880;
DT   11-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   01-OCT-2014, entry version 66.
DE   RecName: Full=13S globulin seed storage protein 2;
DE   AltName: Full=Legumin-like protein 2;
DE   Contains:
DE     RecName: Full=13S globulin seed storage protein 2 acidic chain;
DE   Contains:
DE     RecName: Full=13S globulin seed storage protein 2 basic chain;
DE   Flags: Precursor;
GN   Name=FA18;
OS   Fagopyrum esculentum (Common buckwheat) (Polygonum fagopyrum).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; Gunneridae;
OC   Pentapetalae; Caryophyllales; Polygonaceae; Polygonoideae; Fagopyreae;
OC   Fagopyrum.
OX   NCBI_TaxID=3617;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=cv. Kitayuki; TISSUE=Immature seed;
RX   PubMed=11308332; DOI=10.1021/jf0011485;
RA   Fujino K., Funatsuki H., Inada M., Shimono Y., Kikuta Y.;
RT   "Expression, cloning, and immunological analysis of buckwheat
RT   (Fagopyrum esculentum Moench) seed storage proteins.";
RL   J. Agric. Food Chem. 49:1825-1829(2001).
CC   -!- FUNCTION: Seed storage protein.
CC   -!- SUBUNIT: Hexamer; each subunit is composed of an acidic and a
CC       basic chain derived from a single precursor and linked by a
CC       disulfide bond. {ECO:0000250}.
CC   -!- MISCELLANEOUS: The sequence of the probable beta chain is highly
CC       homologous to the N-terminal sequence of BW24KD, a major buckwheat
CC       allergen.
CC   -!- SIMILARITY: Belongs to the 11S seed storage protein (globulins)
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D87982; BAA21760.1; -; mRNA.
DR   PIR; T10698; T10698.
DR   ProteinModelPortal; O23880; -.
DR   Allergome; 698; Fag e 1.
DR   GO; GO:0045735; F:nutrient reservoir activity; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR006044; 11S_seedstore_pln.
DR   InterPro; IPR006045; Cupin_1.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin.
DR   Pfam; PF00190; Cupin_1; 2.
DR   PRINTS; PR00439; 11SGLOBULIN.
DR   SMART; SM00835; Cupin_1; 2.
DR   SUPFAM; SSF51182; SSF51182; 3.
PE   2: Evidence at transcript level;
KW   Disulfide bond; Seed storage protein; Signal; Storage protein.
FT   SIGNAL        1     20       {ECO:0000255}.
FT   CHAIN        21    313       13S globulin seed storage protein 2
FT                                acidic chain. {ECO:0000250}.
FT                                /FTId=PRO_0000032005.
FT   CHAIN       314    504       13S globulin seed storage protein 2 basic
FT                                chain. {ECO:0000250}.
FT                                /FTId=PRO_0000032006.
FT   DISULFID     46     79       {ECO:0000250}.
FT   DISULFID    122    320       Interchain (between acidic and basic
FT                                chains). {ECO:0000255}.
SQ   SEQUENCE   504 AA;  57043 MW;  CDCA322394A28194 CRC64;
     MSTKLILSFS LCLMVLSCSA QLWPWQKGQG SRPHHGRQQH QFQHQCDIQR LTASEPSRRV
     RSEAGVTEIW DHDTPEFRCT GFVAVRVVIQ PGGLLLPSYS NAPYITFVEQ GRGVQGVVIP
     GCPETFQSDS EFEYPQSQRG RHSRQSESEE ESSRGDQHQK IFRIREGDVI PSPAGVVQWT
     HNDGNDDLIS VTLLDANSYH KQLDENVRSF FLAGQSQRET REEGSDRQSR ESDDDEALLG
     ANILSGFQDE ILHELFRDVD RETISKLRGE NDQRGFIVQA QDLKLRVPQD FEEEYERERG
     DRRRGQGGSG RSNGVEQGFC NLKFRRNFNT PTNTYVFNPR AGRINTVNSN SLPILEFLQL
     SAQHVVLYKN AIIGPRWNLN AHSALYVTRG EGRVQVVGDE GKSVFDDKVQ RGQILVVPQG
     FAVVLKAGRE GLEWVELKNS GNAITSPIGG RTSVLRAIPV EVLANSYDIS TKEAYKLKNG
     RQEVEVFRPF QSRDEKERER FSIV
//
ID   14KL_BRUA1              Reviewed;         147 AA.
AC   B2SAT5;
DT   20-JAN-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   11-NOV-2015, entry version 45.
DE   RecName: Full=Lectin-like protein BA14k;
DE   Flags: Precursor;
GN   OrderedLocusNames=BAbS19_II04750;
OS   Brucella abortus (strain S19).
OC   Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC   Brucellaceae; Brucella.
OX   NCBI_TaxID=430066;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=S19;
RX   PubMed=18478107; DOI=10.1371/journal.pone.0002193;
RA   Crasta O.R., Folkerts O., Fei Z., Mane S.P., Evans C.,
RA   Martino-Catt S., Bricker B., Yu G., Du L., Sobral B.W.;
RT   "Genome sequence of Brucella abortus vaccine strain S19 compared to
RT   virulent strains yields candidate virulence genes.";
RL   PLoS ONE 3:E2193-E2193(2008).
CC   -!- FUNCTION: Has immunoglobulin-binding and hemagglutination
CC       properties, and can bind to mannose. Essential for virulence. May
CC       be involved in LPS biosynthesis or polysaccharide transport (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass
CC       membrane protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the BA14k family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CP000888; ACD73972.1; -; Genomic_DNA.
DR   RefSeq; WP_002965908.1; NC_010740.1.
DR   STRING; 430066.BAbS19_II04750; -.
DR   PRIDE; B2SAT5; -.
DR   EnsemblBacteria; ACD73972; ACD73972; BAbS19_II04750.
DR   GeneID; 3827602; -.
DR   KEGG; bmc:BAbS19_II04750; -.
DR   PATRIC; 17815442; VBIBruAbo38055_0525.
DR   HOGENOM; HOG000274446; -.
DR   OMA; HVAWCAN; -.
DR   OrthoDB; EOG6358FW; -.
DR   BioCyc; BABO430066:GHI6-2518-MONOMER; -.
DR   Proteomes; UP000002565; Chromosome 2.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   InterPro; IPR012413; BA14K.
DR   Pfam; PF07886; BA14K; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Complete proteome; Lectin; Membrane; Signal;
KW   Transmembrane; Transmembrane helix; Virulence.
FT   SIGNAL        1     26       {ECO:0000255}.
FT   CHAIN        27    147       Lectin-like protein BA14k.
FT                                /FTId=PRO_0000361295.
FT   TRANSMEM     80    100       Helical. {ECO:0000255}.
SQ   SEQUENCE   147 AA;  16823 MW;  7CEE6F1FB2BB38DB CRC64;
     MNSFRKTCAG ALALIFGATS IVPTVAAPMN MDRPAINQNV IQARAHYRPQ NYNRGHRPGY
     WHGHRGYRHY RHGYRRHNDG WWYPLAAFGA GAIIGGAISQ PRPVYRAPAG SPHVQWCYSR
     YKSYRASDNT FQPYNGPRKQ CRSPYSR
//